Profrug of the compound cyanamide

LAP94AUndetermined Publication Date: 2025-09-19EISAI R&D MANAGEMENT CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
LAP94
Authority / Receiving Office
LA · LA
Patent Type
Applications
Current Assignee / Owner
Priority Date
2006-12-08
Filing Date
2007-07-26
Publication Date
2025-09-19

AI Technical Summary

Technical Problem

Current cinnamide compounds have low water solubility, limiting their effectiveness as therapeutic agents for Alzheimer's disease, particularly in suppressing the production of amyloid beta peptides Aβ40 and Aβ42, which are key contributors to the disease.

Method used

Quaternary salification of the imidazole moiety of cinnamide compounds enhances their water solubility, forming novel prodrugs that can be administered orally or parenterally, thereby increasing their therapeutic potential.

Benefits of technology

The enhanced water solubility of these prodrugs improves their bioavailability and efficacy as prophylactic or therapeutic agents for Alzheimer's disease, effectively suppressing Aβ40 and Aβ42 production.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure P%2F94_DRAWING_001
    Figure P%2F94_DRAWING_001
  • Figure P%2F94_DRAWING_002
    Figure P%2F94_DRAWING_002
  • Figure P%2F94_DRAWING_003
    Figure P%2F94_DRAWING_003
Patent Text Reader

Abstract

Disclosed is an optimal prodrug of a cinnamide compound represented by Formula (I) below.(See attach)In the formula, Ra and Rb respectively represent a Cl-6 alkyl group or the like; Xa represents a methoxy group or a fluorine atom; Y represents a phosphono group or the like; and A represents a cyclic lactam derivative.
Need to check novelty before this filing date? Find Prior Art

Description

Specification Prodrugs of cinnamide compounds Technical field

[0001] INDUSTRIAL APPLICABILITY The present invention provides novel prodrugs of cinnamide compounds that are useful for the treatment of diseases caused by amyloid beta (hereinafter referred to as A / 3) typified by Alzheimer's disease, and that are suitable for oral and parenteral administration. Concerning drugs used as ingredients. More specifically, the present invention relates to a novel prodrug of a cinnamide compound or a pharmacological agent thereof, in which the water solubility of the cinnamide compound is enhanced by quaternary salification of the imidazole moiety of the cinnamide compound molecule. Tolerable salts and drugs containing them as active ingredients. Background technology

[0002] Aβ protein, which is a metabolite of amyloid precursor protein (hereafter referred to as APP and ! / ), is considered to be greatly involved in the degeneration and loss of nerve cells, as well as the manifestation of dementia symptoms. The main component of the alpha protein is alpha 40, which consists of 40 amino acids, and alpha 42, which has two more amino acids at the C-terminus. These A / 3's 40 and 42 are major constituents of highly cohesive senile plaques, and mutations in the APP and presenelin genes seen in familial Alzheimer's disease are associated with these A / 3's 40 and 42 known to increase 42. Compounds that suppress the production of A / 3 40 and 42 are expected as therapeutic or prophylactic agents for diseases caused by Aβ typified by Alzheimer's disease. The present inventors discovered a cinnamide compound as a non-peptidic compound that suppresses the production of α / 340 and 42, which has excellent efficacy (eg, Patent Document 1).

[0003] In general, the usefulness of a compound as a drug may be limited by its low water solubility. For example, it is well known that the low solubility in water of the azole compounds, which are well-known antifungal agents, sometimes hinders their development as parenteral dosage forms.

[0004] A method of addressing this problem is disclosed, for example, in US Pat. ing. Prodrug power S by a similar phosphonoxymethyl group or its derivative represented by the following formula, described in Non-Patent Document 1

[0005] In addition, Professor Stella Valentino of the University of Kansas et al. [Chemical 2] A- [In the formula, R. 2 and R 3 is a substituent containing a tertiary or secondary amine of the parent compound, and R 4 and R 5 is an organic or inorganic residue] is disclosed in Patent Document 3 (claim page 48, line 3, page 48, line 10). This compound is generally described as having an external anion (A) attached to the quaternary amine center and an external cation attached to the phosphate double anion charge (page 18 of the specification, line 28--page 24 line 11). Among others, pharmaceutical compounds whose quaternary amines are classified as aromatic compounds are exemplified on page 22, line 1, page 23, line 3 of the description. For example, miconazole containing an imidazolyl group is exemplified. However, neither the listed compounds nor the compounds of the examples disclose the imidazolyl group-containing cinnamide derivatives that characterize the present invention, and the compounds of the present invention are neither disclosed nor suggested.

[0006] In addition, in Patent Document 4, as a prodrug of an antifungal compound, for example, Compounds have been described. [3 [In the formula, R 1 is an alkyl group, etc., and R 2 represents hydrogen atoms, alkyl groups, etc., and R 7 indicates a triazolinole group, a tetrazolyl group, etc.]

[0007] As mentioned above, azole antifungal agents have been reported as quaternary ammonium salt-type prodrugs, but his quaternary salt-type prodrugs of phenylimidazole derivatives, commonly found in cinnamide compound structures, have not yet been reported. known! Patent Document 1: International Publication No. WO2005 / 115990 Pamphlet Patent Document 2: US Pat. No. 6,235,728 Patent Document 3: International Publication No. W099 / 33846 Pamphlet Patent Document 4: International Publication No. WO98 / 43970 pamphlet Non-Patent Document 1: Yasutsugu Ueda, et al., Phosspnonomethyl Prodrugs of tne Broad Spectrum antifungal Azole, Ravuconazole: Synthesis and Biological Properties, Bioorganic &Medicinal Chemistry Letters 13 (2003) 3669-3672 Invention disclosure Problems to be Solved by Inventions

[0008] A cinnamide compound that suppresses the production of A / 340 and 42 from APP as described above is expected as a therapeutic or preventive agent for diseases caused by Aβ typified by Alzheimer's disease. There is a demand for prodrugs that increase the water solubility of cinnamide compounds and further enhance the usefulness of cinnamide compounds as drugs. Accordingly, an object of the present invention is to provide a prodrug of a cinnamide compound and a drug containing the prodrug as an active ingredient, in which the solubility of the cinnamide compound in water is enhanced and the usefulness of the cinnamide compound as a drug is further enhanced. to do. Means to solve problems

[0009] The present inventors have made extensive studies and found that the water-solubility of cinnamide compounds is greatly improved by quaternary salification of the imidazole moiety of the molecule, thus completing the present invention.

[0010] That is, the present invention Formula (I) [Chemical 4] [Wherein, R and R are the same or different, a hydrogen atom or a C16 alkyl group a b shows X represents a methoxy group or a fluorine atom, Y is —CO— (O) —R Μ (wherein R is the same selected from Substituent Group A1 or n c a c may be substituted with 1 to 5 different substituents, C16 alkyl group, 6 to 14 membered aromatic hydrocarbon ring group, 5 to 14 membered aromatic heterocyclic group, 6 to 14 membered nonaromatic group represents a hydrocarbon ring group or a 5- to 14-membered non-aromatic heterocyclic group, n represents 0 or 1, M— represents an anion), -P (= 0) (OR) Μ (In the formula, R is selected from the permutation group A2 a d 2 a d represents a C1-6 alkyl group, which may be substituted with 1 to 3 substituents which may be the same or different and may be substituted, and M has the above meaning), -P (= 0) (OH). a2 M— (wherein M— has the meaning given above), P (= 0) (— O— ) (OH) or P (= 0) (101) (— O— M + ) (where M + 'Yang' A is the formula (A— 1 ) [Chemical 5] [In the formula, (a) R 2 , R. 3 and R 4 are the same or different and represent a hydrogen atom or a C1-6 alkyl group, and X is a C16 alkylene group (the C16 alkylene group is 1 to 3 hydroxyl groups or C16 alkyl group (the C16 alkyl group may be substituted with 1 to 3 hydroxyl groups), X is an oxygen atom or a methylene group (the methylene 2 The group may be substituted with 1 or 2 C16 alkyl groups ! / ,), Ar is — X — Ar (wherein Ar is the same or different 1! / , and may be substituted with 3 substituents selected from Substituent Group A2! / , 6! / represents a 14-membered aromatic hydrocarbon ring group or 5! / represents a 14-membered aromatic heterocyclic group, and X represents a single bond or an oxygen atom), or (b) — is a benzene ring (the The benzene ring is a C3-8 cycloalkyl group condensed with the same or different 1 to 3 substituents selected from the substituent group A2 (1 The methylene group may be substituted with an oxygen atom! / , )] or the expression (A— 2) [In the formula, represents a single bond or a double bond, and Ar represents the same or 2 may be substituted with 1 or 3 different substituents, 6 or 14-membered aromatic hydrocarbon ring groups or 5- to 14-membered aromatic heterocyclic groups, R. 5 and R 6are the same or different and represent a group selected from Substituent Group A2, Z and Z are the same or different, 1 2 optionally substituted with 1 or 2 identical or different substituents selected from Substituent Group A2, optionally substituted with a methylene group or vinylene group, an oxygen atom or a C16 alkyl group or C1-6 acyl group a good imino group, and p, q and r are the same or different and represent an integer of 0 to 2] or a pharmacologically acceptable salt; Substituent group Al: (1) hydroxyl group, (2) cyano group, (3) C3-8 cycloalkoxy group, (4) C16 alkoxy group (the C16 alkoxy group is a halogen atom, hydroxyl group, cyano group, C3 (5) 1 or 2 C16 alkyl groups (the C16 alkyl The group may be substituted with 1 or 3 halogen atoms! / , optionally substituted with ! / , an amino group, (6) 1 or 2 C1-6 alkyl groups (the C1 —6 the alkyl group may be optionally substituted with 1 to 3 halogen atoms); (7) a carboxyl group, (8) a pyridinyl group and (9) a sugar residue. Substituent group A2: (1) halogen atom, (2) hydroxyl group, (3) cyano group, (4) C3-8 cycloalkyl (5) C3-8 cycloalkoxy group, (6) C1-6 alkyl group (the C1-6 alkyl group is a halogen atom, hydroxyl group, cyano group, C3-8 cycloalkyl group, C1-6 alkoxy group and a C3-8 cycloalkoxy group), (7) a C1-6 alkoxy group (the C16 alkoxy group is a halogen atom, a hydroxyl group, a cyano (8) 1 or 2 C16 alkyl groups (the C1 6 alkyl group may be substituted with 1 to 3 halogen atoms), an optionally substituted amino group and (9) 1 or 2 C16 alkyl groups (the C16 alkyl group is 1! / , and may be substituted with 3 halogen atoms! 2) the compound or pharmacologically acceptable salt according to 1) above, wherein X represents a methoxy group; 3) the compound or pharmacologically acceptable salt according to 1) above, wherein X represents a fluorine atom; 4) Y is P ( = 0) (OH) Μ (where Μ— represents an anion), Ρ ( = 0) (— 2 a a O1) (OH) or — P ( = 0) (— O— ) (— O— M + ) (where M + indicates a cation) b b The compound or pharmacologically acceptable salt according to 1) above, which shows 5) Ar may be substituted with 1 to 3 identical or different substituents selected from Substituent Group A2, 6, 14-membered aromatic hydrocarbon ring group, or 5, , a compound or a pharmacologically acceptable salt according to 1) above, which represents a 14-membered aromatic heterocyclic group; 6) Ar represents a phenyl group or a pyridinyl group, which may be substituted with 1 to 3 identical or different substituents selected from Substituent Group A2. acceptable salts for; 7) Ar is a phenyl group or pyridinyl group, or a phenyl group or pyridinyl group substituted with 1 to 3 halogen atoms, the compound described in 1) above, or a pharmacologically acceptable salt; 8) X is =1^1(0^1)—1^ 7 (where 1^ 7 represents the same 16 alkyl group), the compound or pharmacologically acceptable salt according to 1) above; 9) The compound or pharmacologically acceptable salt according to 1) above, wherein X represents a methylene group 10) The compound or pharmacologically acceptable salt according to 1) above, wherein X represents an oxygen atom 2 11) Z and Z are the same or different, 1 2 represents a methylene group or an oxygen atom optionally substituted with a rhogen atom or a hydroxyl group, 5 and R 6 are the same or different and represent a C16 alkyl group, a halogen atom or a hydrogen atom, the compound or pharmacologically acceptable salt according to 1) above; 12) Z and Z are the same or different and are methylene groups (the methylene groups are 1 or 1 2 2, which may be substituted with a C16 alkyl group, a halogen atom or a hydroxyl group); 13) Z and Z are the same or different and are methylene groups (the methylene groups are 1 or 1 2 2, which may be substituted with a C16 alkyl group, a halogen atom or a hydroxyl group), p and q are 1, r is 0, the compound according to 11) above, or a pharmacologically acceptable salt; 14) Z represents a methylene group (the methylene group may be substituted with 1 or 2 C16 alkyl groups, halogen atoms or hydroxyl groups), Z represents an oxygen atom, p, q and r 2 is the compound or pharmacologically acceptable salt according to 11) above, which represents 1; 15) Z is an oxygen atom, Z is a methylene group (the methylene group is 1 or 2, C1 1 2 —6 optionally substituted with an alkyl group, a halogen atom or a hydroxyl group), and p, q and r are 1, the compound or pharmacologically acceptable salt according to 11) above; 16) The compound according to 11) above, wherein Z, Z represents an oxygen atom, and p, q and r represent 1 1 2 or a pharmacologically acceptable salt; 17) Ar represents a phenyl group substituted with 1 to 3 halogen atoms, as described in 11) above. 2 compounds or pharmacologically acceptable salts thereof; 18) Ar represents a phenyl group substituted with 2 or 3 halogen atoms, as described in 11) above. 2 compounds or pharmacologically acceptable salts thereof; 19) The compounds or pharmacologically acceptable dissolved salt; 20) Compounds or pharmacologically acceptable salts according to 1) above selected from the following group: 1) 3- {4 {1 {[(S)- 1 4 fluorophenyl)ethyl] 2-oxopiperidine-(3E)-ylidenemethyl}-2-methoxyphenyl}- 5-methyl- 1- (phosphonooxymethyl) 3H — imidazolone 1um trifluoroacetate, 2) 1-acetoxymethyl-3- {4-{l- [(S)-1 (4-fluorophenyl)ethyl]-2-oxopiperidine-(3E)-ylidenemethyl}-2-methoxyphenyl}- 5—methyl 3H—imidazole 1 um iodide, 3) 3-{4-{l-[(lR, 2R)- 2 hydroxy-1- (3, 4, 5-triphenyleophenyl)propyl] 2 foxopiperidine-(3E) ylidenemethyl} 2 methoxyphenyl} — 5-methyl-1-(phosphonooxymethyl) 3H-imidazole-1-ium trifluoroacetate, 4) 3-[2-phenyl-4-[(S)-4-[(1R, 2R)-2-hydroxy-1-(3,4,5-trifluorophenylene)propyl]-6-methyl-3-oxomorpholine-(2Z ) ylidenemethyl-phenyl]5-methyl-1-phosphonooxymethyl-3H-imidazole-1-im-triphenylacetate, 5) 3-{2-methoxy-4[(33,8&3)-5-oxo3-(3,4,5-trifluorophenyl)hexahydroindolizine-(6E)-ylidenemethyl]phenyl}-5- methyl-1-phosphonooxymethyl 3H-imidazolone-1-ium trifluoroacetate, 6) 3-{4-{(S)-4-[(S)-l-(2,6-difluoropyridin-3-yl)ethyl]6-methyl-3-oxomorpholine-(2Z)ylidene-methyl}2-methoxyphenyl}—5-methyl-1-phosphonooxymethyl-3H-imidazole-1-im chloride, 7) 3— {4- {[(3S, 8aS) 3-(4-chlorophenyl)-5-oxohexahydroindolizine-(6E) ylidenemethyl] 2 methoxyphenyl} 5 methyl-1 (phosphonooxymethyl) 3H— imidazole-1um trifluoroacetate, 8) 3-{4-{(S)-4-[(lR, 2R)-l-(3, 4 difluorophenyl)-2-hydroxypropyl] 6-methyl-3 oxomorpholine-(2Z) ylidenemethyl} 2 Luorophenyl}—5-methyl-1-phosphonooxymethyl-3H-imidazole-1um trifluoroacetate, 9) 3- {2 methoxy- 4- [(6S, 9aS)- 4 foxo 6- (3, 4, 5 trifluorophenyl) hexahydroquinolizine-(3E)-ylidenemethyl]phenyl}- 5- methyl-1-(phosphonooxymethyl)3H-imidazole-1-um trifluoroacetate, 10) 3-{2-methoxy-4-[(41^, 9&3)-6-oxo-4-(3,4,5-trifluorophenyl)hexahydropyrido[2,l-c][l,4]foxazine-(7E)-ylidenemethyl] phenyl}-5-methyl-1-phosphonooxymethyl-3H-imidazole-1-thium trifluoroacetate, 11) 3-{4-{(S)-4-[(lR, 2R)-2-hydroxy-1-(3,4,5-triphenyl-phenyl)propyl]-6-methyl-3-foxomorpholine-(2Z)ylidenemethyl} 2 methoxyphenyl]— 5 methyl 1— (phosphonooxymethyl) 3H imidazole 1 um triphenylacetate, 12) 3- {4 [(6S, 9aR)-6- (4-chloro-phenyl) 4 foxohexahydroquinolisine-(3E) ylidenemethyl] 2 methoxyphenyl} 5 methyl 1-phosphonofoxymethyl-3H-imidazole-1um trifluoroacetic acid salt, 13) 3- {2 methoxy-4- [(IS, 6R, 9aR)- 1 methyl 4-oxo 6- (3, 4 , 5-trifluorophenyl) tetrahydro [1, 4] oxazino [3, 4-c] [l.4] foxazine-(3Z)-ylidenemethyl]phenyl-5-methyl-1-phosphonooxymethyl-3H-imidazolone-1ium trifluoroacetate, 14) 3— {4— [(IS, 6R, 9aR)—6— (4-phenylphenyl)-1-methyl-4-oxotetrahydro[1, 4]oxazino[3, 4-c][ l, 4]oxazine-(3Z)-ylidenemethyl ]— 2 methoxyphenyl} - 5 methyl 1-phosphonooxymethyl-3H-imidazole 1 um trifluoroacetate, 15) 3- {2 methoxy-4- [(IS, 6S, 8aR)- 1 methyl 4 oxo 6- (3, 4 , 5-trifluorophenyl)tetrahydropyro[2, l-c][l, 4]foxazine-(3Z)-ylidenemethyl-phenyl] 5-methyl-1-phosphonooxymethyl-3H-imidazole-1-thium triphenylacetate , 16) 3-{4-[(lS, 6R, 9aR)-6-(3,4-difluorophenyl)-1-methyl-4-oxotetrahydro[1,4]oxazino[3,4-c][l, 4 ]foxazine-(3Z)-ylidene methyl]-2-methoxyphenyl}-5-methyl 1-phosphonooxymethyl 3H-imidazole-1ium trifluoroacetate and 17) 3-{4-[(6R, 9aR)-l, 1-dimethinole-4-xo-6- (3, 4, 5-trifluorophenyl)tetrahydro[1, 4]foxazino[3, 4-c] [l, 4]foxazine-(3Z)-ylidenemethyl]-2-methoxyphenyl}-5-methyl-1-phosphonooxymethyl-3H-imidazolone-imtrifluoroacetate; 21) Compounds according to 1) above selected from the following group: 1 ) monohydrogen phosphate 1 {4 [(E)- {1 [(1S)- 1 4 fluorophenyl)ethyl] - 2 oxopiperidine- 3 ylidene}methyl] 2 methoxyphenyl} - 4 methyl 1H-imidazo- Lou 3—thiomethyl, 2) Phosphate-hydrogen 1 {4-[ )-{1 [(11^, 21¾-2-hydroxy-1-(3,4,5-trifluorophenyl)propyl]-2-oxopiperidine-3ylidene}methyl ]-2-methoxyphenyl}4-methyl-1H-imidazo-3-thiomethyl, 3) monohydrogen phosphate 1 {2 fluoro 4 [(Z)- {(6S)- 4 [(1R, 2R) 2 hydroxy 1- (3, 4, 5-trifluorophenylene) propyl]- 6-methyl 3-oxomorpholine-2ylidene}methyl]phenyl}4-methyl-1H-imidazol-3thiomethyl, 4) monohydrogen phosphate 1 (2-methoxy-4 {(E)- [(3S, 8aS)-5-oxo-3- (3, 4, 5-trifluorophenyl) hexahydroindolizine 6(5H)- ylidene]methyl}phenyl) 4-methyl 1H imidazo-mono-3-thiomethyl, 5) monohydrogen phosphate 1 {4 [(Z)- {(6S)- 4 [(1S)- 1-(2, 6-difluoropyridine 3-yl) ethyl] 6 methyl 3 foxomorpholine 2 ylidene} methyl] 2 methoxyphenyl 2-methinole 4-methinole 1 H imidazole 3 iomethinole , 6) monohydrogen phosphate 1 (4 {(E)- [(3S, 8aS) 3-(4-chlorophenyl)-5-foxohexahydroinsolidine-6 ​​(5H)-ylidene]methyl}- 2 methoxyphenyl l) -4-methyl-1H-imidazo-3-iomethyl, 7) monohydrogen phosphate 1 {4 [(Z)- {(6S)- 4 [(1R, 2R)- 1-(3,4 difluorophenyl) 2 hydroxypropyl] 6 methyl 3 oxomorpholine-2 ylidene} methyl ] 2 fluorophenyl}-4 methyl 1 H imidazo-1-3 thiomethyl, 8) monohydrogen phosphate 1-(2-methoxy-4 {(E)-[(6S,9aS)4-oxo-6-(3,4,5-trifluorophenyl)hexahydro-2H-quinolizine-3(4H)-ylidene] methyl}phenyl) 4-methyl 1 H imidazo-mono-3-thiomethyl, 9) monohydrogen phosphate 1— (2 methoxy— 4— {(E)— [(4R, 9aS)—6 oxo—4— (3, 4, 5 trifluorophenyl) hexahydropyride [2, l-c][l , 4]foxazine 7(6H)-ylidene]methyl}phenyl) 4-methyl-1H imidazo-1-3-thiomethyl, 10) Phosphate-hydrogen 1 {4-[ )-{(63)-4 [(11^, 2 )-2-hydroxy-1-(3,4,5 trifluorophenylole)propyl]-6 methyl 3 oxomorpholine - 2- ylidene} methyl] 2 methoxyphenyl} - 4 methyl 1 H imidazo-methyl]- 3 methyl, 11) monohydrogen phosphate 1— (4— {(E)— [(6S, 9aR)—6— (4-chlorophenyl)—4 foxohexahydro-2H quinolizine-3(4H)—ylidene]methyl} — 2 methoxyphenyl) 4-methyl-1H-imidazo-3-thiomethyl, 12) monohydrogen phosphate 1-(2-methoxy-4 {(Z)- [(IS, 6R, 9aR)- 1-methylol-4-oxo-6- (3, 4, 5-trifluorophenyl)tetrahydro-1H-[ 1, 4]oxazino [3,4-c][l,4]oxazine 3(4H)-ylidene]methyl}phenyl)-4-methyl-1H-imidazo-3-thiomethyl, 13) Phosphate-hydrogen 1-(4-{)-[(13,6R,9aR)-6-(4-chlorophenyl)-1-methyl-4-oxotetrahydro-1H-[1,4]foxazino[3,4 — c][l, 4]oxazazine-3(4H)-ylidene]methyl} 2 methoxyphenyl) 4-methyl 1H imidazole-3-thiomethyl, 14) monohydrogen phosphate 1-(2-methoxy-4- {(Z)- [(IS, 6S, 8aR)- 1-methylol-4-oxo-6- (3, 4, 5 trifluorophenyl) tetrahydro-1H- pyro [2, l-c][ 1 , 4]oxazine 3 (4H)-ylidene]methyl}phenyl) 4 methyl 1 H imidazo Lou 3—thiomethyl, 15) monohydrogen phosphate 1-(4 {(Z)— [ (IS, 6R, 9aR)-6-(3,4-difluorophenyl)-1-methyl-4-oxotetrahydro-1H—[1,4]oxazino [3, 4-c] [l , 4 ]oxazine 3 (4H)-ylidene]methyl}-2 methoxyphenyl)-4-methyl-1H imidazo-nole 3-thiomethyl and 16) monohydrogen phosphate 1-(4 {(Z) [ (6R, 9aR) - l , 1 dimethyl-4-oxo-6- (3, 4, 5-trifluorophenyl)-tetrahydro-1H-[1 , 4]oxazino [3, 4—c] [1 , 4]oxazine 3 (4H)-ylidene]methyl}-2-methoxyphenyl)-4 methyl 1H-imidazo-nole 3-thiomethyl; 22) A drug containing, as an active ingredient, the compound or a pharmacologically acceptable salt thereof according to any one of 1) to 21) above; 23) The drug of 22) above, which is a prophylactic or therapeutic agent for diseases caused by amyloid beta; and 24) The drug according to 23) above, which is amyloid beta-induced disease severity S, Alzheimer's disease, senile dementia, Down's syndrome, or amyloidosis. Regarding. The invention's effect

[0011] The compound of general formula (I) or a pharmacologically acceptable salt of the present invention increases the water solubility of the cinnamide compound by quaternary salification of the imidazole moiety of the cinnamide compound molecule, thereby making the cinnamide compound drug. A prodrug of a cinnamide compound that further enhances the usefulness as i n It is a compound that can be converted into a cinnamide compound, which is the active substance, in vitro and in vivo, and is a novel compound that has not been described in literature and that is extremely useful as a prophylactic or therapeutic agent for diseases caused by A / 3.

[0012] The meaning of the symbols, terms, etc. described in the specification of the present application will be explained below, and the present invention will be described in detail.

[0013] In the present specification, the structural formula of a compound may represent a certain isomer for convenience. including isomers and mixtures of isomers such as isomers, tautomers, etc. It may be either one of the isomers or a mixture, without being limited to the above formula description. Therefore, the present invention is not limited to the force that has an asymmetric carbon atom in the molecule and may exist in an optically active form and a racemic form, and includes both. Further crystalline polymorphs may exist but are likewise not limited to any single crystalline form or mixture thereof or solvates other than the anhydride which may be in amorphous form. It can be As used herein, "disease caused by A / 3" means Alzheimer's disease (for example, Klein WL, et al., Alzheimer's disease—affected bram: Presence of oligomeric Aβ ligands (ADDLs) suggests a molecular basis for reversible memory loss, Proceeding National Academy of Science USA, 2003, Sep 2, 100 (18), p. 10417— 10422; Nitsch RM, et al. 16, Antibodies against β-amyloid slow cognitive decline in Alzheimer's s disease, Neuron, 2003, May 22, 38 (4), p. 547–554: Jarrett JT, et al., The carboxy terminus of the β amyloid protein is critical for the seeding of amyloid formation: Implications for the pathogenesis of Alzheimers' disease, Biochemistry, 1993, May 11, 32 (18), p. 4693— 4 697; Glenner GG, et al., Alzheimer's disease; initial report of the purification and characterization of a novel cerebrovascular amylo id protein, Biochemical and biophysical research communications, 1984, May 16, 120 (3), p. 885-890; Masters CL, 6 others, Amyloid plaque core protein in Alzheimer disease and Down syndrome, Proceeding National Academy of Science ce USA, 1985, June, 82 (12), p. 4245 — 4249; Gouras GK, 1 person, Intraneuronal Αβ 42 accumulation in human brain, American journal of pathology, 2000, Jan, 156, p. 15 Scheuner D, et al., Secreted amyloid β-protein similar to that in the senile plaques of Alzheimer's disease is increased i n vivo by the presenilin 1 and 2 and APP mutations linked to f amilial Alzheimer's disease, Nature Medicine, 1996, Aug, 2(8), p.86 4— 870 ; Forman MS, et al., Differential effects of the Swedish mut ant amyloid precursor protein on β-amyloid accumulation and secretion in neurons and nonneuronal cells, The journal of Diological chemistry, 1997, Dec 19, 272 (51) , p. 32247–32253), senile dementia (e.g., Blass JP, Brain metabolism and brain disease: Is metabolic deficiency the proximate cause of Alzheimer dementia? Journa 1 of Neuroscience Research, 2001, Dec 1, 66 (5). ), p. 851–856), Frontal head type dementia (e.g., Evin G, et al. 11, Alternative transcripts of pres enilm— 1 associated with frontotemporal dementia, Neuroreport, 2002, Apr 16, 13 (5) , p. 719-723), Pick's disease (e.g., Yasuhara 〇, 3 others, Accumulation of amyloid precursor protein in brain lesions of patients with Pick disease, Neuroscience Letters, 1994, Apr 25, 171-2), pp. 63-66), Down syndrome (e.g. Teller JK, 10 others, Presence of soluble amyloid β-peptide precedes amyloid plaque formation m Do own's syndrome, Nature Medicine, 1996, Jan, 2 (1) , p. 93— 95 ;Tokud a T, 6 others, Plasma levels of amyloi d β proteins A / 3 1-40 and A β 1-42 (43) are elevated in Down's syndrome, Annals of Neurology, 1997, Feb, 41 (2), p. 271-273), March ¾ Evidence ior presenilin—1 involvement mamyioid angiopathy in the Alzheimer's disease—affected brain, Brain Research, 1998, Apr 13, 789 (2) , pp. 307-314; Barelli H, et al., 15 others, Characterization of new polyclonal antibodies specific for 40 and 42 amino acid-long amyloid β peptides: their use to examine the cell biology of presenilins and the immunohistochemistry of sporadic Alzhei mer's disease and cerebral amyloid angiopathy cases, Molecular Medicine, 1997, Oct, 3 (10), p. 695-707; Calhoun ME et al., Neurona 1 overexpression of mutant amyloid precursor protein results in prominent deposition of Cerebrovascular amyloid, Proceeding National Academy of Science USA, 1999, Nov 23, 96 (24), p. 14088-1409 3; Dermaut B, et al. 10, Cerebral amyloid angiopathy is a pathogenic lesion in Alzheimer's Disease due to a novel presenilin- 1 mutation , Brain, 2001, Dec, 124 (12), p. core type e senile plaques in the APP 692Ala > Gly mutation, Acta Neuropathologica (Berl), 1998, Sep, 96 (3), p. 253— 260; Herzig MC, 14 others, A / 3 is targeted to the vasculature in a mouse model of hereditary cerebral hemorrhage with amyloidosis, Nature Neuroscience, 2004, Sep, 7 (9), p. 954-960; is related to Alzheimer's disease, Proceeding National Academy of Science USA, 1987, Aug, 84 (16), p. 5991-5994; emorrhage , Dutch type, Sc ience, 1990, Jun 1, 248 (4959), p. 1124-1126), cognitive impairment (e.g., Laws SM, 7 others, Association between the presenilin- 1 mutation Glu318Gly and complaints of memory impairment, Neurobiology of Aging, 2002, Jan—Feb, 23 (1; see p. 55—58), memory and learning disorders (e.g., Vaucher E, 5 others, Object recognition me mory and cholinergic parameters m mice expressing human preseni lin 1 transgenes, Experimental Neurology, 2002 Jun, 175 (2), p. 398 — 406; Morgan D, 14 others, A β peptide vaccination prevents memory loss in an animal model of Alzheimer's disease, Nature, 2000 D ec 21— 28, 408 (6815), p. 982— 985 ; Moran PM, et al., Age— related learning deficits in transgenic mice expressing the 751— amino acid isoform of human β—amyloid precursor protein, Proceeding National Academy of Science USA, 1995, June 6, 92(12), p.5341—53 45), amyloidosis, cerebral ischemia (e.g. Laws SM, 7 others, Association between the presenilm— 1 mutation ^lu 18^1y and complai nts of memory impairment, Neurobiology of Aging) , 2002, Jan--Feb, 23 (1), p. 55--58; Role of influence, Proceeding National Academy of Science USA, 2002, Feb 5, 99(3), p. 1610-1615; Zhang F, et al. 4, In creased susceptibility to ischemic brain damage in transgenic mice overexpressing the amyloid precursor protein, The journal of neuroscience, 1997, Oct 15, 17(20), p. , Sadowski M, et al., Links between the pathology of Alzheimer's disease and vascular dementia, Neurochemical Research, 2004, Jun, 29(6), p. Riordan S, 7 others, Presenilin- 1 mutation (E280G) , spastic paraparesis, and cranial MRI white-matter abnormalities, Neurology, 2002, Oct 8, 59 i) y 1108-1110), multiple sclerosis (eg, Gehrmann J, et al., Amyloid precursors or protein APP) expression in multiple sclerosis lesions, Glia, 1995, Oct, 15(2), p. 141-151 ; Reynolds WF, 6 others, Myeloperoxidase polymorphism is associated with gender-specific risk for Alzheimer's disease, Experimental Neurology, 1999, Jan, 155(1), p. 31-41), head injury, cranial injury ( For example, Smith DH, 4 others, Protein accumulation in traumatic brain injury, NeuroMolecular Medicine, 2003, 4 1-2), p. Molecular evidence of presenilm 1 mutation m lamilial early onset dementia, American journal of Medical Genetics, 2002, Apr 8, 114(3), p. 292-298), prion disease, familial amyloid neuropathy, triplet repeat disease (e.g., Kirkitadze MD, 2 others, Paradigm shifts in Alzheimer's disease an d other neurodegenerative disorders: the emerging role of oligomeric assemblies, Journal of Neuroscience Research, 2002, Sep 1, 69 (5), p. 567— 577; Evert BO, et al. 3― expressing cell lines and spinocere bellar ataxia type 3 brains, The Journal of Neuroscience, 2001, Aug 1, 2 1 (1 5), p. 5389 - 5396; Mann DM, et al., Deposition of amyloid (A4) protein within the brains of persons with dementing disorders other than Alzheimer's disease and Down's syndrome, Neuroscience Letters, 1990, Feb 5, 109 (1-2), p. 68-75), Norkinson's disease (e.g. , Primavera J, et al., Brain accumulation of amyloid—β in Non-Alzheimer Neurodegeneration, Journal of Alzheimer's Disease, 1999, Oct, 1 (3), p. 183—193), Lewy body dementia (e.g. , Giasson BI, et al., Interactions of amyloidogemc proteins. NeuroMolecular Medicme, 2003, 4 (1-2), p. 49-58; deficits in a tra ncgenic mouse model linking Alzheimer's disease and Par inson's disease, Proceeding National Academy of Science USA, 2001, Oct 9, 98 (21), p. 12245— 12250; the cerebral cortex in Dementia with Lewy bodies is acc ompanied by a relative increase in Aβ PP mRNA isoforms containing the Kunitz protease inhibitor, Neurochemistry International, 2005, Feb, 46 (3), p. 253-260; Primavera J, and 4, Brain accumulation of amyloid—β in Non—Alzheimer Neurodegeneration, Journal of Alzheimer's Disease, 1999, Oct, 1 (3), p. ML, 6 others, Amyloid plaques in Guam amyotrophic lateral sclerosis / par insonism— dementia complex contain species oi A β similar to those found in the amyloid plaques of Alzheimer's disease and pathological aging, Acta Neuropath ologica (Berl), 1998, Feb, 95 (2), p. 117-122; Ito H, et al., Demonstration of β amyloid protein— containing neurofibrillary tangles in parkinsonism— dementia complex on Guam, Neuropathology and applied Neurobiology, 1991, Oct, 17 (5), p. 365-373), frontotemporal dementia parkinsonism linked to chromosome 17 (e.g., Rosso SM, et al., Coe xistent tau and amyloid pathology in hereditary frontotemporal dem entia with tau mutations, Annals of the New York academy of sciences, 2000, 920, p. M, 4 others, Low amyloid (α β ) plaque load and relative predominance of diffuse plaques distinguish argyrophnic grain disease from Alzheimer's disease, Neuropathology and applied neurobiology, 1999, Aug, 25 (4), p. 295 — 305), Niemann-Pick disease (eg, Jin LW, et al., Intracellular accumulation of amyloidogenic iragments oi amyloid—β precursor protein in neurons with Niemann—Pick type C defects is associated with endosomal abnormalities, American Journal of P athology, 2004, Mar, 164 (3), p. 975-985), amyotrophic lateral sclerosis Acta Neuropathologica (Berl), 1999, May, 97 (5), p. 463-468; Tamaoka A, 4 others, Increased amyloid β protein in the skin of patients with amyotrophic lateral sclerosis, Journal of Neurology, 2000, Aug, 247 (8), p. 633—635; Hamilton RL, et al., Alzheimer's disease pathology in amyotrophic lateral scle rosis, Acta Neuropathologica, 2004, Jun, 107 (6), p. 515–522 ; Turner BJ, 6 others, Brain β- amyloidaccumulation in transgenic mice expres sing mutant superoxide dismutase 1, Neurochemical Research, 2004, Dec, 29 (12), p. gy of cerebrospinal fluid and interstitial fluid oi the CNS: ^ignifi cancer for Alzheimer disease, prion disorders and multiple sclerosis, Journal of Neuropathology and Experimental Neurology, 1998, Oct, 57 (10), p. 885-894; Silverberg GD, et al., Alzheimer's disease, normal pressure hydrocephalus, and senescent changes in C^F circulatory physiology : a hypothesis, Lancet neurology, 2003, Aug, 2 (8), p. 506-511; Weller RO, et al., Cerebral amyloid angiopathy: Ac cum ulation of A / 3 in interstitial fluid drainage pathways in Alzheimer's disease Yow HY, et al., A role for cerebrovascular disease in determining the pattern of β-amyloid deposition in Alzhei mer's disease. , Neurology and applied ne urobiology, 2002, 28, p. 149 ; Weller RO, et al., Cerebrodiseas e is a major factor in the lailure of elimination of A β from the aging human brain, Annals of the New York academy of science s, 2002, Nov. , 977, p. 162-168), paraplegia (e.g., O' Riordan S, 7 others, Presenilin- 1 mutation (E280G) , spastic paraparesis, and crania 1 MRI white-matter abnormalities, Neurology, 2002, Oct 8, 59 (7), p. 1108— 1110; Matsubara— Tsutsui M, et al. 7, Molecular evidence of presenilin 1 mutation in familial early onset dementia, American journal of Medical Genetics, 2002, Apr 8, 114 (3 ), pp. 292-298; Smith MJ, et al. 11, Variable phenotype of Alzheimer's disease with spas tic paraparesis, Annals of Neurology, 2001, 49 pp. 125-129; A variant of Alzheimer's disease with spastic par are sis and unusual plaques due to deletion of exon 9 of presenilin 1, Nature Medicine, 1998, Apr; 4 (4), p. 452-455), progressive supranuclear Hemp ¾ For example, Barrachina M, 6 others, Amyloid— β deposition in the cerebral cortex in Dementia with Lewy bodies is accompanied by a relative increase in A β PP mRNA isoforms containing the Kunitz prot ease inhibitor, Neurochemistry International, 2005, Feb, 46 (3), p. 25 3— 260; Primavera J, et al., Brain accumulation of amyloid— [i in Non— see Alzheimer Neurodegeneration, Journal of Alzheimer's Disease, 1999, Oct, 1 (3), p. (For example, Atwood CS, 3 others, Cerebrovascular requirement for sealant, anti― coagulant and remodeling molecules that allow for the maintenance of vascular integrity and blood supply, Brain Research Reviews, 2003, Sep, 43, p.16 4— 178 ; Lowenson JD, 2 others, Protein aging: Extracellular amyloid formation and intracellular repair, Trends in cardiovascular medicine , 1994, 4 (1) , p. 3-8), convulsions (e.g., Singleton AB, 13 others, Pathology of early— onset Alzheimer's disease cases bearing the Thr丄 I d— 114ins presenilin— 1 mutation , Brain, 2000, Dec, 123 (Ptl 2), p. 2467-2474), mild cognitive impairment (e.g., Gattaz WF, 4 others, Platelet phosphorl lpase A2 activity m Alzheimer's disease and mild cognitive impairment, Journal of Neural Transmission, 2004, May, 111 (5) , p. 591— 6 01 ; Assini A, et al., Plasma levels of amyloid [i-protein 42 are increased in women with mild cognitive impariment, Neurology, 200 4, Sep. 14, 63 (5), p. 828-831), arteriosclerosis (e.g., De Meyer GR, et al., Platelet phagocytosis and processing of β-amyloid precursor protein as a mechanism of macrophage activation in atherosclerosis, Circulation Researcher, 2002, Jun 14, 90 (11) , p. 1197-1204). As used herein, the term "C1-6 alkyl group" refers to an alkyl group having 1 to 6 carbon atoms, and preferred groups include, for example, methyl group, ethyl group, n-propyl group, i-propinole group, n Butyl group, i-butyl group, tertiary-butyl group, n-pentyl group, i-pentyl group, neopentyl group, n-hexyl group, 1-methylpropyl group, 1, 2-dimethylpropyl group, 1-ethylpropyl group, 1-methyl-2 —ethylpropyl group, 1-ethyl-2-methylepropinole group, 1,1,2-trimethinolef. Ropinole group, 1-methylolef group, chinole group, 2-methylolebutyl group, 1,1-dimethylbutyl group, 2,2-dimethylbutyl group, 2-ethylbutyl group , 1,3-dimethylbutyl group, 2-methylpentyl group, 3-methylpentyl group, and other linear or branched alkyl groups.

[0016] The term "6- to 14-membered aromatic hydrocarbon ring group" refers to a monocyclic, bicyclic or tricyclic aromatic hydrocarbon ring group having 6 to 14 carbon atoms. monocyclic, bicyclic or tricyclic groups such as phenyl, indyl, naphthyl, fazulenyl, heptalenyl, biphenyl, fluorenyl, phenylenyl, phenanthrenyl and anthracenyl groups; , and 14-membered aromatic hydrocarbon ring groups.

[0017] The term "5- to 14-membered aromatic heterocyclic group" refers to a monocyclic, bicyclic or tricyclic aromatic heterocyclic group having 5 to 14 carbon atoms. ) pyrrolyl group, pyridinyl group, pyridazinyl group, pyrimidinyl group, pyrajyl group, virazolinyl group, imidazolyl group, indolyl group, isoindolyl group, indolizinyl group, purinyl group, indazolyl group, quinolyl group, isoquinolyl group, quinolidinyl group, phthalajyl group , naphthyridinyl group, quinoxalinyl group, quinazolinyl group, cinnolinyl group, pteridinyl group, imidazotriazinyl group, vilazinopyridazinyl group, atalidinyl group, phenanthridinyl group, rubbazolyl group, perimidinyl group, phenanthridinyl group , a nitrogen-containing aromatic heterocyclic group such as a phenacyl group, (2) a sulfur-containing aromatic heterocyclic group such as a chenyl group and a benzochenyl group, (3) a furyl group, a vilanyl group, a cyclopentaviranyl group, a benzofuranyl group, (4) thiazolyl, isothiazolyl, benzthiazolinole, benzthiadiazolyl, phenothiazinyl, isoxazolyl, furazanyl, phenoxazinyl, virazolo containing two or more heteroatoms selected from the group consisting of a nitrogen atom, a sulfur atom and an oxygen atom, such as a xazolyl group, imidazothiazolyl group, thienofuryl group, furopyrrolyl group, pyridoxazinyl group, etc. An aromatic heterocyclic group consisting of and the like can be mentioned.

[0018] The term “6- to 14-membered non-aromatic hydrocarbon ring group” refers to a cyclic aliphatic hydrocarbon group consisting of 6 to 14 carbon atoms, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclo xyl, cycloheptyl, cyclooctyl, spiro[3 4]octanyl, decanyl, indanyl, 1-acenaphthyl, cyclopentacy otatur group, benzocyclootatur group, indyl group, tetrahydronaphthyl group, 6,7,8,9-tetrahydro-5H-benzocycloheptyl group, 1,4-dihydronaphthalenyl group and the like.

[0019] The term "5- to 14-membered non-aromatic heterocyclic group" means 1) the number of atoms constituting the ring is ¾ to 14, and 2) the atoms constituting the ring have 1 to 5, for example, a nitrogen atom, 3) a 5- to 14-membered non-aromatic heteroatom containing a heteroatom such as O or S, and optionally containing one or more carbonyl groups, double bonds or triple bonds in the ring; Not only a monocyclic group, but also a saturated heterocyclic group condensed with an aromatic hydrocarbon ring group, or a saturated hydrocarbon ring group or saturated heterocyclic group condensed with an aromatic heterocyclic group. Specific examples of 5- to 14-membered non-aromatic heterocyclic groups include azetidyl ring, pyrrolidinyl ring, piperidinyl ring, azepanyl ring, azocanyl ring, tetrahydrofuranyl ring, tetrahydrovilanyl ring, morpholinyl ring, thiomorpholinyl ring and piperazinyl ring. ring, thiazolidinyl ring, dioxanyl ring, imidazolinyl ring, thiazolinyl ring, 1,2-benzopyranyl ring, isochromanyl ring, chromanyl ring, indolinyl ring, isoindolinyl ring, azaindanyl group, azatetrahydronaphthyl group, azachromanyl group, tetrahydro benzofuranyl group, tetrahydrobenzochenyl group, 2, 3, 4, 5 tetrahydro-benzo[b]thenyl group, 3, 4 dihydro-2H-benzo[b][l, 4]dioxepinyl group, indan-1-onyl group, 6, 7 dihydro-5H dihydropentavirazinyl group, 6, 7 dihydro-5H—[1]pyridinyl group, 6, 7 dihydro-5H [1] pyridinyl group, 5, 6 dihydro-4H cyclopenta[b]thenyl group, 4, 5, 6, 7-tetrahydro-benzo[b]thenyl group, 3, 4 dihydro-2H naphthalene-1-onyl group, 2 , 3-dihydro-isoindole-1-onyl group, 3,4-dihydro-2H-isoquinoline-1-onyl group, 3,4-dihydro-2H-benzo[1,4]oxapinyl group and the like.

[0020] The “C1-6 alkylene group” refers to an alkylene group having 1 to 6 carbon atoms, and preferred groups include, for example, methylene group, ethylene group, propylene group, butylene group, pentylene group and the like.

[0021] "Cl-6 acyl group" means a group in which one hydrogen atom in an alkyl group having 1 to 6 carbon atoms is substituted with a carbonyl group, and a preferred group is, for example, an acetyl group , propionyl group, and butylyl group. "C3-8 cycloalkyl ring condensed with benzene ring" means, for example, the formula [Chemical 7] etc. The benzene ring in these formulas may be substituted with 1 to 3 identical or different substituents selected from Substituent Group A2. You can replace it! / ,. In the formula (A-2), "Z represents a methylene group, a vinylene group, an oxygen atom, or an imino group optionally substituted with a C1-6 alkyl group or a C1-6 acyl group" means A specific illustration of a cyclic structural moiety containing a group, a vinylene group, an oxygen atom or an imino group is, for example, the formula [Chemical 8] etc. The methylene group and vinylene group in the cyclic structure portion of these formulas may be substituted with one or two identical or different substituents selected from the substituent group A2. In formula (A-2), "Z is a methylene group, a vinylene group, an oxygen atom or a C1-6 2 “Indicating an imino group which may be substituted with a alkyl group or a C1-6 acyl group” specifically illustrates the cyclic structural moiety containing the methylene group, vinylene group, oxygen atom or imino group. and, for example, the expression [Chemical 9] etc. The methylene group and vinylene group in the cyclic structure portion of these formulas may be substituted with one or two identical or different substituents selected from the substituent group A2. In the above formula (A-2), Z or Z, "the same 16 alkyl group or the same 16 1 2 A more specific illustration of the imino group moiety in the case of “an imino group that may be substituted with a silyl group” is, for example, the formula [Chemical 10] e., etc. Substituent Group Al represents the following groups. (1) a hydroxyl group, (2) a cyano group, (3) a C3-8 cycloalkoxy group, (4) a C16 alkoxy group (the C1-6 alkoxy group is a halogen atom, a hydroxyl group, a cyano group, a C3-8 cycloalkyl and 1 to 3 substituents selected from the group consisting of C3-8 cycloalkoxy groups (5) optionally substituted with 1 or 2 C16 alkyl groups (the C16 alkyl groups may be substituted with 1 or 3 halogen atoms); ! / , an amino group, (6) a carbamoyl group optionally substituted with 1 or 2 C16 alkyl groups (the C16 alkyl groups may be substituted with 1 to 3 halogen atoms); (7) a carboxyl group, (8) a pyridinyl group and (9) a sugar residue. Substituent Group A2 represents the following groups. (1) a halogen atom, (2) a hydroxyl group, (3) a cyano group, (4) a C3-8 cycloalkyl group, (5) a C3-8 cycloalkoxy group, (6) a C1-6 alkyl group (the C16 The alkyl group may be substituted with 1 to 3 substituents selected from the group consisting of halogen atoms, hydroxyl groups, cyano groups, C3-8 cycloalkyl groups, C16 alkoxy groups and C3-8 cycloalkoxy groups. ), (7) a C1-6 alkoxy group (the C1-6 alkoxy group is selected from the group consisting of a halogen atom, a hydroxyl group, a cyano group, a C3-8 cycloalkyl group and a C3-8 cycloalkoxy group1 (8) 1 or 2 C16 alkyl groups (the C16 alkyl groups may be substituted with 1 to 3 halogen atoms); and (9) 1 or 2 C16 alkyl groups (the C16 alkyl groups may be substituted with 1 or 3 halogen atoms! / ). / , strong lbamoyl group.

[0027] Here, "halogen atom" means fluorine atom, chlorine atom, bromine atom, iodine atom and the like, preferably fluorine atom, chlorine atom and bromine atom.

[0028] The term “C3-8 cycloalkyl group” refers to a cyclic alkyl group having 3 to 8 carbon atoms, and preferred groups in this group include, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclo A heptyl group, a cyclooctyl group, and the like can be mentioned.

[0029] The term "C3-8 cycloalkoxy group" refers to a cyclic alkyl group having 3 to 8 carbon atoms in which one hydrogen atom is substituted with an oxygen atom. A cyclobutoxy group, a cyclopentoxy group, a cyclohexoxy group, a cycloheptyloxy group, a cyclooctoxy group and the like can be mentioned.

[0030] The "C1-6 alkyl group" means the same groups as described above, and preferred groups include the same groups as those described above.

[0031] "C16 alkyl group (the C16 alkyl group is a halogen atom, hydroxyl group, cyano group, C 1 selected from the group consisting of a 3-8 cycloalkyl group, a C16 alkoxy group and a C3-8 cycloalkoxy group, and may be substituted with 3 substituents! / , examples include, for example, methyl group, trifluoromethyl group, hydroxymethyl group, cyanomethyl group, ethyl group, 2-hydroxyethyl group, n-propyl group, i-propyl group, 3-hydroxy-n-propyl group, tert-butyl group, n-pentyl group, i-pentyl group, neopentyl group, n-hexyl group, 1 methylpropyl group, 1, 2-dimethylpropyl group, 1-ethylpropyl group, 1-methyl-2-ethylpropyl group, 1 -ethyl 2-methylpropyl group, 1,1,2-trimethinolepropinole group, 1-methinoleph, thinole group, 2,2-dimethynoleth, thinole group, 2-ethylbutyl group, 2 methylpentyl group, 3 methyl A pentyl group and the like can be mentioned.

[0032] The term "C16 alkoxy group" refers to an alkyl group having 1 to 6 carbon atoms in which a hydrogen atom is substituted with an oxygen atom. Preferred groups include, for example, methoxy, ethoxy, n-propoxy, i-propoxy group, n-butoxy group, i-butoxy group, sec-butoxy group, tertiary-butoxy group, n-pentoxy group, i-pentoxy group, sec-pentoxy group, tertiary-pentoxy group, n-hexoxy group, i-hexoxy group , 1, 2-dimethynolepropoxy group, 2-methynolepropoxy group, 1-methynolepropoxy group, 2-methynolepropoxy group, 1-methynolepropoxy group, 2-methynolepropoxy group, 1, 1, 2-trimethynolepropoxy group, 1, 1 , 2—Trimethinolev. Butoxy group, 1,1-dimethynolebutoxy group, 2,2-dimethynolebutoxy group, 2-ethynolebutoxy group, 1,3 dimethylbutoxy group, 2 methylpentoxy group, 3 methylpentoxy group, hexyloxy group etc.

[0033] The "amino group optionally substituted with 1 or 2 C1-6 alkyl groups" means an amino group whose hydrogen atom may be substituted with 1 or 2 alkyl groups having 1 to 6 carbon atoms. , Preferred substituted amino groups include, for example, methylamino, dimethylamino, ethylamino, diethylamino, n-propylamino and di-n-propylamino groups.

[0034] "C16 alkyl group (the C16 alkyl group may be substituted with 1 to 3 halogen atoms)" means an alkyl group having 1 to 6 carbon atoms, the hydrogen atoms of which are 1 to 3 halogen atoms. An atom-substituted alkyl group is shown, and preferred examples of the substituted alkyl group include trifluoromethyl group and the like.

[0035] The term "a carbamoyl group optionally substituted with 1 or 2 CI-6 alkyl groups" means 1 or 2 alkyl groups having 1 to 6 carbon atoms, the hydrogen atom of which is optionally substituted with a carbamoyl group. Preferred groups of the substituted carbamoyl group representing a bamoyl group include, for example, a methyl carbamoyl group, a dimethylcarbamoyl group, an ethylcarbamoyl group, a diethylcarbamoyl group, an n-propyl carbamoyl group, a di-n-propyl carbamoyl group, and the like. can be mentioned.

[0036] "C16 alkoxy group (the C16 alkoxy group may be substituted with 1 to 5 halogen atoms)" means an alkoxy group having 1 to 6 carbon atoms, the hydrogen atom of which is 1 to 3 halogen atoms. represents a C16 alkoxy group which may be substituted with, and preferred examples of the substituted C16 alkoxy group include a trifluoromethoxy group and the like.

[0037] Sugar residues include monosaccharides such as glucose and fructose, disaccharides such as sucrose, trisaccharides, and oligosaccharides. , polysaccharides, etc.

[0038] The term "methylene group (the methylene group may be substituted with 1 or 2 C16 alkyl groups, halogen atoms or hydroxyl groups)" specifically illustrates, for example, the formula [Chemical 11] etc.

[0039] In formula (I), Y is CO—(O) — R Μ P (= 0) (OR ) Μ or n c a d 2 a “M _” when P ( = 0) (OH) -M— is defined as one proton removed from an organic or inorganic acid. 2 a a Examples of organic acids include acetic acid, trifluoroacetic acid, propionic acid, methanesulfonic acid, benzenesulfonic acid, toluenesulfonic acid, and trifluoromethanesulfonic acid. Examples include hydrochloric acid, sulfuric acid, phosphoric acid, hydrofluoric acid, hydrobromic acid, hydroiodic acid, and water. Specifically, "M-" includes, for example, chlorine ion, bromide ion, iodine ion, HS O_, HSO_, HPO_, OH— and so on.

[0040] In formula (I), "Μ +" when the Y force -Ρ (= 0) (―〇-) (- 0 "Μ +) is a positive ion, that is, a positively charged atom or group of atoms. Examples include sodium ion, potassium ion, and quaternary ammonium ion.

[0041] As used herein, the term "pharmacologically acceptable salt" refers to a compound of general formula (I) and a pharmacologically acceptable salt that serve as prophylactic or therapeutic agents for diseases caused by A / 3. It is not particularly limited as long as it is formed. Specifically, for example, hydrohalides (e.g., hydrofluoride, hydrochloride, hydrobromide, hydroiodide, etc.), inorganic acid salts (e.g., sulfate, nitrate, perchlorate, phosphate, carbonate, bicarbonate, etc.), organic carboxylate (e.g. acetate, oxalate, maleate, tartrate, fumarate, citrate, etc.), organic sulfone acid salts (e.g. methanesulfonate, trifluoromethanesulfonate, ethanesulfonate, benzenesulfonate, toluenesulfonate, camphorsulfonate, etc.), amino acid salts (e.g. aspartate, glutamate etc.), quaternary amine salts, alkali metal salts (eg, sodium salts, potassium salts, etc.), alkaline earth metal salts (eg, magnesium salts, calcium salts, etc.), and the like.

[0042] Next, the compounds of formula (I) of the present invention are described.

[0043] In the compound of formula (I), Compounds or pharmacologically acceptable salts in which R and R 1 are hydrogen atoms or C16 alkyl groups are preferred.

[0044] In the compound of formula (I), Compounds or pharmacologically acceptable salts in which X is a methoxy group or a fluorine atom are preferred.

[0045] In the compound of formula (I), Ύ-CO-(O)-R Μ (wherein R is a C16 alkyl group, which may be substituted with 1 to 5 identical or different substituents selected from Substituent Group A1, represents a 6- to 14-membered aromatic hydrocarbon ring group, a 5- to 14-membered aromatic heterocyclic group, a 6- to 14-membered non-aromatic hydrocarbon ring group, or a 5- to 14-membered non-aromatic heterocyclic group, and η is , represents 0 or 1, and Μ _ represents an anion), -P ( = 0) (OR ) Μ _ (wherein R is from the substituent group A2 to represents a C16 alkyl group which may be substituted with 1 to 3 identically or differently selected substituents, M— represents an anion), -P (= 0) (OH) Μ — (in the formula, Μ— represents an anion), -Ρ (= 0) (— Ο— ) (ΟΗ) or -Ρ (= 0) (— Ο— ) (— Ο— Μ + ) b (In the formula, M + represents a cation) or a pharmacologically acceptable salt. Mashigu Y force P ( = 0) (OR ) Μ _ (wherein R is the same selected from the substituent group A2 or d 2 a d represents a C16 alkyl group which may be substituted with 1 to 3 different substituents, M represents an anion), -P (= 0) (OH) Μ- (wherein, M— represents an anion), 2 aa ― P ( = 0) (― O― ) (OH) or ― P ( = 0) (― O― ) (― O― M + ) (where M + is a cation b b ion) or a pharmacologically acceptable salt is more preferred. Y is —P (= 0) (OH) Μ— (where Μ— represents an anion), -Ρ (= 0) (-0 2 aa ) (OH) or — P ( = 0) (— O— ) (— O— M + ) (where M + indicates a cation) b b Most preferred are compounds or pharmacologically acceptable salts.

[0046] In the compound of the formula (I), when Y is S CO—(O) —R Μ—, R is S, and 1 to 5 identical or different substituents selected from substituted ncac group A1 are Compounds or pharmacologically acceptable salts that are optionally substituted C16 alkyl groups are preferred. (1) a water ncac acid group, (2) an amino group optionally substituted with 1 or 2 CI6 alkyl groups (the CI6 alkyl group may be substituted with 1 to 3 halogen atoms) a C16 alkyl group optionally substituted with 1 to 5 substituents selected from the group consisting of (3) a carboxyl group, (4) a pyridinyl group and (5) a sugar chain residue, Or a pharmacologically acceptable salt is more preferable.

[0047] In the compound of formula (I), when Y force S - P ( = 0) (OR ) Μ -, R force substituent d 2 a d 1 to 3 identical or different substituents selected from group A2 A compound or a pharmacologically acceptable salt that is a C 16 alkyl group optionally substituted with In the compound of formula (I), when Y is -P (= 0) (OR) Μ—, R may be substituted with 1 to d2ad to 3 hydroxyl groups or CI6 alkyl groups, C1 Compounds or pharmacologically acceptable salts with 6 alkyl groups are more preferred.

[0048] In the compound of formula (I), A is preferably a compound represented by Formula (A-1) or Formula (A-2) or a pharmacologically acceptable salt.

[0049] In the compound of formula (A-1), R. 2 , R. 3 and R 4 is preferably a hydrogen atom or a CI-6 alkyl group, or a compound or a pharmacologically acceptable salt. In the compound of formula (A-1), X 1S C16 alkylene group (the C16 alkylene group may be substituted with 1 to 3 hydroxyl groups or a C16 alkyl group (the C16 alkyl group may be substituted with 1 or 3 hydroxyl groups! / ,) optionally substituted with) or a pharmacologically acceptable salt is preferred X , =CH— CH (OH)— R 7 (In the formula, R 7 represents a C1-6 alkyl group) or a pharmacologically acceptable salt.

[0050] In the compound of formula (A1), Ar force —X — Ar— (wherein Ar is a 14-membered aromatic hydrocarbon ring group substituted with 1 to 3 substituents selected from Substituent Group A2) or a 14-membered aromatic heterocyclic group, and X represents a single bond or an oxygen atom) or a pharmacologically acceptable salt is preferred. A compound or a pharmacologically acceptable salt that is a phenyl group or a pyridinyl group optionally substituted by a halogen atom with an Ar force of 1 to 3 is more preferred. A compound or a pharmacologically acceptable salt which is a phenyl group optionally substituted by a halogen atom of Ar 11 to 3 is most preferred.

[0051] In formula (A-2), R. 5 and R 6 is the same or different and is a group selected from the following Substituent Group A2, preferably a compound or a pharmacologically acceptable salt R. 5 and R 6 are the same or different and are preferably a hydrogen atom or a C16 alkyl group or a pharmaceutically acceptable salt.

[0052] In formula (A-2), Z and Z force are the same or different, 1 or 2 selected from Substituent Group A2 A compound or a pharmacologically acceptable salt that is an optionally substituted methylene group or vinylene group, an oxygen atom or an imino group optionally substituted by a C16 alkyl group or a C16 acyl group is preferred. Mashigu Z and Z force are the same or different, 1 or 2 selected from Substituent Group A2 1 2 A compound or a pharmacologically acceptable salt that is a methylene group or an oxygen atom that may be substituted with a substituent is more preferable. Z and Z Forces The same or different, 1 or 2 C1-6 alkyl groups or halogen 1 2 Compounds or pharmacologically acceptable salts which are a methylene group or an oxygen atom which may be substituted with a rhogen atom are most preferred.

[0053] In formula (A-2), optionally substituted with 1 to 3 substituents selected from Ar force substituent group A2, 6 2 However, compounds or pharmacologically acceptable salts that are 14-membered aromatic hydrocarbon ring groups or 5- to 14-membered aromatic heterocyclic groups are preferred. A compound or pharmacology that is a phenyl group substituted with a halogen atom of Ar 1 1 to 3 2 A scientifically acceptable salt is more preferred.

[0054] In formula (A-2), Compounds or pharmacologically acceptable salts in which p, q and r are the same or different and represent an integer of 0 to 2 are preferred. A compound in which p, q and r are 1, a compound in which p, q is 1 and r is 0, or a pharmacologically acceptable salt is more preferred.

[0055] In the present invention, preferred specific compounds of the compounds represented by formula (I) or pharmacologically acceptable salts include the following compounds. 1) 3- {4- {1- {[(S)- 1- (4-fluorophenyl)ethyl]- 2- oxopiperidine-(3E)-ylidenemethyl}- 2- methoxyphenyl}- 5-methyl- 1 - (phosphonooxymethyl) 3H-imidazolone 1ium trifluoroacetate, 2) 1-acetoxymethyl-3- {4-{l- [(S)-1 (4-fluorophenyl)ethyl]-2-oxopiperidine-(3E)-ylidenemethyl}-2-methoxyphenyl}- 5—methyl 3H—imidazole 1 um iodide, 3) 3-{4-{l-[(lR, 2R)- 2 hydroxy-1- (3, 4, 5-triphenyleophenyl)propyl] 2 foxopiperidine-(3E) ylidenemethyl} 2 methoxyphenyl} — 5-methyl-1-(phosphonooxymethyl) 3H-imidazole-1-ium trifluoroacetate, 4) 3-[2-phenyl-4-[(S)-4-[(1R, 2R)-2-hydroxy-1-(3,4,5-trifluorophenylene)propyl]-6-methyl-3-oxomorpholine-(2Z ) ylidenemethyl-phenyl]5-methyl-1-phosphonooxymethyl-3H-imidazole-1-im-triphenylacetate, 5) 3-{2-methoxy-4[(33,8&3)-5-oxo3-(3,4,5-trifluorophenyl)hexahydroindolizine-(6E)-ylidenemethyl]phenyl}-5- methyl-1-phosphonooxymethyl 3H-imidazolone-1-ium trifluoroacetate, 6) 3-{4-{(S)-4-[(S)-l-(2,6-difluoropyridin-3-yl)ethyl]6-methyl-3-oxomorpholine-(2Z)ylidene-methyl}2-methoxyphenyl}—5-methyl-1-phosphonooxymethyl-3H-imidazole-1-im chloride, 7) 3— {4- {[(3S, 8aS) 3-(4-chlorophenyl)-5-oxohexahydroindolizine-(6E) ylidenemethyl] 2 methoxyphenyl} 5 methyl-1 (phosphonooxymethyl) 3H— imidazole-1um trifluoroacetate, 8) 3-{4-{(S)-4-[(lR, 2R)-l-(3,4 difluorophenyl)-2-hydroxypropyl] 6-methyl-3 oxomorpholine-(2Z) ylidenemethyl}2 fluorophenyl}— 5-methyl-1-phosphonooxymethyl-3H-imidazole-1 um trifluoroacetate, 9) 3- {2 methoxy- 4- [(6S, 9aS)- 4 foxo 6- (3, 4, 5 trifluorophenyl) hexahydroquinolizine-(3E)-ylidenemethyl]phenyl}- 5- methyl-1-(phosphonooxymethyl)3H-imidazole-1-um trifluoroacetate, 10) 3-{2-methoxy-4-[(41^, 9&3)-6-oxo-4-(3,4,5-trifluorophenyl)hexahydropyrido[2,l-c][l,4]foxazine-(7E)-ylidenemethyl] phenyl}- 5-methyl- 1-phosphonooxymethyl- 3H-imidazole- 1-im refluoroacetate, 11) 3-{4-{(S)-4-[(lR, 2R)-2-hydroxy-1-(3,4,5-triphenyl-phenyl)propyl]-6-methyl-3-foxomorpholine-(2Z)ylidenemethyl} 2 methoxyphenyl]— 5 methyl 1— (phosphonooxymethyl) 3H imidazole 1 um triphenylacetate, 12) 3- {4 [(6S, 9aR)-6- (4-chloro-phenyl) 4 foxohexahydroquinolisine-(3E) ylidenemethyl] 2 methoxyphenyl} 5 methyl 1-phosphonofoxymethyl-3H-imidazole-1um trifluoroacetic acid salt, 13) 3- {2 methoxy-4- [(IS, 6R, 9aR)- 1 methyl 4-oxo 6- (3, 4 , 5-trifluorophenyl) tetrahydro [1, 4] oxazino [3, 4-c] [l.4] foxazine-(3Z)-ylidenemethyl]phenyl-5-methyl-1-phosphonooxymethyl-3H-imidazolone-1ium trifluoroacetate, 14) 3— {4— [(IS, 6R, 9aR)—6— (4-phenylphenyl)-1-methyl-4-oxotetrahydro[1, 4]oxazino[3, 4-c][ l, 4]oxazine-(3Z)-ylidenemethyl ]— 2 methoxyphenyl} - 5 methyl 1-phosphonooxymethyl-3H-imidazole 1 um trifluoroacetate, 15) 3- {2 methoxy-4- [(IS, 6S, 8aR)- 1 methyl 4 oxo 6- (3, 4 , 5-trifluorophenyl)tetrahydropyro[2, l-c][l, 4]foxazine-(3Z)-ylidenemethyl-phenyl] 5-methyl-1-phosphonooxymethyl-3H-imidazole-1-thium triphenylacetate , 16) 3-{4-[(lS, 6R, 9aR)-6-(3,4-difluorophenyl)-1-methyl-4-oxotetrahydro[1,4]oxazino[3,4-c][l, 4 ]foxazine-(3Z)-ylidene methyl]-2-methoxyphenyl}-5-methyl 1-phosphonomethyl-3H-imidazole-1ium trifluoroacetate and 17) 3-{4-[(6R, 9aR)-l, 1-dimethinole-4-xo-6- (3, 4, 5-trifluorophenyl)tetrahydro[1, 4]foxazino[3, 4-c] [l, 4]foxazine-(3Z)-ylidenemethyl]-2-methoxyphenyl}-5-methyl-1-phosphonooxymethyl-3H-imidazolone-1ium trifluoroacetate. In the present invention, preferred compounds represented by formula (I) include the following compounds. 1 ) monohydrogen phosphate 1 {4 [(E)- {1 [(1S)- 1 4 fluorophenyl)ethyl] - 2 oxopiperidine- 3 ylidene}methyl] 2 methoxyphenyl} - 4 methyl 1H-imidazo- Lou 3—thiomethyl, 2) Phosphate-hydrogen 1 {4-[ )-{1 [(11^, 21¾-2-hydroxy-1-(3,4,5-trifluorophenyl)propyl]-2-oxopiperidine-3ylidene}methyl ]-2-methoxyphenyl}4-methyl-1H-imidazo-3-thiomethyl, 3) monohydrogen phosphate 1 {2 fluoro 4 [(Z)- {(6S)- 4 [(1R, 2R) 2 hydroxy 1- (3, 4, 5-trifluorophenylene) propyl]- 6-methyl 3-oxomorpholine-2ylidene}methyl]phenyl}4-methyl-1H-imidazol-3thiomethyl, 4) monohydrogen phosphate 1 (2-methoxy-4 {(E)- [(3S, 8aS)-5-oxo-3- (3, 4, 5-trifluorophenyl) hexahydroindolizine 6(5H)- ylidene]methyl}phenyl) 4-methyl 1H imidazo-mono-3-thiomethyl, 5) monohydrogen phosphate 1 {4 [(Z)- {(6S)- 4 [(1S)- 1-(2, 6-difluoropyridine 3-yl) ethyl] 6 methyl 3 foxomorpholine 2 ylidene} methyl] 2 methoxyphenyl 2-methinole 4-methinole 1 H imidazole 3 iomethinole , 6) monohydrogen phosphate 1 (4 {(E)- [(3S, 8aS) 3-(4-chlorophenyl)-5-foxohexahydroinsolidine-6 ​​(5H)-ylidene]methyl}- 2 methoxyphenyl l) -4-methyl-1H-imidazo-3-iomethyl, 7) monohydrogen phosphate 1 {4 [(Z)- {(6S)- 4 [(1R, 2R)- 1-(3,4 difluorophenyl) 2 hydroxypropyl] 6 methyl 3 oxomorpholine-2 ylidene} methyl ] 2 fluorophenyl} - 4 methyl 1 H imidazo- 3 thiomethinole, 8) monohydrogen phosphate 1-(2-methoxy-4 {(E)-[(6S,9aS)4-oxo-6-(3,4,5-trifluorophenyl)hexahydro-2H-quinolizine-3(4H)-ylidene] phenyl) 4-methyl 1 H imidazo-phenyl 3-thiomethyl, 9) monohydrogen phosphate 1— (2 methoxy— 4— {(E)— [(4R, 9aS)—6 oxo—4— (3, 4, 5 trifluorophenyl) hexahydropyride [2, l-c][l , 4]foxazine 7(6H)-ylidene]methyl}phenyl) 4-methyl-1H imidazo-1-3-thiomethyl, 10) Phosphate-hydrogen 1 {4-[ )-{(63)-4 [(11^, 2 )-2-hydroxy-1-(3,4,5 trifluorophenylole)propyl]-6 methyl 3 oxomorpholine - 2- ylidene} methyl] 2 methoxyphenyl} - 4 methyl 1 H imidazo-methyl]- 3 methyl, 11) monohydrogen phosphate 1— (4— {(E)— [(6S, 9aR)—6— (4-chlorophenyl)—4 foxohexahydro-2H quinolizine-3(4H)—ylidene]methyl} — 2 methoxyphenyl) 4-methyl-1H-imidazo-3-thiomethyl, 12) monohydrogen phosphate 1-(2-methoxy-4 {(Z)- [(IS, 6R, 9aR)- 1-methylol-4-oxo-6- (3, 4, 5-trifluorophenyl)tetrahydro-1H-[ 1, 4]oxazino [3,4-c][l,4]oxazine 3(4H)-ylidene]methyl}phenyl)-4-methyl-1H-imidazo-3-thiomethyl, 13) Phosphate-hydrogen 1-(4-{)-[(13,6R,9aR)-6-(4-chlorophenyl)-1-methyl-4-oxotetrahydro-1H-[1,4]foxazino[3,4 — c][l, 4]oxazazine-3(4H)-ylidene]methyl} 2 methoxyphenyl) 4-methyl 1H imidazole-3-thiomethyl, 14) monohydrogen phosphate 1-(2-methoxy-4 {(Z)- [(IS, 6S, 8aR)- 1-methinolate-4-oxo-6- (3, 4, 5 trifluorophenyl) tetrahydro-1H-pyro [2,l-c][1,4]oxazine 3 (4H)—ylidene]methyl}phenyl) 4 methyl 1H imidazol-3-thiomethyl, 15) monohydrogen phosphate 1-(4 {(Z)-[(IS, 6R, 9aR)-6-(3, 4-difluorophenyl)-1-methyl-4-oxotetrahydro-1H-[1, 4]oxazino [3, 4-c][l, 4]oxazine 3(4H)-ylidene]methyl}-2-methoxyphenyl)-4-methyl-1H imidazo-nole 3-thiomethyl and 16) monohydrogen phosphate 1 4 {(Z)— [(6R, 9aR)-l, 1 dimethyl-4 oxo 6— (3, 4, 5-trifluorophenyl) tetrahydro- 1H—[1, 4] oxazino [ 3, 4—c] [1 , 4]oxazine 3 (4H)-ylidene]methyl}-2 methoxyphenyl)-4 methyl 1H-imidazole-3-thiomethyl.

[0057] The above is a preferred embodiment of the compound of general formula (I). , can be selected to the maximum extent included in the scope of the compounds of general formula (I).

[0058] The method for producing the compound of general formula (I) of the present invention is described below. general formula (I) [Chemical 12] 3 [In the formula, A, X, Y, R and R have the same meanings as above. ] are synthesized, for example, according to the following general production methods 1 and 2. It should be noted that suitable protecting groups known to those skilled in the art are conveniently used at each step in preparing the compounds of the present invention (e.g., T. Greene et al., "Protective Groups in Organic Synthesis," John Wiley & Sons. Inc., New York). , 1999) and appropriately include a protection reaction step and a deprotection step.

[0059] [General manufacturing method 1] A representative [general production method 1] of the compound of general formula (I) according to the present invention is described below. [Chemical 13] [Progress] (1) (2) (I) [Wherein, A, X, Y, R and R have the same meanings as above, L is a fluorine atom, a chlorine atom, a bromine atom, a halogen atom such as an iodine atom, a methanesulfonate group, a paratoluene Pr and Pr are hydroxyl-protecting groups (e.g., methyl, ethyl, alinyl, etc.). 1 2 alkyl groups such as benzyl group, triphenylethinole group, tertiarybutyl group, propionitrile group, trichloroethyl group and trimethylsilylethyl group; aryl groups such as phenyl group and quinolinyl group; A silyl group such as a dimethylsilyl group and a tertiarybutyldiphenylsilyl group. M— represents a halogen ayuone group such as a fluorine atom, a chlorine atom, a bromine atom and an iodine atom, and an organic acid anion group such as methanesulfonic acid and benzenesulfonic acid. ]

[0060] The above [General production method 1] follows [Step 1 1], condenses compound (1) and compound (2), and deprotects the resulting compound (3) in [step 1 2]. is an example of a method for producing a compound of general formula (I).

[0061] [Preparation of compound of general formula (I)] The compound of general formula (I) can be prepared by deprotecting compound (3) according to [Step 12]. That is, [Steps 1 and 2] are not particularly limited as long as the reaction-like conditions differ depending on the starting material, and known methods described in many documents can be used. For example, i) acid hydrolysis reaction, ii) base hydrolysis reaction, iii) hydrogenolysis reaction, iv) reductive decomposition reaction, V) photolysis reaction, vi) elimination reaction, etc. (for example, T. Greene , "Protective Groups in Organic ≥>synthesis" (John Wiley & Sons. Inc., New York, 1999, pp. 660-700).

[0062] In the case of i), for example, compound (3) is preferably stirred in a solvent in the presence of 1.0 to 100.0 equivalents of acid relative to compound (3). This reaction is targeted by Pr and Pr. A 1 2 syaributyl group is particularly preferred. The acid used in this reaction varies depending on the starting material and is not particularly limited, but is preferably, for example, an organic acid such as trifluoroacetic acid or methanesulfonic acid, or an inorganic acid such as hydrochloric acid, hydrobromic acid or sulfuric acid. , and Lewis acids such as boron trichloride, boron tribromide, and boron triiodide. The solvent to be used is not particularly limited as long as it dissolves the starting material and the acid to be used to some extent. Preferred examples include ethyl acetate, toluene, acetonitrile, THF, 1,4-dioxane, ethanol, methanol, Propanol, methylene chloride, chloroform, water, etc. or mixtures thereof be. In some cases, acids are used as solvents. The reaction temperature should be sufficient to complete the reaction without promoting the formation of undesirable by-products, and is preferably, for example, ice cold to 100°C. The reaction is complete in ~24 hours and the progress of the reaction can be monitored by known chromatographic techniques. Undesired by-products can be removed by techniques known to those skilled in the art such as conventional chromatographic techniques and / or crystallization.

[0063] In the case of ii), for example, compound (3) is preferably stirred in a solvent in the presence of 1.0 to 100.0 equivalents of a base relative to compound (3). The base used in this reaction varies depending on the starting material and is not particularly limited, but preferably includes, for example, sodium hydroxide, potassium hydroxide, lithium hydroxide, ammonia and the like. The solvent to be used is not particularly limited as long as it dissolves the starting material and the base to be used to some extent. is a mixture of The reaction temperature should be sufficient to complete the reaction without promoting the formation of unwanted by-products, and is preferably between room temperature and 150°C, for example. The reaction is complete in ~24 hours and the progress of the reaction can be monitored by known chromatographic techniques. Undesired by-products can be removed by techniques known to those skilled in the art such as conventional chromatographic techniques or / and crystallization.

[0064] In the case of iii), for example, compound (3) is preferably treated in the presence of a metal catalyst in an amount of 0.01 to 0.5 equivalents relative to compound (3) under a hydrogen atmosphere of normal pressure to 5 MPa or in the presence of a hydrogen donor A method of stirring in a solvent in the presence of The metal catalyst used in this reaction varies depending on the starting material and is not particularly limited, but preferred examples include palladium on carbon, rhodium on carbon, ruthenium on carbon, palladium hydroxide and platinum oxide. The hydrogen donor varies depending on the starting material and is not particularly limited, but is preferably, for example, formic acid, ammonium formate, 1,4-cyclohexahexadiene and the like. The solvent to be used varies depending on the starting material and the metal catalyst to be used, and is not particularly limited, but is preferably, for example, ethyl acetate, chloroform, methylene chloride, toluene, THF, dioxane, ethanol, methanol, propanol, water. etc. or mixtures thereof. The reaction temperature should be sufficient to complete the reaction without promoting the formation of undesirable by-products, and is preferably, for example, room temperature to 100°C. This reaction is complete in ;!~ 24 hours However, the progress of the reaction can be monitored by known chromatographic techniques. Undesired by-products can be removed by conventional chromatographic techniques or / and techniques known to those skilled in the art, such as crystallization.

[0065] In the case of iv), for example, compound (3) is preferably stirred in a solvent in the presence of 1.0 to 10.0 equivalents of a metal reagent relative to compound (3). The reaction is Pr and Pr 1 2 is particularly preferred when it is a trichloroethyl group. The metal reagent used in this reaction varies depending on the starting material and is not particularly limited, but is preferably, for example, sodium, zinc, copper, iron, mercury, etc., or a mixed complex thereof. The solvent to be used varies depending on the starting material and the metal reagent to be used, and is not particularly limited. Preferred examples include DMF, THF, 1,4 dioxane, acetonitrile, liquid ammonia, etc., or mixtures thereof. . The reaction temperature should preferably be such that it is sufficient to complete the reaction without promoting the formation of by-products, preferably from 78 to 100°C, for example. The reaction is complete in 1-24 hours and the progress of the reaction can be monitored by known chromatographic techniques. Undesired by-products can be removed by techniques known to those skilled in the art, such as conventional chromatographic techniques or / and crystallization.

[0066] In the case of V), for example, compound (3) is preferably stirred in a solvent under irradiation with light. The light source used in this reaction varies depending on the starting material and is not particularly limited, but is preferably an ultraviolet light source such as a mercury lamp. The solvent to be used varies depending on the starting material and is not particularly limited, but preferably includes, for example, toluene, ethanol, methanol, propanol, etc., or mixtures thereof. In order to allow the reaction to proceed efficiently, for example, 1.0 to 100.0 equivalents of a base such as pyridine may preferably be added to compound (3). The reaction temperature should preferably be such that it is sufficient to complete the reaction without promoting the formation of by-products, preferably, for example, from 78 to 100°C. The reaction is complete in ~24 hours and the progress of the reaction can be monitored by known chromatographic techniques. Undesired by-products can be removed by techniques known to those skilled in the art, such as conventional chromatographic techniques and / or crystallization.

[0067] In the case of vi), for example, compound (3) is preferably stirred in a solvent in the presence of 1.0 to 10.0 equivalents of a releasing agent relative to compound (3). Elimination used in this reaction The agent varies depending on the starting material and is not particularly limited, but is preferably a base such as triethylamine, diisopropylethylamine, or lutidine (in this case, Pr and Pr are propionitrile groups Especially preferred.), tetrabutylammonium funoreolite 2 Fluorine anionic reagents such as di, pyridinium fluoride, and hydrofluoric acid (where Pr and Pr are trimethylsilylethyl, tertiarybutyldimethylsilyl, tertiarybutyldimethylsilyl, 1 2 A yaributyldiphenylsilyl group is particularly preferred. ), halogenanion groups such as trimethylsilane iodide, trimethylsilane bromide, sodium iodide and potassium iodide (in this case, methyl group, ethyl group, benzyl group and phenyl group are particularly preferred), and the like. The solvent to be used varies depending on the starting material and is not particularly limited. Preferred examples include tetrahydrofuran, dimethylformamide, 1,4-dioxane, methylene chloride, chloroform, acetonitrile, toluene, ethanol, and methanol. , propanol, ethyl acetate, water, etc., or mixtures thereof. The reaction temperature should be a temperature sufficient to drive the reaction to completion without promoting the formation of unwanted by-products, preferably from -78 to 100°C, for example. The reaction is complete in ~24 hours and the progress of the reaction can be monitored by known chromatographic techniques. Undesired by-products can be removed by techniques known to those skilled in the art such as conventional chromatographic techniques or / and crystallization. The compound obtained by the above method can be converted to the compound of general formula (I) having the desired anion M- by ion exchange, if necessary. The ion exchange is preferably carried out, for example, by using an anionic ion exchange resin, or by using an organic acid (preferably, for example, acetic acid, trifluoroacetic acid, benzenesulfonic acid, methanesulfonic acid, citric acid, maleic acid, etc.) or It can be carried out by treatment with an inorganic acid (preferably, for example, hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, nitric acid, phosphoric acid, etc.). Alternatively, the compound obtained by the above method is treated with reversed-phase chromatography (preferably, the carrier used is, for example, C18 silica gel, etc.) to obtain a bipolar ion type compound of general formula (I). It can also lead to compounds. In addition, the amphoteric ion type compound of general formula (I), for example, an alkali metal salt (preferably, for example, sodium hydroxide, potassium hydroxide, lithium hydroxide, etc.) or an alkaline earth salt (preferably is treated with, for example, calcium hydroxide, magnesium hydroxide, magnesium oxide, calcium oxide, magnesium chloride, calcium chloride, etc.). can lead to compounds of general formula (I) with the desired cation M + . b

[0069] [Preparation of compound (3)] Compound (3) can be prepared by condensing compound (1) and compound (2) according to [Step 11]. That is, [Step 1-1] varies depending on the starting materials, but is not particularly limited as long as the conditions are similar to those of this reaction, and known methods described in many documents can be used (for example, See "The Chemical Society of Japan, Experimental Chemistry Course (Volume 20) Organic Synthesis [II]", Maruzen Co., Ltd., July 1992, pp. 284-288). Preferably, for example, compound (1) is treated with 1.0-5.0 equivalents of compound ( 2) is stirred in a solvent. The base used in this reaction varies depending on the starting material and is not particularly limited, but is preferably, for example, diisopropylethylamine, triethylamine, pyridine, lutidine, Organic amines such as 0]undecene, alkali metal hydrides such as sodium hydride and lithium hydride, alkali metal salts such as sodium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate and cesium carbonate, and alkaline earths metal hydroxides, etc. The solvent to be used is not particularly limited as long as it dissolves the starting material and the base to be used to some extent. Preferred examples include dimethoxyethane, 1,4-dioxane, tetrahydrofuran, dimethylformamide, dimethylsulfoxide, acetone, methyl ethyl ketone, acetonitrile, methylene chloride, chloroform, ethanol, methanol, propanol, water, etc., or mixtures thereof. Depending on the case, the reaction may be carried out without solvent or with no added base. The reaction temperature is preferred, and should be sufficient to complete the reaction without promoting the formation of by-products, preferably between ice-cold and 100°C, for example. The reaction is complete in ~24 hours and the progress of the reaction can be monitored by known chromatographic techniques. Undesired by-products can be removed by techniques known to those skilled in the art, such as conventional chromatographic techniques or / and crystallization.

[0070] [Preparation of compound (1)] Compound (1) can be produced by the known method described in International Publication No. WO2005 / 115990 pamphlet, the methods of Reference Examples 1 to 6 below, or methods equivalent thereto.

[0071] [Reference example 1] [Chemical 14] [In the formula, R. 2 , R, R 4 , X (when said X contains a hydroxyl group, it may have a protecting group), X, X and Ar have the same meanings as above. ] 2 I

[0072] In the above [Reference Example I], aldehyde compound (5) and 0 3-3.0 equivalents of amide compound (6a) relative to aldehyde compound (5) are subjected to aldol reaction in [Step 3 I] to obtain aldol This is an example of a method of producing compound (I) by dehydration reaction after conversion to adduct (7a).

[0073] [Conversion from aldol adduct (7a) to compound (I)] Compound (I) can be converted from aldol adduct (7a) by the dehydration reaction of [Step 3-2]. That is, the dehydration reaction in [Step 3-2] is not particularly limited as long as the reaction-like conditions differ depending on the starting materials, and known methods described in many documents can be used. (For example, "Experimental Chemistry Lectures edited by The Chemical Society of Japan (Vol. 19) Organic Synthesis [1]", Maruzen Co., Ltd., June 1992, p. 194-226). Preferably, i) a method of treating the caro isomer (7a) with an acid with an acid (for example, "The Chemical Society of Japan, Experimental Chemistry Course (Volume 19) Organic Synthesis [I]", Maruzen Co., Ltd., 1992 194-196, June 2009), ii) after converting the alcohol group of the aldol adduct (7a) into a sulfonate group, a carboxylate group, or a leaving group such as a halogen atom, it is treated with a base. (for example, described in "The Chemical Society of Japan, Experimental Chemistry Course (Volume 19), Organic Synthesis [1]", Maruzen Co., Ltd., June 1992, p. 198-205).

[0074] In the case of i), the acid, solvent and temperature conditions to be used are not particularly limited depending on the starting materials, but 0.1-10 equivalents of hydrochloric acid, sulfuric acid and phosphoric acid are used with respect to the aldol adduct (7a). , potassium hydrogen sulfide, oxalic acid, p-toluenesulfonic acid, trifluoroboric acid ether complex, thionyl chloride, alumina oxide, and the like are used. Although the reaction may be carried out without a solvent, a solvent or a mixture thereof that dissolves the starting materials to some extent without inhibiting the reaction is used as the solvent. Preferably, water, acetone, dimethylsulfoxide, hexamethylphosphoroamide and the like are used. In some cases, a combination of 0.1 to 10 equivalents of an acid with respect to the aldol adduct (7a) and an organic base such as pyridine may improve the reaction rate and reaction yield. The reaction temperature should be sufficient to complete the reaction without promoting the formation of undesired by-products, preferably between room temperature and 200°C. Under preferred reaction conditions, the reaction is preferably complete, eg, in 0.5 to 24 hours, and the progress of the reaction can be monitored by known chromatographic techniques. Undesired by-products can be removed by techniques known to those skilled in the art such as conventional chromatographic techniques, extraction procedures or / and crystallization.

[0075] In the case of ii), the leaving group preferably includes, for example, an acetyl group, a methanesulfonate group, a p-toluenesulfonate group, a chlorine atom, a bromine atom, an iodine atom and the like. The technique for conversion to these leaving groups is not particularly limited depending on the starting materials, and methods known to those skilled in the art can be used. Halogen solvents such as methylene chloride and chloroform, nonpolar solvents such as toluene and benzene, ether solvents such as tetrahydrofuran and ethylene glycol dimethyl ether, and mixed solvents thereof can be preferably used. , for example, 1.0 to 10.0 equivalents of acetyl chloride relative to the aldol adduct (7a), an acetylating agent such as acetic anhydride, a sulfonic acid esterifying agent such as methanesulfonyl chloride or p-toluenesulfonyl chloride Alternatively, 1.0 to 10 equivalents of a halogenating agent such as thionyl chloride can be used with respect to the aldol adduct (7a). The reaction temperature should be sufficient to complete the reaction without promoting the formation of unwanted by-products, preferably -78 to 100°C, for example. Under preferred reaction conditions, the reaction is preferably complete, eg, in 1 to 24 hours, and the progress of the reaction can be monitored by known chromatographic techniques. unwanted side effects Components can be removed by techniques known to those skilled in the art such as conventional chromatographic techniques, extraction procedures or / and crystallization. The second step, the elimination reaction, is preferably carried out using, for example, a halogen solvent such as methylene chloride, a nonpolar solvent such as toluene, a polar solvent such as acetonitrile, dimethylformamide, or dimethylsulfoxide, tetrahydrofuran, or ethylene glycol. In an ether solvent such as dimethyl ether or a mixed solvent thereof, preferably as a base, for example, diazabicycloundecene, pyridine, 4-dimethylamino Organic bases such as pyridine and triethylamine, quaternary ammonium salts such as tetrabutylammonium hydroxide, alkali metal salts of alcohols such as sodium methoxide and potassium tertiary butoxide, alkali metal hydroxides such as sodium hydroxide, carbonate It is preferable to use an alkali metal carbonate such as lithium or potassium carbonate or an organic metal reagent such as lithium diisopropylamide. It is also possible to use an organic base such as pyridine as a solvent. The reaction temperature should be sufficient to drive the reaction to completion without promoting the formation of undesirable by-products, preferably from -78 to 100°C, for example. Under preferred reaction conditions, the reaction is preferably complete, eg, in 1 to 24 hours, and the progress of the reaction can be monitored by known chromatographic techniques. Undesired by-products can be removed by techniques known to those skilled in the art such as conventional chromatographic techniques, extraction procedures or / and crystallization. [Preparation of aldol adduct (7a)] Aldol adduct (7a) can be prepared, for example, from aldehyde compound (5) and amide compound (6a) according to [Procedure 3-1]. That is, the aldol reaction in [Step 3-1] varies depending on the starting materials, but is not particularly limited as long as it is the conditions for this reaction, and methods known to those skilled in the art can be used (for example, "The Chemical Society of Japan Ed. Experimental Chemistry Course (Vol. 20) Organic Synthesis

[0011] ", Maruzen Co., Ltd., July 1992, pp. 94-100). Preferably, for example, i) amide compound (6a) is alkaline with a base such as lithium diisopropylamide, sodium hydride or sodium methoxide in an amount of 1 0-5 0 equivalents relative to amide compound (6a). A method of reacting a metal enolate with an aldehyde compound (5) (e.g., “The Chemical Society of Japan, Experimental Chemistry Course (Volume 20) Organic Synthesis

[0011] ”, Maruzen Co., Ltd., July 1992, p. 97 — 98), ii) amide compound (6a) at 1.0-5.0 equivalents relative to amide compound (6a) to an alkali metal enolate, preferably with a silicon halide reagent such as trimethylchlorosilane or tertiarybutyldimethylchlorosilane, once with a silyl enol ether. After that, preferably, a method of reacting with an aldehyde compound (5) in the presence of a Lewis acid such as titanium tetrachloride or boron trifluoride (for example, "Experimental Chemistry Lectures edited by the Chemical Society of Japan (No. 20 Vol.) Organic Synthesis

[0011] ”, Maruzen Co., Ltd., July 1992, ρ 96-97). The solvent and reaction temperature to be used vary depending on the starting materials and are not particularly limited. However, a solvent or a mixed solvent thereof that dissolves the starting materials to some extent without inhibiting the reaction is preferably used, for example, tetrahydrofuran, 1,4-dioxane. Alternatively, an ether solvent such as diethyl ether, a halogen solvent such as methylene chloride, 1,2-dichloroethane or chloroform, or a nonpolar solvent such as toluene or xylene can be used. The reaction temperature should be sufficient to complete the reaction without promoting the formation of unwanted by-products, and is preferably, for example, 78°C to room temperature. Under preferred reaction conditions, the reaction is preferably complete, eg, in 0.5 to 24 hours, and the progress of the reaction can be monitored by known chromatographic techniques. Undesired by-products can be removed by techniques known to those skilled in the art such as conventional chromatographic techniques, extraction procedures or / and crystallization.

[0077] [Preparation of aldehyde compound (5)] Aldehyde compound (5) can be prepared by a known method described in International Publication No. WO2005 / 115990.

[0078] [Preparation of amide compound (6a)] [Chemical 15] ] (8b) [In the formula, L , R. 2 , R. 3 , R. 4 , (when the ^ contains a hydroxyl group, it may have a protecting group), X or Ar has the same meaning as above, R 5 ° is a hydroxyl group which may have a protecting group of I to 3 2 I Indicates an optionally substituted CI-6 alkyl group. ]

[0079] The above reaction formula shows an example of the method for preparing the amide compound (6a). That is, (i) starting from amine compound (8a), which is commercially available or prepared by a method known to those skilled in the art, is converted to compound (8c) according to [Step 4I], and then [ (ii) if the substituents of X contain at least one hydrogen atom, commercially available forces or methods known to those skilled in the art. XR2 (1) (8b) as a starting material is converted to compound (8c) according to [Step 43], and then constructed to form an oxomorpholine ring in [Step 42].

[0080] [Conversion of compound (8c) to amide compound (6a)] [Step 42] is not particularly limited as long as the reaction conditions vary depending on the starting material, and can be carried out by a method known to those skilled in the art. Preferably, for example, compound (8c) and compound (8f) in an amount of I.0-10 equivalents relative to compound (8c) are vigorously stirred in a two-phase reaction solvent of an organic solvent and a basic aqueous solution. The reaction proceeds well. The solvent and reaction temperature to be used vary depending on the starting material and are not particularly limited, but a solvent that dissolves the starting material to some extent without inhibiting the reaction is preferred. Examples include ether solvents such as diethyl ether, A halogen-based solvent such as methylene chloride, 1,2-dichloroethane or chloroform, or a non-polar solvent such as toluene or xylene can be used. As the basic aqueous solution, preferably, for example, sodium hydroxide, lithium hydroxide Aqueous solutions of alkaline metal salts such as aluminum, sodium carbonate, potassium carbonate, cesium carbonate or sodium bicarbonate can be used. The reaction temperature should be sufficient to drive the reaction to completion without promoting the formation of undesired by-products, preferably e.g. — 78°C to room temperature. Under preferred reaction conditions, the reaction is preferably complete, eg, in 0.5 to 24 hours, and the progress of the reaction can be monitored by known chromatographic techniques. Undesired by-products can be removed by techniques known to those skilled in the art such as conventional chromatographic techniques, extraction procedures or / and crystallization.

[0081] Further, preferably, for example, compound (8c) and compound (8f) in an amount of 1.0 to 10 equivalents relative to compound (8c) are mixed under basic conditions, whereby the reaction may proceed conveniently. . The solvent and reaction temperature to be used vary depending on the starting material and are not particularly limited, but a solvent that dissolves the starting material to some extent without inhibiting the reaction is preferred. Examples include diethyl ether, tetrahydrofuran, and the like. Ether solvents, halogen solvents such as methylene chloride, 1,2-dichloroethane or chloroform, or nonpolar solvents such as toluene or xylene can be used. The base used varies depending on the starting material and is not particularly limited, but is preferably 1.0 to 10 equivalents relative to compound (8c). For example, sodium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate, Alkali metal salts such as cesium carbonate or sodium bicarbonate, organic bases such as diazabicycloundecene, pyridine, 4-dimethylaminopyridine, and triethylamine can be used. The reaction temperature should be sufficient to drive the reaction to completion without promoting the formation of unwanted by-products, preferably from -78°C to room temperature, for example. Under preferred reaction conditions, the reaction is preferably complete, eg, in 0.5 to 24 hours, and the progress of the reaction can be monitored by known chromatographic techniques. Undesired by-products can be removed by techniques known to those skilled in the art such as conventional chromatographic techniques, extraction procedures or / and crystallization. 〇

[0082] [Preparation of compound (8f)] Compound (8f) can be prepared using commercially available resources or methods known to those skilled in the art. Compound (8f) preferably includes, for example, chloroacetyl chloride, bromoacetyl bromide, and the like.

[0083] [Preparation of compound (8c)] Compound (8c) is commercially available or can be prepared by methods known to those skilled in the art. Preferably, for example, (i) starting with amine compound (8a), which is commercially available or prepared using methods known to those skilled in the art, according to [Step 41], or (ii) It can be prepared according to [Step 4-3] starting from compound (8b) which is commercially available or prepared by a method known to those skilled in the art.

[0084] [Conversion from compound (8a) to compound (8c)] [Step 41] is not particularly limited as long as the reaction-like conditions vary depending on the starting material, and include methods known to those skilled in the art. Preferred is, for example, a ring-opening reaction using compound (8a) and 1·0-10 equivalents of xylan compound (8d) relative to compound (8a). The solvent and reaction temperature to be used vary depending on the starting material and are not particularly limited, but a solvent that dissolves the starting material to some extent without inhibiting the reaction or a mixed solvent thereof is preferable. For example, an ether solvent such as diethyl ether. Alternatively, a halogen-based solvent, a halogen-based solvent such as methylene chloride, 1,2-dichloroethane or chloroform, or a non-polar solvent such as toluene or xylene can be used. Alternatively, good results may be obtained even without solvent. The reaction temperature is preferred / should be sufficient to complete the reaction without promoting the formation of by-products, preferably between room temperature and 300°C, for example. Under preferred reaction conditions, the reaction is preferably complete, eg, in 0.5 to 24 hours, and the progress of the reaction can be monitored by known chromatographic techniques. Undesired by-products can be removed by techniques known to those skilled in the art such as conventional chromatographic techniques, extraction procedures or / and crystallization. Alternatively, preferably, for example, addition of a Lewis acid such as boron trifluoride, titanium tetraisopropoxide, lithium perchlorate, etc. may favorably progress the reaction stress (for example, Synthesis, 2004, Vol. 10, pl 563—see 1565).

[0085] [Preparation of compound (8a)] It is commercially available or can be prepared using methods known to those skilled in the art. If it is not commercially available, for example, methods known to those skilled in the art described in literature (for example, "New Experimental Chemistry Course edited by the Chemical Society of Japan (Volume 14) Synthesis and reaction of organic compounds

[0111] ", Maruzen Co., Ltd. , February 1978, p. 1332-1399). Preferably, for example i) conversion of the corresponding carbonyl derivative to compound (8a) in a reductive amination reaction, or ii) reduction of the corresponding carbonyl derivative to an alcohol derivative followed by substitution known to those skilled in the art. reaction via an amine equivalent (preferably e.g. an azide group, an imide group, etc.) to prepare compound (8a) by transformation reactions known to those skilled in the art, or iii) conversion of the corresponding carbonyl derivative to an oxime derivative. or iv) conversion of the corresponding forein compound to an alcohol derivative by oxidation reaction followed by substitution reaction known to those skilled in the art to give an amine equivalent ( V) converting the corresponding forephine compound into an aminoalcohol derivative through an addition reaction, Techniques for preparing compound (8a) by transformation reactions known to those skilled in the art can be mentioned. Compound (8a) is commercially available as an optically active compound, or prepared as an optically active compound by a method known to those skilled in the art (for example, Chem. Rev, 1994, vol.94, p2483-2547, Tetrahedron Letters, 1996, 37, p3219-3222, Organic Letters, 2000, 2, p2821-2824), and by using this raw material as a starting raw material, the optically active compound of the present invention can be obtained. Compounds can also be prepared.

[0086] [Preparation of Oxirane compound (8d)] It is commercially available or can be prepared using methods known to those skilled in the art. If it is not commercially available, for example, a method known to those skilled in the art described in literature (for example, "New Experimental Chemistry Course edited by the Chemical Society of Japan (Volume 14) Synthesis and reaction of organic compounds [I]", Maruzen Co., Ltd. , November 1977, pp. 567-611)). Compound (8d) is commercially available as an optically active substance, or prepared as an optically active substance by a method known to those skilled in the art (for example, K. B. ≥>harpless "Comprehensive Organic Synthesis, B. M. Trost, Pergamon, 1991, Vol. 7, Chapter 3-2) can be used, and the compound of the present invention can also be prepared as an optically active compound by using this raw material as a starting material.

[0087] [Conversion from compound (8b) to compound (8c)] [Step 43] is not particularly limited as long as the reaction conditions vary depending on the starting material, and include methods known to those skilled in the art. Preferably, for example, compound (8b) and carbon dioxide reductive amination reaction of compound (8e). , pp. 1380–1384). For example, carbonyl compound (8e) and 0.5-5.0 equivalents of compound (8b) relative to carbonyl compound (8e), more preferably typical inorganic acids such as hydrochloric acid or sulfuric acid, methane Organic acids such as sulfonic acid, p-toluenesulfonic acid or camphorsulfonic acid, or acid catalysts such as organic acid salts such as pyridinium or p-toluenesulfonate (preferably, for example, 0.01-0 for carbonyl compound (8e) 5 equivalents), the imine derivative obtained by the dehydration reaction by heating under reflux is preferably added, for example, with 1.0 to 10 equivalents of a metal such as lithium aluminum hydride or sodium borohydride relative to the imine derivative. A preferred technique is hydride reduction to give the desired amine derivative. or preferably after treatment in an inert solvent such as tetrahydrofuran in the presence of a Lewis acid catalyst such as titanium tetraisopropoxide (preferably 0.01-0.5 equivalents relative to the carbonyl compound (8e)) , can be reduced with a metal hydride such as sodium borohydride at 1.0-10 equivalents relative to the carbonyl compound (8e). Alternatively, the carbonyl derivative (8e) is preferably combined with, for example, 0.5 - 5.0 equivalents of the compound (8b) relative to the carbonyl compound (8e), preferably, for example, dichloromethane, 1,2-dichloromethane In an inert solvent such as chloroethane, tetrahydrofuran, methanol or ethanol, preferably, for example, 1.0-10 equivalents of sodium triacetoxyborohydride or cyanoborohydride relative to the carbonyl compound (8e) Reduction with sodium metal hydride to give the desired amine derivative is also preferred. For convenient reaction, an acidic substance such as 1.0 to 10 equivalents of acetic acid or hydrochloric acid can be added to the carbonyl compound (8e). The reaction temperature varies depending on the starting material and is not particularly limited, but is preferably a temperature sufficient to complete the reaction without promoting the formation of by-products. is, for example, room temperature to 100 degrees. Under preferred reaction conditions, the reaction is preferably complete, eg, in 0.5 to 24 hours, and the progress of the reaction can be monitored by known chromatographic techniques. Desirable by-products can be removed by techniques known to those skilled in the art such as conventional chromatographic techniques, extraction procedures or / and crystallization.

[0088] [Preparation of compound (8b)] It is commercially available or can be prepared using methods known to those skilled in the art. If it is not commercially available, for example, methods known to those skilled in the art described in literature (for example, "New Experimental Chemistry Course edited by the Chemical Society of Japan (Volume 14) Synthesis and reaction of organic compounds

[0111] ", Maruzen Co., Ltd. , February 1978, pp. 1332-1399)). Compound (5b) is commercially available as an optically active substance, or prepared as an optically active substance by a method known to those skilled in the art (for example, Tetrahedron Letters, 1996, 37, p3219-3222). ) can be used, and the compound of the present invention can be prepared as an optically active compound by using the present raw material as a starting material.

[0089] [Preparation of carbonyl compound (8e)] It is commercially available or can be prepared using methods known to those skilled in the art. If it is not commercially available, for example, methods known to those skilled in the art described in literature (for example, "New Experimental Chemistry Course edited by the Chemical Society of Japan (Volume 14) Synthesis and reaction of organic compounds

[0011] ", Maruzen Co., Ltd. , December 1977, p. 633-875).

[0090] [Reference example 2] [Chemical 16] [In the formula, A , R. 2 , R. 3 , R. 4 , X, X 2 has the same meaning as above, is a triphenylphosphonium group, a phosphite ester group or a silyl group, V is a methyl group, ethyl group, benzyl group, farinole group, triphenylolemethinole group, tertiary butyl group or Tertiary Indicates a carboxyl-protecting group such as a butyldimethylsilyl group. ]

[0091] The above [Reference Example 2] is a method of subjecting aldehyde compound (5) and amide compound (9b) to the condensation reaction of [Step 5-1] to prepare compound (1), or a method of preparing compound (1), or Ester compound (9a) is subjected to the condensation reaction in [Step 5-1] to give compound (10), and to reaction with amine compound (8a) in [Step 5-2] to give compound (1 ) is an example of a method for preparing.

[0092] [Step 5— 1 ] The condensation reaction in [Step 5-1] varies depending on the starting materials, but is not particularly limited as long as the conditions are similar to those of this reaction, and known techniques described in many documents can be used. , Wittig reaction, Horner-Emmons reaction, or Peterson reaction (for example, ``The Chemical Society of Japan, Experimental Chemistry Lecture (Vol. 19) Organic Synthesis [1]'', Maruzen Co., Ltd., June 1992, p. 57— 85) is preferable.

[0093] The Wittig reaction is preferably, for example, compound (9b) or (9a) (wherein L is rifenylphosphonium halide salt) and 0 8 - 1.5 equivalents of aldehyde compound (5) relative to compound (9b) or (9a) to compound (9b) or (9a). Stir in a solvent in the presence of 1.0 - 5.0 equivalents of a base. In this reaction, i) a method of first treating compound (9b) or (9a) with a base to form a phosphorus ylide and then adding aldehyde (5), ii) compound (9b) or (9a) and There is a method of adding a base in the presence of the aldehyde compound (5). This reaction is preferably carried out in the presence of a solvent from the viewpoint of operability and stirring efficiency. polar solvents such as nitromethane, acetonitrile, 1-methyl-2-pyrrolidone, N,N-dimethylformamide, dimethylsulfoxide, tetrahydrofuran, 1,4 dioxane, 1 Ether solvents such as 2-dimethoxyethane, non-polar solvents such as benzene, toluene, and xylene, alcohol solvents such as ethanol and methanol, halogen solvents such as chloroform and dichloromethane, water, etc. or mixed solvents etc. The base to be used has a strength S that varies depending on the starting material and solvent, and is preferably alkaline metal hydroxides such as sodium hydroxide, potassium hydroxide, lithium hydroxide, sodium carbonate, sodium carbonate, sodium hydrogen carbonate, and the like. alkali metal carbonate, sodium methoxide, potassium tertiary butoxide and other alcohol alkali metal salts; triethylamine, pyridine, diazabicyclononene and other organic bases; Examples include alkali metal hydrides such as sodium hydride. The reaction temperature should be sufficient to complete the reaction without promoting the formation of unwanted by-products, preferably between 78 and 150°C. Under preferred reaction conditions, the reaction is complete in 1 to 24 hours and the progress of the reaction can be monitored by known chromatographic techniques. Desirable by-products can be removed by techniques known to those skilled in the art such as conventional chromatographic techniques, extraction procedures or / and crystallization. The Horner-Emmons reaction is preferably carried out, for example, with compound (9b) or (9a) (wherein L is a phosphite ester) and compound (9b) or (9a) with 0.8-1 5 3 Amount of aldehyde compound (1) is stirred in a solvent in the presence of 1.0 to 5.0 equivalents of base relative to compound (9b) or (9a). In this reaction, i) compound (9b) or (9a) and a base are first There is a method of adding aldehyde compound (5) after treatment to form carbanion, and ii) a method of adding a base in the presence of compound (9b) or (9a) and aldehyde compound (5). From the viewpoint of operability and stirring efficiency, this reaction is preferably carried out in the presence of a solvent. Although it is not particularly limited as long as it can , nonpolar solvents such as benzene, toluene and xylene, alcoholic solvents such as ethanol and methanol, water, and mixed solvents thereof can be used. The base used varies depending on the starting material and solvent. Preferably, alkali metal hydroxides such as sodium hydroxide, potassium hydroxide and lithium hydroxide, alkalis such as sodium carbonate, thorium carbonate and sodium hydrogen carbonate are used. Metal carbonates, alkali metal salts of alcohols such as sodium methoxide and potassium tert-butoxide, organic bases such as triethylamine, pyridine and jazabicyclononene, organic metals such as butyllithium and lithium diisobutylamide, and hydrogen such as sodium hydride. and alkali metal ammonium salts such as sodium amide and the like. The reaction temperature should be sufficient to complete the reaction without promoting the formation of unwanted by-products, preferably between 78 and 150°C. Under preferred reaction conditions, the reaction is preferably complete, eg, in 1 to 24 hours, and the progress of the reaction can be monitored by known chromatographic techniques. Undesired by-products can be removed by techniques known to those skilled in the art such as conventional chromatographic techniques, extraction procedures or / and crystallization. The Peterson reaction is preferably performed, for example, on compounds (9b) or (9a) (wherein L 3 is a silyl group) and 0.8 - 1.5 equivalents of aldehyde compound (1) with respect to compound (9b) or (9a), and 1.0 equivalent with respect to compound (9b) or (9a). - 5. Stir in solvent in the presence of 0 equivalent of base. In this reaction, i) a method of first treating compound (9b) or (9a) with a base to form a carbanion and then adding aldehyde compound (5), ii) a method of adding compound (9b) or (9a) and aldehyde There is a method of adding a base in the presence of compound (5). From the viewpoint of operability and stirring efficiency, this reaction is preferably carried out in the presence of a solvent. It varies depending on the base used, and is not particularly limited as long as it does not inhibit the reaction and dissolves the starting materials to some extent. Preferred examples include 1-methyl-2-pyrrolidone, N,N-dimethylformamide, dimethylsulfoxide, and the like. polar solvents such as tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, etc., non-polar solvents such as benzene, toluene, and xylene, alcoholic solvents such as ethanol and methanol, water, etc., or any of these Mixed solvents can be used. The base to be used varies depending on the starting material and solvent, but is preferably, for example, alkali metal hydroxides such as sodium hydroxide, potassium hydroxide and lithium hydroxide, sodium carbonate, potassium carbonate, sodium hydrogen carbonate and the like. Alkali metal carbonates, alkali metal salts of alcohol such as sodium methoxide and potassium tertiary butoxide, organic bases such as triethylamine, pyridine and jazabicyclononene, organic metals such as butyllithium and lithium diisobutylamide, sodium hydride. and alkali metal hydrides such as sodium amide, and alkali metal ammonium salts such as sodium amide. The reaction temperature should be sufficient to complete the reaction without promoting the formation of unwanted by-products, preferably -78 to 150°C, for example. Under preferred reaction conditions, the reaction is preferably complete, eg, in 1 to 24 hours, and the progress of the reaction can be monitored by known chromatographic techniques. Undesired by-products are removed by techniques known to those skilled in the art, such as conventional chromatographic techniques, extraction procedures or / and crystallization. [Step 5— 2] [Step 5-2] is an example of a method for preparing compound (1) by condensing compound (10) and amine compound (8a). In this step, for example, i) deprotection of the protective group of compound (10) by a method known to those skilled in the art (for example, T. Greene et al., "Protective Groups in Organic syntnesis" (John Wiley & Sons. Inc., New York, 1981), dehydration condensation with amine compound (8a) by a method known to those skilled in the art Co., Ltd., February 1978, pp. 1136-1162, "Organic Chemistry Experiment Guide [4]", Kagaku Dojin, September 1990, pp. 27-52, etc.), treat under basic conditions or ii) after coupling compound (10) with amine compound (8a) by methods known to those skilled in the art , deprotection of the protecting group, followed by intramolecular amidation to convert to compound (1). In addition, by selecting appropriate conditions for this step, compound (10) and amine compound (8a) can be converted into compound (1) in one step. [Preparation of amide compound (9b)] [Chemical 17] [Eh 6— 2] (8k) [wherein Ar has the same meaning as above, R 7 is low indicates an alkyl group. ]

[0098] The above reaction formula shows an example of a method for preparing the amide compound (9b). That is, the amide compound (9b) varies depending on the starting material, but can be prepared by a method known to those skilled in the art. , is prepared from compound (8c) as a starting material according to [Step 6-2], converted to compound (1 lc) in [Step 6-3], or from compound ( ) as a starting material After conversion to compound (8k) in [Step 6-2], preparation in [Step 6-4] can be mentioned.

[0099] [Conversion from amide compound (6a) to amide compound (9b)] [Step 6-1] is not particularly limited as long as the reaction conditions vary depending on the starting materials, and methods known to those skilled in the art can be used. Preferably, for example, [Step 6-1] is i) a Wittig reagent (in :, L is a triphenylene group) and an amide compound 3 Substance (6a) is prepared by a method known to those skilled in the art (for example, described in “Experimental Chemistry Course (Volume 19) Organic Synthesis [1]” edited by the Chemical Society of Japan, Maruzen Co., Ltd., June 1992, ρ 430-438) After halogenation with , it is reacted with triphenylphosphine (see, for example, Organic Reaction, 1965, vol. 14, p. 270). Alternatively, [Step 6-1] is ii) a Homer-Emmons reagent (wherein L is a phosphite ester), and the amide compound (6a) is converted by a method known to those skilled in the art (e.g. 3 For example, "The Chemical Society of Japan, Experimental Chemistry Course (Vol. 19) Organic Synthesis [1]", Maruzen Co., Ltd., June 1992, ρ 430-438). (see, for example, Chemical Review, 1981, 81, 415) or the Becker reaction with metal phosphonites (see, for example, Journal of the American Chemical Society, 1945, 67, 1180). ), etc.) to prepare an amide compound (9b). Alternatively, in [Step 6-1], a method of preparation from amide compound ½a) and chloroformic phosphate in the presence of a base can also be used (see, for example, Journal of Organic Chemistry, 1989, vol. 54, p. 4750). . [Step 6-1] (iii) Peterson's reagent (wherein L is a silyl group), and in the presence of a base, the amide compound ½a) and tri 3 Techniques for preparation from alkylsilyl chlorides can also be used (see, eg, Journal of Organometallic Chemistry, 1983, 248, 51). [Conversion from amide compound (1 lc) to amide compound (9b)] [Step 6-3] is not particularly limited as long as the conditions are different depending on the starting material, and a method known to those skilled in the art can be used. Preferably, for example, [Step 6-3] reduces the ester carbonyl moiety to an alcohol form (for example, "The Chemical Society of Japan, Experimental Chemistry Course (Volume 26) Organic Synthesis [VIII]", Maruzen Co., Ltd., 1992 159–266, April 2009), then converted to halogen compounds (for example, “The Chemical Society of Japan, New Experimental Chemistry Course (Vol. 14) Synthesis and Reactions of Organic Compounds [1]”, Maruzen Co., Ltd.). November 1977, pp. 331-450) to the Wittig reagent (9b) (see e.g. Organic Reaction, 1965, 14:270), or the Arbuzov reaction (e.g. Chemical Review , 1981, 81, 415) and the Horner-Emmons reagent (9b). Alternatively, Wittig reagent (9b) (for example, Svnth. Commun., 1996, vol. 26, p. 3091-3095, Tetrahedr on Lett., 2001, vol. 42, p. 1309-1331).

[0101] [Preparation of amide compound (11c)] Amide compound (11c) can be prepared by methods known to those skilled in the art, which vary depending on starting materials. Preferably, it can be prepared, for example, using compound (8c) as a starting material through [Step 6-2]. This step is preferably carried out, for example, by vigorously stirring compound (8c) and compound (8g), which is 1.0 to 10 equivalents relative to compound (8c), in a two-phase reaction solvent consisting of an organic solvent and a basic aqueous solution. The reaction proceeds expediently. The solvent and reaction temperature to be used vary depending on the starting material and are not particularly limited, but a solvent or a mixed solvent thereof that dissolves the starting material to some extent without inhibiting the reaction is preferable. For example, ether solvents such as diethyl ether, halogen solvents such as methylene chloride, 1,2-dichloroethane or chloroform, or nonpolar solvents such as toluene or xylene can be used. As the basic aqueous solution, it is preferable to use an equivalent weight of 1.0 or more, preferably an aqueous solution of an alkali metal salt such as sodium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate, cesium carbonate or sodium hydrogen carbonate. can be used. The reaction temperature should be sufficient to complete the reaction without promoting the formation of unwanted by-products, and is preferably, for example, -78°C to room temperature. Under preferred reaction conditions, the reaction is preferably complete, eg, in 0.5 to 24 hours, and the progress of the reaction can be monitored by well-known chromatographic techniques. Undesired by-products can be removed by techniques known to those skilled in the art such as conventional chromatographic techniques, extraction procedures or / and crystallization.

[0102] Alternatively, [Step 6-2] is preferably carried out in the presence of a base such as triethylamine, isopropylethylamine or an organic amine such as pyridine (preferably, for example, 1.0-5 0 equivalent), preferably, for example, a method of reacting compound (8c) with 1.05.0 equivalent of compound (8g) can also be used. The solvent and reaction temperature to be used vary depending on the starting materials and are not particularly limited, but solvents that dissolve the starting materials to some extent without inhibiting the reaction are preferred. Ether solvents such as ether, halogen solvents such as methylene chloride, 1,2-dichloroethane or chloroform, or nonpolar solvents such as toluene or xylene can be used. Reaction temperature should promote the formation of unwanted by-products The temperature should be sufficient to complete the reaction, preferably from 78°C to 100°C, for example. Under preferred reaction conditions, the reaction is preferably complete, eg, in 0.5 to 24 hours, and the progress of the reaction can be monitored by known chromatographic techniques. Undesired by-products can be removed by techniques known to those skilled in the art such as conventional chromatographic techniques, extraction procedures or / and crystallization.

[0103] Alternatively, [Step 6-2] comprises compound (8c) and 1.0-20 equivalents of compound (8h: R 7 (lower alkyl) may be conveniently heated to proceed the reaction. The solvent and reaction temperature to be used vary depending on the starting material and are not particularly limited, but a solvent or a mixed solvent thereof that dissolves the starting material to some extent without inhibiting the reaction is preferable. For example, ether solvents such as diethyl ether, halogen solvents such as methylene chloride, 1,2-dichloroethane or 1,2-dichlorobenzene, non-polar solvents such as toluene or xylene, dimethylformamide or N-methylpyrrolidone, etc. polar solvents or alcoholic solvents such as methanol, ethanol, 2-propanol or tertiary butanol can be used. Alternatively, the reaction may proceed conveniently even without a solvent. The reaction temperature is preferred / should be sufficient to complete the reaction without promoting the formation of by-products, preferably for example from 50°C to 200°C. Under preferred reaction conditions, the reaction is preferably complete, eg, in 0.5 to 24 hours, and the progress of the reaction can be monitored by known chromatographic techniques. Undesired by-products can be removed by techniques known to those skilled in the art such as conventional chromatographic techniques, extraction procedures or / and crystallization.

[0104] Alternatively, [Step 6-2] is carried out using compound (8c) and 1.0-5.0 equivalents of compound (8i) relative to compound (8c) under the reaction conditions described above or a combination thereof. sometimes. Further, for example, by adding a phase transfer catalyst such as a quaternary ammonium salt such as tetraptylammonium chloride or benzyltriethylammonium chloride, or an acidic compound such as p-toluenesulfonic acid or camphorsulfonic acid, the reaction proceeds conveniently. There is a child.

[0105] [Preparation of compounds (8g), (8h) and (8i)] Compounds (8g), (8h) and (8i) are commercially available or can be prepared by methods known to those skilled in the art. manufactured. If it is not commercially available, it can be prepared by esterifying or halogenating the corresponding oxalic acid derivative by methods known to those skilled in the art.

[0106] [Compound (8k) force, conversion to laoxomorpholine compound (9b)] [Steps 6-4] are not particularly limited as long as the reaction conditions vary depending on the starting materials, and methods known to those skilled in the art can be used. Preferably, for example, the forephine moiety of the compound (8k) is converted to a hemiacetal derivative by an oxidative cleavage reaction and an intramolecular cyclization reaction, and converted to a halogen compound (for example, "New Experimental Chemistry Lectures edited by the Chemical Society of Japan (Chapter 14) Synthesis and Reaction of Organic Compounds [1]”, Maruzen Co., Ltd., November 1977, p. , page 270), or the Arbuzov reaction (see, eg, Chemical Review, 1981, 81, 415) to the Horner-Emmons reagent (9b). Alternatively, Wittig reagent (9b) (for example, Synth. Commun., 1996, vol. 26, p. 3091-3095, Tet rahedron Lett., 2001) can be obtained by reacting a hemiacetal derivative with a triarylphosphorus hydrobromide. 42, p. 1309-1331). The oxidative cleavage reaction of the olefin site varies depending on the starting material, but is not particularly limited as long as the conditions are similar to those of this reaction, and known techniques described in many documents can be used. , "New Experimental Chemistry Lectures edited by the Chemical Society of Japan (Vol. 15) Oxidation and Reduction [1-2]", Maruzen Co., Ltd., September 1976, p. 563-603). Under suitable reaction conditions, the oxidative cleavage reaction and the intramolecular cyclization reaction can proceed continuously, which is convenient for preparing compound (9b)! / .

[0107] [Preparation of compound (8k)] Compound (8k) is preferably prepared, for example, using compound ( ) and compound (8i) in an amount of 1.0 to 5.0 equivalents relative to compound ( ) according to [Step 6-2] described above. can.

[0108] [Preparation of compound ( )] Compound ( ) is commercially available or produced by methods known to those skilled in the art. If not commercially available, e.g. R 4 and X combine to form a nitrogen-containing heterocycle Intramolecular nodroamination reaction of an amine compound or a sulfonylamide compound having an alenyl group using a metal catalyst (see Journal of The American Chemical Society ciety, 2003, 125, pi 1956, Tetrahedron Lett., 1998, 39, p. 5421-5424). This reaction is not particularly limited as long as the conditions for this reaction vary depending on the starting material, and the metal catalyst is preferably, for example, 0.001 to 0.1 equivalent of a palladium complex relative to the starting material, Examples include palladium acetate (11), dichlorobis(triphenylphosphine)palladium (II), tetrakis(triphenylphosphine)noradium (0), and allylpalladium chloride dimer. or, preferably, phosphorus ligands such as 2,2,-bis(diphenylphosphino)-1,1,-binaphthyl, 1,1,-bis(diphenylphosphino)hue Preferably, for example, adding 0.001 to 0.1 equivalent to the starting material may allow the reaction to proceed conveniently. Alternatively, preferably, for example, 0.001 to 10 equivalents of hydrochloric acid, acetic acid, or the like relative to the starting material may be added to allow the reaction to proceed conveniently. The solvent and reaction temperature to be used vary depending on the starting material and are not particularly limited. However, a solvent or a mixed solvent thereof that dissolves the starting material to some extent without inhibiting the reaction is preferable as the organic solvent. Preferably, ether solvents such as diethyl ether or tetrahydrofuran, methylene chloride or Halogen solvents such as 1,2-dichloroethane, non-polar solvents such as toluene or xylene, polar solvents such as dimethylformamide or N-methylpyrrolidone, or alcoholic solvents such as methanol, ethanol, 2-propanol or tertiary butanol. Using power S can. The reaction temperature should be sufficient to complete the reaction without promoting the formation of undesired by-products, and is preferably, for example, 50°C to 200°C. Under preferred reaction conditions, the reaction is preferably complete, eg, in 0.5 to 24 hours, and the progress of the reaction can be monitored by known chromatographic techniques. Undesired by-products can be removed by techniques known to those skilled in the art such as conventional chromatographic techniques, extraction procedures or / and crystallization. [Preparation of compound (9a)] [Chemical 18] (9g) [In the formula, the same meaning as Show taste. ]

[0110] The above reaction formula shows an example of preparation of compound (9a). That is, compound (9a) is commercially available or can be obtained by techniques known to those skilled in the art, such as those shown in the reaction schemes above (for example, C. Patois et al., "Synth. Commun.", 1991). 22, p. 2391 or J. A. Jackson et al., J. Org. Chem., 1989, 20, p. 5556). For example, in [Step 7-1], phosphonate ester compound (9c) is mixed with 1.0 to 2.0 equivalents of compound (9d) with respect to phosphonate ester compound (9c) under basic conditions. treatment to obtain the desired compound (9a). Alternatively, for example, in [Step 7-2], compound (9e) is treated with 1.0 to 2.0 equivalents of ester compound (9f) relative to compound (9e) under basic conditions. is the step to obtain the desired compound (9a). Alternatively, for example, the desired compound (9a) can be obtained from compound (9g) according to [Step 7-3] similar to [Step 7-1].

[0111] The base used in this step varies depending on the starting material, but is not limited. : It is preferable to use 1.0 to 1.5 equivalents of dosodium or the like with respect to the starting material. The solvent used in this step varies depending on the starting material and is not particularly limited as long as it dissolves the starting material to some extent without inhibiting the reaction. Examples include hexane, toluene, diethyl ether, tetrahydrofuran, N N-dimethylformamide, hexamethylphosphoric acid triamide, or the mixed solvent described above are preferred. The reaction temperature is preferred / should be sufficient to complete the reaction without promoting the formation of by-products, preferably from -78°C to 150°C. Under preferred reaction conditions, the reaction is complete in 1-24 hours and the progress of the reaction can be monitored by known chromatographic techniques. Undesired by-products can be removed by techniques known to those skilled in the art such as conventional chromatographic techniques or / and crystallization. The phosphonate ester compound (9c), compound (9d), compound (9e), ester compound (9f) and compound (9g) used in this step are commercially available or prepared using techniques known to those skilled in the art. You can get it with power. [Reference example 3] [Chemical 19] [In the formula, indicates a single or double bond and Ar, Z, Z, R 5 , R. 6 , Xa, p, q and r are 2 1 2 has the same meaning as ]

[0113] [Preparation of compound (1)] Aldol adduct (7b) of compound (1) can be prepared according to [Step 8-2]. That is, the dehydration reaction in [Step 8-2] is not particularly limited as long as the reaction conditions differ depending on the starting material, and known methods described in many documents can be used (for example, , ``Experimental Chemistry Lectures edited by the Chemical Society of Japan (Volume 19) Organic Synthesis [1]'', Maruzen Co., Ltd., June 1992, ρ 194-226). Preferably, for example, i) a method of treating the aldol adduct (7b) with an acid of 0.1 to 100.0 equivalents relative to the aldol adduct (7b) (for example, "Japan Chemical Society Ed. Experimental Chemistry Course (Vol. 19) Organic Synthesis

[0001] ”, Maruzen Co., Ltd., June 1992, p. Carboxylic acid ester group such as group, sulfonic acid ester group Alternatively, after conversion to a leaving group such as a halogen atom, preferably, for example, a method of treating the aldol adduct (7b) with 1.0-10.0 equivalents of a base (for example, "The Chemical Society of Japan, New Jikken Kagaku Koza (Vol. 19) Organic Synthesis [I], Maruzen Co., Ltd., June 1992, p. 198-205).

[0114] In the case of i), the acid, solvent and temperature conditions to be used are not particularly limited depending on the starting materials, but are preferably, for example, hydrochloric acid, sulfuric acid, phosphoric acid, potassium hydrogen sulfide, oxalic acid, p-toluenesulfone Acids, trifluoroboric acid ether complexes, thionyl chloride, anolamina oxide and the like are used. Although the reaction may be carried out without a solvent, a solvent or a mixture thereof that dissolves the starting materials to some extent without inhibiting the reaction is used as the solvent. Preferably, for example, nonpolar solvents such as toluene and benzene, polar solvents such as acetone, dimethylsulfoxide and hexamethylphosphoroamide, halogen-based solvents such as chloroform and methylene chloride, water, and the like are used. In some cases, preferably, for example, a combination of an acid and an organic base such as pyridine may improve the reaction rate and reaction yield. The reaction temperature should be sufficient to complete the reaction without promoting the formation of unwanted by-products, and is preferably, for example, room temperature to 200°C. Under preferred reaction conditions, the reaction is preferably complete, e.g., in 1 to 24 hours, and the progress of the reaction follows known It can be monitored with oral matography techniques. Undesired by-products can be removed by techniques known to those skilled in the art such as conventional chromatographic techniques, extraction procedures or / and crystallization. In the case of ii), the leaving group preferably includes, for example, an acetyl group, a methanesulfonate group, a p-toluenesulfonate group, a chlorine atom, a bromine atom, an iodine atom and the like. The technique for conversion to these leaving groups is not particularly limited depending on the starting materials, and methods known to those skilled in the art can be used. Preferably, for example, halogen solvents such as methylene chloride and chloroform, nonpolar solvents such as toluene and benzene, ether solvents such as tetrahydrofuran and ethylene glycol dimethyl ether, or mixed solvents thereof. 1.0 to 10.0 equivalents of acetyl chloride, acetic anhydride and other acylating agents, methanesulfonyl chloride, p-toluenesulfonyl chloride and other sulfonate esterifying agents, or halogens such as thionyl chloride, with respect to compound (7b) It is possible to use a chemical agent. Also, in this step, a base such as pyridine or triethylamine is preferably used, for example, in an amount of 1.0-10.0 equivalents relative to the aldol adduct (7b), or used as a reaction solvent. In some cases, it may be possible to obtain the desired product efficiently. The reaction temperature should be sufficient to drive the reaction to completion without promoting the formation of unwanted by-products, and is preferably -78 to 100°C, for example. Under preferred reaction conditions, the reaction is preferably complete, eg, in 1 to 24 hours, and the progress of the reaction can be monitored by known chromatographic techniques. Undesired by-products can be removed by techniques known to those skilled in the art such as conventional chromatographic techniques, extraction procedures or / and crystallization. The second step, the elimination reaction, is preferably carried out using, for example, halogen-based solvents such as methylene chloride and chloroform, nonpolar solvents such as toluene and benzene, polar solvents such as acetonitrile, dimethylformamide, and dimethylsulfoxide, and tetrahydrochloride. In an ether solvent such as furan, ethylene glycol dimethyl ether, or a mixed solvent thereof, the base is preferably an organic base such as diazabicycloundecene, pyridine, 4-dimethylaminopyridine, triethylamine, or water. Quaternary ammonium salts such as tetraptylammonium oxide, alkali metal salts of alcohols such as sodium methoxide and potassium tertiarybutoxide, alkali metal hydroxides such as sodium hydroxide, alkali metal carbonates such as lithium carbonate and potassium carbonate , lithium diisopropylamide, etc. It is preferable to use, for example, 1.0 to 10.0 equivalents of an organometallic reagent or the like with respect to the aldol adduct (7b). It is also possible to use an organic base such as pyridine as a solvent. The reaction temperature should be sufficient to complete the reaction without promoting the formation of undesired by-products, preferably between -78 and 100°C, for example. Under preferred reaction conditions, the reaction is preferably complete, eg, in 1 to 24 hours, and the progress of the reaction can be monitored by known chromatographic techniques. Undesired by-products can be removed by techniques known to those skilled in the art such as conventional chromatographic techniques, extraction procedures or / and crystallization. [Preparation of aldol adduct (7b)] Aldol adduct (7b), for example, from aldehyde compound (5) and 1.0-5.0 equivalents of ratatam compound (6b) with respect to aldehyde compound (5) [Step 8-1] can be done. That is, the aldol reaction in [Step 8-1] is not particularly limited as long as the reaction conditions differ depending on the starting material, and methods known to those skilled in the art can be used (for example, "The Chemical Society of Japan Experimental Chemistry Course (Volume 20) Organic Synthesis [II]", Maruzen Co., Ltd., July 1992, pp. 94-100). Preferably, for example, i) the ratatam compound (6b), preferably, for example, 1.0-5.0 equivalents of a base (preferably, for example, lithium diisopropylamide, butyllithium, sodium amide, sodium hydride, sodium methoxy, or potassium tertiarybutoxide, etc.) to convert it into an alkali metal enolate, and then react it with an aldehyde compound (5) (for example, the Chemical Society of Japan ed. Vol.) Organic Synthesis

[0011] , Maruzen Co., Ltd., July 1992, p. 1. 0-5.0 equivalents of a base (preferably, for example, lithium diisopropylamide, butyl lithium, sodium amide, sodium hydride, sodium methoxide, or potassium tertsyributoxide, etc.) to an alkali metal enolate and halogenation After reacting with a silicon reagent (preferably, for example, trimethylchlorosilane or tertiarybutyldimethylchlorosilane) to form a silyl enol ether, it is preferably, for example, 0.05 to ratatam compound (6b). - 5. A method of reacting with an aldehyde compound (5) in the presence of 0 equivalent of a Lewis acid (preferably, for example, titanium tetrachloride or boron trifluoride). (for example, "The Chemical Society of Japan, Experimental Chemistry Course (Volume 20) Organic Synthesis [II]", Maruzen Co., Ltd., July 1992, pp. 96-97). The solvent and reaction temperature to be used vary depending on the starting materials and are not particularly limited. Ether solvents such as , 1,4 dioxane or diethyl ether, halogen solvents such as methylene chloride, 1,2-dichloroethane or chloroform, or nonpolar solvents such as toluene and benzene can be used. The reaction temperature should be sufficient to drive the reaction to completion without promoting the formation of undesired by-products, and is preferably, for example, 78°C to room temperature. Under preferred reaction conditions, the reaction is preferably complete in, for example, 0.5 hours, 24 hours, and the progress of the reaction can be monitored by known chromatographic techniques. Undesired by-products can be removed by techniques known to those skilled in the art such as conventional chromatographic techniques, extraction procedures or / and crystallization. [Preparation of ratatam compound (2)] [Chemical 20] During, indicates a single or double bond and Ar , L , Z , Z , R 5 , R. 6 , p, q and r have the same meanings as above, L is an alkyl ester group such as a methyl ester group and an ethyl ester group, Alkyl ketone groups such as cetyl group, paraalkyl ketone groups such as phenylmethyl ketone group, aryl ketone groups such as benzoyl group, L is alkoxy group such as methoxy group and ethoxy group 6 L is a carbamate-based protecting group such as a methyl carbamate group, a benzyl carbamate group or a tert-butyl kanolebamate group, or an amide-based protecting group such as an acetyl group, L is a halogen atom such as a bromine atom or an iodine atom, L is nitrile group, methyl ester group 8 9 Alkyl ester groups such as an acetyl group, alkyl ketone groups such as an acetyl group, L is a hydrogen atom, methyl 16 Alkyl groups such as a chill group and an ethyl group, a phenyl group which may be substituted with 1 to 3 substituents selected from the substituent group A1, an ester group such as a methyl ester group and an ethyl ester group, dimethyl phosphate , a phosphate ester group such as diethyl phosphate, an alkylsulfonyl group such as methylsulfonyl group, or an arylsulfonyl group such as phenylsulfonyl group, etc. L is an alkylketone group such as acetyl group, an arylketone group such as benzoyl group 17 , alkyl ester groups such as formyl group, methyl ester group and ethyl ester group; A hydroxyl-protecting group such as a diphenylsilyl group, V is a hydrogen atom, methyl carbamate, benzyl carbamate, 2 - represents a carbamate protecting group such as a butylcarbamate group. ] The above reaction formula shows one example of a method for preparing the ratatam compound (6b). That is, (i) an imide compound (10a), which is commercially available or prepared using a method known to those skilled in the art (see, for example, Tetrahedron: Asymmetry, 1998, Vol. 9, p.4361) as a starting material, [ (ii) a method of preparing ratatam compound (6b) by converting to alkoxylatatam compound (10b) according to step 9-1], followed by carburizing reaction and ring-closing reaction in [step 9-2]; Starting from the 4-pyridone compound (10c), which is either commercially available or prepared using a method known to those skilled in the art (see, for example, Tetrahedron Letters, 1986, Vol. 27, p. 4549), acylation is performed according to [Step 93]. (10d), followed by ring closure in [Step 94] to prepare the ratatam compound (6b), or (iii) a commercially available method, or a method known to those skilled in the art (e.g., European Journal of Organic Chemistry, 2004, Vol. 23, p4823) as a starting material, converted to an amide alcohol compound (10f) according to [Step 95], followed by [Step 96 ] to close the ring or (iv) commercially available methods for preparing the ratatam compound (6b), or methods known to those skilled in the art (e.g., Tetrahedron Letters, 1998, vol. 39, p5421, and Tetrahedron Letters, 2004). , Vol. 45, see p. 4895) was used as a starting material, and the vinyl group-substituted cyclic amine compound (10 g) was converted into an acylated compound (10 h) according to [Step 9 7]. A method for ring closure in [Step 98] to prepare the ratatam compound (6b), or (V) a commercially available method or a method known to those skilled in the art (for example, Journal of the Organic Chemistry, 2001, 66, p886 Using the cycloalkyl ketone compound (10i) prepared using ) as the starting material, following [Steps 9-9], converted to the azide compound (10j), followed by ring closure in [Steps 9-10]. A method for preparing the ratatam compound (6b), or (vi) using a vinyl group-substituted cyclic amine compound (10 g) as a starting material according to [Step 9 11], converting to a compound (10k), followed by [Step 9 12] to prepare the ratatam compound (6b), or (vii) the compound (101), which is commercially available or prepared using a method known to those skilled in the art, as a starting material. , After conversion to compound (10m) according to [step 9 13], in [step 9 14] the nitrogen atom is deprotected and subjected to intramolecular reductive amination reaction to give compound (10η), and in [step 9 15] It shows a method for preparing a ratatam compound (6b) by deprotecting the oxygen atom followed by ring closure. [Conversion of imide compound (10a) to alkoxylatatam compound (10b)] Partial reduction of the imide group in [Step 91] can be carried out by a method known to those skilled in the art, as long as the reaction conditions differ depending on the starting material. Preferably, for example, the imide compound (10a) and 1.0 to 5.0 equivalents of sodium borohydride relative to the imide compound (10a) are added in an alcoholic solvent such as methanol (for example, "The Chemical Society of Japan" New Experimental Chemistry Course (Vol. 26) Organic Synthesis [VIII]”, Maruzen Co., Ltd., April 1992, p. 1 0 to 5 0 equivalents of borane in an ether solvent such as tetrahydrofuran (for example, ``New Experimental Chemistry Course edited by the Chemical Society of Japan (Volume 26) Organic Synthesis [VIII]'', Maruzen Co., Ltd. Company, April 1992, p. The desired alkoxylactam compound (10b) can be obtained by reaction in a solvent. or preferably, for example, the imide compound (10a) And 1.0 to 5.0 equivalents of sodium borohydride with respect to the imide compound (10a) in the presence of 0.1 to 5.0 equivalents of inorganic acid such as sulfuric acid with respect to the imide compound (10a) is stirred in an alcoholic solvent such as methanol (see, for example, Tetrahedron: Asymmetry, 1998, Vol. 9, p.4361) to obtain the desired alkoxylatatam compound (10b) in one step. . The reaction temperature is preferred / should be sufficient to complete the reaction without promoting the formation of by-products, preferably, for example, from 78°C to 100°C. Under preferred reaction conditions, the reaction is preferably complete, eg, in 1 to 24 hours, and the progress of the reaction can be monitored by known chromatographic techniques. Undesired by-products can be removed by techniques known to those skilled in the art, such as conventional chromatographic techniques, extraction procedures or / and crystallization. [Conversion of alkoxylatatam compound (10b) to lactam compound (6b)] [Step 9-2] converts L of the alkoxylatatam compound (10b) to a Wittig reagent (e.g., " Five Chemical Society of Japan, Experimental Chemistry Course (Vol. 24) Organic Synthesis [VII], Maruzen Co., Ltd., September 1992, p. 254-262), 0 § 1 (see, for example, ``Experimental Chemistry Lectures (Volume 24) Organic Synthesis [VI]'' edited by the Chemical Society of Japan, Maruzen Co., Ltd., September 1991, p. 59-72), or Olefins by reacting with alkyllithium reagents (see, e.g., "The Chemical Society of Japan Ed. Experimental Chemistry Course (Vol. 24) Organic Synthesis [VI]", Maruzen Co., Ltd., September 1991, ρ 9-51). After derivatization, the desired ratatam compound (6b) can be obtained by reacting with an acid such as hydrochloric acid, preferably, for example, an alkoxylatatam compound (10b) and an alkoxylatatam compound (10b). In the presence of 1.0 - 10.0 equivalents of cerium chloride with respect to alkoxylatatam compound (10b), 1.0 - 10.0 equivalents of a Grignard reagent such as trimethylsilylmethylmagnesium chloride is added to an ether solvent such as tetrahydrofuran. By stirring moderately and then reacting with an inorganic acid such as hydrochloric acid (see, for example, Tetrahedron: Asymmetry, 1998, vol. 9, p. 4361), the desired ratatam compound (6b) can be obtained in high yield. The reaction temperature is preferred / should be sufficient to complete the reaction without promoting the formation of by-products, preferably between 78°C and 100°C, for example. Under reaction conditions, the reaction is preferably complete, for example, in 1 to 24 hours, and the progress of the reaction can be monitored by known chromatographic techniques. can be removed by techniques known to those skilled in the art such as conventional chromatographic techniques, extraction procedures or / and crystallization.

[0121] [4 Conversion of pyridone compound (10c) to acylated form (10d)] [Step 93] consists of a deprotection reaction of the amine moiety followed by an amidation reaction. For the deprotection reaction of compound (10c), deprotection reactions described in many well-known documents can be used (for example, T.W. Green. "Protective Groups in Organic ≥>synthesis", John Wiley & Sons. Inc., 1981), the amine compound is obtained from the corresponding carbamate compound (preferably, for example, tert-butyl carbamate compound, benzyl carbamate compound, 9-fluorenylmethyl carbamate compound, etc.). or from corresponding amide compounds (preferably, for example, formamide compounds, acetamide compounds, trifluoroacetamide compounds, etc.). Although the conditions for this deprotection reaction vary depending on the starting materials, there are no particular limitations as long as the conditions are similar to those for this reaction, and known methods can be used. Under preferred reaction conditions, the reaction is preferably complete in, for example; Undesired by-products can be removed by techniques known to those skilled in the art, such as conventional chromatographic techniques or / and crystallization. The amidation reaction varies depending on the starting materials, but is not particularly limited as long as the conditions are similar to those of this reaction, and known methods described in many documents can be used (for example, "The Chemical Society of Japan Edited New Experimental Chemistry Course (Volume 14) Synthesis and Reaction of Organic Compounds

[0011] , Maruzen Co., Ltd., February 1978, pp. 1136-1162). Preferably, for example, i) a method of reacting the amine compound with 1.0 to 5.0 equivalents of an acid halogen compound with respect to the amine compound under basic conditions Lecture (Volume 14) Synthesis and reaction of organic compounds

[0011] ”, Maruzen Co., Ltd., February 1978, p. 0 to 5.0 equivalents of a carboxylic acid compound are reacted using 1.0 to 5.0 equivalents of a condensing agent with respect to the amine compound (for example, "Experimental Procedures for Organic Chemistry"). Pulling [4]”, Kagaku Doujin, September 1990, p. 27-52).

[0122] In the case of i), the base to be used varies depending on the starting material and is not particularly limited. triethylamine, N,N-diisopropylethylamine, lutidine, quinoline, isoquinoline and the like. The solvent to be used is not particularly limited as long as it dissolves the starting material to some extent without inhibiting the reaction, but preferred examples include tetrahydrofuran, 1,4-dioxane and the like. Bases may also be used as solvents. Alternatively, a two-layer distribution system can be used in which an alkaline aqueous solution, preferably an aqueous solution of, for example, sodium hydroxide or potassium hydroxide, is used as a base, and a halogen-based solvent such as methylene chloride or 1,2-dichloroethane. The reaction temperature is preferred / should be sufficient to drive the reaction to completion without promoting the formation of by-products, preferably between ice cold and 100°C. Under favorable reaction conditions, the reaction is preferably complete, eg, in 1-24 hours, and the progress of the reaction can be monitored by known chromatographic techniques. Undesired by-products can be removed by techniques known to those skilled in the art, such as conventional his chromatographic techniques or / and crystallization. In the case of ii), the condensing agent used varies depending on the starting material and is not particularly limited. propyl) carposimide, benzotriazole-1-yloxy tris(dimethylamino)phosphonium hexafluorophosphate, diethyl cyanophosphonate, or bis(2-oxo-3-oxazolidinyl)phosphinic chloride, etc., depending on the carboxylic acid used. 1.0-2.0 equivalents can be used as appropriate. For efficient reaction, N-hydroxysuccinimide, N-hydroxybenzotriazole, etc. may preferably be added in an amount of 1.0 to 2.0 equivalents relative to the carboxylic acid compound used. This reaction is preferably carried out in the presence of a solvent from the viewpoint of operability and stirring efficiency. The solvent to be used varies depending on the starting materials and the condensing agent used, and should dissolve the starting materials to some extent without inhibiting the reaction. Halogen-based solvents such as methylene chloride and 1,2-dichloroethane, and polar solvents such as tetrahydrofuran and N,N-dimethylformamide are preferably used. The reaction temperature should be sufficient to complete the reaction without promoting the formation of undesired by-products, preferably between ice cold and 100°C. Under preferred reaction conditions, the reaction is preferably complete, e.g. can be monitored by technology. Undesired by-products can be removed by techniques known to those skilled in the art, such as conventional chromatographic techniques or / and crystallization.

[0124] [Acyl compound (10d) ability, conversion to lactam compound (6b)] [Step 94] is a cyclization reaction via radical formation. That is, preferably, for example, compound (10d) is dissolved in a nonpolar solvent such as toluene, preferably, for example, with respect to compound (10d), 0.; In the presence of a radical initiator such as butyronitrile), preferably, for example, compound (10d) is reacted with 1.0 to 2.0 equivalents of an alkyltin reagent such as tryptynoretin to obtain a high yield. can obtain the desired ratatam compound ½b). The reaction temperature is preferred / should be sufficient to drive the reaction to completion without promoting the formation of by-products, preferably between 50 and 150°C, for example. Under preferred reaction conditions, the reaction is preferably complete, eg, in 1-24 hours, and the progress of the reaction can be monitored by known chromatographic techniques. Undesired by-products can be removed by techniques known to those skilled in the art, such as conventional chromatographic techniques and / or crystallization. In addition, after ring formation, a ketone group is used as a scaffold by a method known to those skilled in the art (e.g., reduction reaction (e.g., Chemical Society of Japan, Experimental Chemistry Course (Volume 26) Organic Synthesis [VIII], Maruzen Co., Ltd., 1992). pp. 159-266), addition reactions (see, for example, Chemistry Society of Japan, Experimental Chemistry Course (Vol. 25) Organic Synthesis [VII], Maruzen Co., Ltd., September 1991, pp. 9-72 ), an addition dehydration reaction (see, for example, “The Chemical Society of Japan, Experimental Chemistry Course (Volume 19) Organic Synthesis [I]”, Maruzen Co., Ltd., June 1992, ρ 57-85), etc.), resulting in Ζ can be converted in various ways.

[0125] [Oxazolidine compound (10e) power, conversion to amide alcohol compound (10f)] [Step 95] is an oxidative cleavage reaction of the oxazolidine ring leading to compound (10e) and amide alcohol compound (10f). That is, preferably, for example, compound (10e) is reacted with 2.0 to 10.0 equivalents of potassium permanganate relative to compound (10e) in a water-containing solvent such as a mixture of water and acetone. (See, for example, European Journal of Organic Chemistry, 2004, vol. 23, p. 4823). In the meantime, by reacting compound (10e) with 1.0-10.0 equivalents of bromine (see, for example, Synlett, 1994, 2, 143), The desired amide alcohol compound (10f) can be obtained in high yield. The solvent used in this step varies depending on the starting material and the oxidizing agent used, and is not particularly limited as long as it dissolves the starting material to some extent without inhibiting the reaction. Also, the reaction temperature should be sufficient to complete the reaction without promoting the formation of undesired by-products, and is preferably, for example, ice cold to 100°C. Under preferred reaction conditions, the reaction is preferably complete, eg, in 1-24 hours, and the progress of the reaction can be monitored by known chromatographic techniques. Undesired by-products can be removed by techniques known to those skilled in the art, such as conventional chromatographic techniques or / and crystallization. [Amido alcohol compound (10f) force, conversion to lactam compound (6b)] [Step 9 6] converts L of the amide alcohol compound (10f) to an alcohol or amine 9 followed by a cyclization reaction. That is, the conversion of L in the amidoalcohol compound (10f) to an alcohol varies depending on the starting materials, even under conditions similar to this reaction. 9 For example, a method known to those skilled in the art (see, for example, "The Chemical Society of Japan, Experimental Chemistry Course (Volume 20) Organic Synthesis Reaction

[0011] ", Maruzen Co., Ltd., July 1992, p. 1-30). be able to. Also, the conversion of L of the amide alcohol compound (10f) to an amine varies depending on the starting material. 9 However, if the conditions are similar to this reaction, a method known to those skilled in the art (for example, "The Chemical Society of Japan Ed. Experimental Chemistry Course (Volume 20) Organic Synthetic Reaction

[0011] ", Maruzen Co., Ltd., July 1992, pp. 279—318). The ring closure reaction from the alcohol or the amine varies depending on the starting materials, but if the conditions are similar to those of this reaction, there is a method known to those skilled in the art (for example, Journal of Fluorine Chemistry, 1997, vol. 2, p. 119). (see Scientia Pharmaceutica, 1996, Vol. 64, p. 3, etc.) Preferably, for example, the alcohol is added in an amount of 0.1 to 10 equivalents relative to the alcohol. by heating in the presence of an organic acid such as p-toluenesulfonic acid or camphorsulfonic acid, or an inorganic acid such as sulfuric acid or hydrochloric acid, in a solvent or without a solvent, to obtain a ratatam compound (6b) in a high yield. The ring closure reaction from the amine body can be carried out by a method known to those skilled in the art (for example, Petrochemia, 1990, vol. , Tetrahedron Letters, 1982, 23, 229, etc.) Preferably, for example, the amine is subjected to In the presence of an organic metal such as tetrakistriphenylphosphine palladium or tristriphenylphosphine ruthenium having a concentration of 0 1 - 1.0 and stirring in a solvent such as tetrahydrofuran, toluene, methylene chloride, or dimethylformamide, ratatam Compound (6b) can be obtained in high yield. Needless to say, the solvent used in this step varies depending on the starting materials and reagents used, and is not particularly limited as long as it dissolves the starting materials to some extent without inhibiting the reaction. Also, the reaction temperature should be sufficient to complete the reaction without promoting the formation of undesired by-products, and is preferably, for example, ice cold to 100°C. Under preferred reaction conditions, the reaction is preferably complete, eg, in ~24 hours, and the progress of the reaction can be monitored by known chromatographic techniques. Undesired by-products can be removed by techniques known to those skilled in the art, such as conventional chromatographic techniques or / and crystallization.

[0127] [Conversion from vinyl group-substituted cyclic amine compound (10 g) to acyl compound (1 Oh)] The acyl compound (1 Oh) can be prepared by using a vinyl group-substituted cyclic amine compound (10 g) as a starting material and subjecting it to [Step 97]. That is, [Step 97] is the same method as [Step 93].

[0128] [Acyl compound (10h) ability, conversion to lactam compound (6b)] [Step 98] consists of a Ring closing metathesis reaction followed by a double bond modification reaction. The Ring closing metathesis reaction varies depending on the starting materials. 2012, Vol. 39, p. 3012, etc.). The double bond modification reaction is preferably, for example, i) catalytic hydrogenation (for example, "The Chemical Society of Japan, Experimental Chemistry Course (Volume 26) Organic Synthetic Reaction [VIII]", Maruzen Co., Ltd., 1992 4 pp. 251-266), ii) hydroboration (e.g., ``The Chemical Society of Japan, Experimental Chemistry Course (Vol. 26) Organic Synthetic Reaction [VII]'', Maruzen Co., Ltd., September 1991, p. 83-134), iii) oxidation of carbon-carbon double bonds (e.g., "The Chemical Society of Japan, Experimental Chemistry Course (Vol. 26) Organic Synthetic Reaction [V]", Maruzen Co., Ltd., 1991, 10 month, see ρ 237-267), etc.

[0129] The Ring Closing Metathesis reaction is preferably carried out, for example, on the acyl compound (10 h) is stirred in a solvent in the presence of 0.01-0.2 equivalents of a metal catalyst relative to the acyl compound (lOh). Preferred solvents to be used include halogen solvents such as methylene chloride and chloroform, ether solvents such as tetrahydrofuran, 1,4-dioxane, and 1,2-dimethoxyhetane, and nonpolar solvents such as benzene, toluene, and xylene. etc., or a mixed solvent thereof. The metal catalyst used varies depending on the starting material and solvent. Preferably, for example, bis(tricyclohexylphosphine)benzylidene ruthenium (IV) dichloride, benzyldene [1,3 bis(2,4,6 trimethylphenyl)-2 —imidazolidinylidene]dichloro(tricyclohexylphosphine)ruthenium(IV), [1,3-bis-(2,4,6-trimethylphenyl)-2-imidazolidinylidene]dichloro(ortho-isopropoxyphenylmethylidene ) ruthenium (IV), bis(tricyclohexylphosphine) 3-phenylene 1H-indene-1 ylidene norethenium (II) dichloride, or ruthenium-based catalysts such as 2,6-diisopropylphenylimide neohylidene biphene Molybdenum-based catalysts such as molybdenum (VI), 2,6-diisopropylphenylimide neophylidene molybdenum (VI) bis(hexafluorotertiary butoxide), and the like are used. The reaction temperature should be sufficient to complete the reaction without promoting the formation of unwanted by-products, preferably between room temperature and 100°C. Under preferred reaction conditions, the reaction is preferably complete, eg, in 1 hour to 24 hours, and the progress of the reaction can be monitored by known chromatographic techniques. Undesired by-products can be removed by techniques known to those skilled in the art, such as conventional chromatographic techniques, extraction procedures or / and crystallization.

[0130] [Conversion of cycloalkyl ketone compound (10i) to azide compound (10j)] [Step 9 9] consists of i) a halogenation reaction at the aromatic ring alpha position (-CH—Ar), and ii) it twenty two followed by an azide introduction reaction.

[0131] The halogenation reaction in i) varies depending on the starting material. , Maruzen Co., Ltd., June 1992, ρ 422-458). A preferred method includes, for example, a method of stirring the cycloalkyl ketone compound (10i) with a halogenating agent in an amount of 1.0 to 2.0 equivalents relative to the cycloalkyl ketone compound (10i) in a solvent. be Halogenating agents to be used preferably include, for example, N-bromosuccimide and bromine. Also preferably, for example, 0.01 to 0.5 equivalents of benzoyl peroxide or 2,2-azobis(isobutyronitrile) with respect to the cycloalkyl ketone compound (lOi), or a radical initiator such as In some cases, the reaction can be significantly accelerated by adding an acid catalyst such as hydrobromic acid in an amount of 0.01 to 0.5 equivalents relative to the cycloalkyl ketone compound (10i). The solvent varies depending on the starting material and is not particularly limited as long as it does not inhibit the reaction and dissolves the starting material to some extent, but preferred examples include carbon tetrachloride and benzene. The temperature should be sufficient to drive the reaction to completion without promoting the formation of undesired by-products, preferably between room temperature and 150° C. Under preferred reaction conditions, the reaction is The reaction is preferably complete, e.g., in 1 to 24 hours, and the progress of the reaction can be monitored by known chromatographic techniques.Undesired by-products can be detected by conventional chromatographic techniques, extraction procedures or / and crystallization. It can be removed by techniques known to those skilled in the art. The azidation reaction of ii) varies depending on the starting materials, but if the conditions are similar to those of this reaction, a method known to those skilled in the art (for example, "The Chemical Society of Japan Ed. ]”, Maruzen Co., Ltd., July 1992, p. 415-420). Preferably, for example, the halide is stirred in a solvent with 1.0 to 5.0 equivalents of an azidation agent relative to the halide. The azidating agent to be used preferably includes, for example, sodium azide or trimethylsilyl azide. Further, preferably, for example, the reaction is significantly accelerated by using 0.1 to 5.0 equivalents of a quaternary amine salt such as tetraptylammonium fluoride with respect to the azidating agent used. There is also The solvent to be used varies depending on the starting materials, and is not particularly limited as long as it does not inhibit the reaction and dissolves the starting materials to some extent. Halogen solvents such as form and methylene chloride, non-polar solvents such as benzene and toluene, and polar solvents such as acetone, acetonitrile, dimethylformamide and N-methylpyrrolidine can be used. The reaction temperature should, and is preferably, sufficient to drive the reaction to completion without promoting the formation of unwanted by-products. For example, room temperature to 150°C. Under preferred reaction conditions, the reaction is preferably complete, eg, in 1 to 24 hours, and the progress of the reaction can be monitored by known chromatographic techniques. Undesired by-products can be removed by techniques known to those skilled in the art, such as conventional chromatographic techniques, extraction procedures or / and crystallization.

[0133] [Conversion from azide compound (10j) to ratatam compound (6b)] In [Steps 9-10], azide compound (10j) is stirred in a solvent in the presence of 1.0 to 10.0 equivalents of acid relative to azide compound (10j) to cause a rearrangement reaction to give ratatam compound ½b ) is a method for preparing That is, this step can be carried out by a method known to those skilled in the art (see, for example, Journal of the Organic Chemistry, 2001, vol. 66, p.886) as long as the reaction-like conditions vary depending on the starting materials. . Acids used are preferably, for example, trifluoromethanesulfonic acid, trifluoroacetic acid, sulfuric acid, hydrochloric acid and the like. In this reaction, the acid used can be used as a solvent, but from the viewpoint of operability and stirring efficiency, it is preferable to carry out the reaction in the presence of a solvent. It is not particularly limited as long as it dissolves the starting material to some extent without hindering it, but preferred examples include halogen-based solvents such as chloroform and methylene chloride, and nonpolar solvents such as benzene and toluene. The reaction temperature should be sufficient to complete the reaction without promoting the formation of unwanted by-products, preferably -78 to 50°C, for example. Under preferred reaction conditions, the reaction is preferably complete, eg, in 1 to 24 hours, and the progress of the reaction can be monitored by known chromatographic techniques. Undesired by-products can be removed by techniques known to those skilled in the art such as conventional chromatographic techniques, extraction procedures or / and crystallization.

[0134] [Conversion from vinyl group-substituted cyclic amine compound (10g) to compound (10k)] Compound (10k) can be prepared by subjecting a vinyl group-substituted cyclic amine compound (10g) as a starting material to [Step 911]. That is, [Step 911] consists of a double bond reduction reaction followed by a carburizing reaction. The double bond reduction reaction can be carried out by methods described in many known documents, preferably i) catalytic hydrogenation reaction (for example, Experimental Chemistry Lectures edited by The Chemical Society of Japan (vol. 26). ) Organic Synthetic Reaction [VIII], Maruzen Co., Ltd., April 1992, p. Chemical Society, Experimental Chemistry Course (Vol. 26) Organic Synthetic Reaction [VIII], Maruzen Co., Ltd., April 1992, ρ 165-1856).

[0135] In the case of i), a method of stirring the compound (10 g) in a solvent together with a hydrogen source in the presence of 0.01 to 0.5 equivalents of a metal catalyst relative to the compound (10 g) can be mentioned. The metal catalyst used varies depending on the starting material and is not particularly limited, but preferred examples include palladium carbon, rhodium carbon, ruthenium carbon, palladium hydroxide, platinum oxide, Raney nickel, Wilkinson catalyst and the like. The hydrogen source varies depending on the starting material and the metal catalyst used, and is not particularly limited. Preferred examples include hydrogen gas, formic acid, ammonium formate, cyclohexadiene, and the like. The solvent to be used varies depending on the starting material and the metal catalyst and is not particularly limited, but preferably, for example, methanol, ethanol, ethyl acetate, toluene, THF, 1,4-dioxane, chloroform, chloride Such as methylene, water or mixtures thereof. In addition, an organic acid, inorganic acid, or organic base may be added as appropriate in order to allow the reaction to proceed efficiently. The reaction temperature should be sufficient to drive the reaction to completion without promoting the formation of undesirable by-products, and is preferably, for example, room temperature to 150°C. Under preferred reaction conditions, the reaction is preferably complete, eg, in 1 to 24 hours, and the progress of the reaction can be monitored by known chromatographic techniques. Undesired by-products can be removed by techniques known to those skilled in the art, such as conventional chromatographic techniques, extraction procedures or / and crystallization.

[0136] In the case of ii), the compound (10 g) is stirred in a solvent in the presence of 1·0-10.0 equivalents of a metal or metal salt relative to the compound (10 g). The metal or metal salt to be used varies depending on the starting material and is not particularly limited, but is preferably an alkali metal such as lithium or sodium, an alkaline earth metal such as magnesium or calcium, or a salt thereof. be. The solvent to be used varies depending on the starting material and the metal to be used, but is not particularly limited. Preferred examples include ammonia, methanol, ethanol, tertiary-butanol, tetrahydrofuran, 1,4-dioxane, diethylether, water, and their A mixture. The reaction temperature should be sufficient to drive the reaction to completion without promoting the formation of undesired by-products, preferably, for example -78 to 100°C. Under preferred reaction conditions, the reaction is preferably carried out, for example The reaction is typically complete in 1 to 24 hours and the progress of the reaction can be monitored by known chromatographic techniques. Undesired by-products can be removed by techniques known to those skilled in the art such as conventional chromatographic techniques, extraction procedures or / and crystallization.

[0137] The carbon enrichment reaction following the reduction of the double bond can be carried out using a technique described in many known documents, preferably i) Wittig reaction, ii) Horner-Emmons reaction, iii) Peterson reaction. (For example, "Experimental Chemistry Lectures edited by The Chemical Society of Japan (Vol. 19) Organic Synthesis [I]", Maruzen Co., Ltd., June 1992, ρ 57-85) and the like.

[0138] The Wittig reaction is preferably carried out, for example, with an aldehyde compound derived from compound (10 g) and in the presence of a base of 1.0-5.0 equivalents with respect to the aldehyde compound, with respect to the aldehyde compound at 1.0-3.0 A technique of stirring an equivalent amount of a known Wittig reagent in a solvent can be mentioned. The solvent to be used varies depending on the starting material and the base used, and is not particularly limited as long as it does not inhibit the reaction and dissolves the starting material to some extent. Preferred examples include nitromethane, acetonitrile, 1-methyl Polar solvents such as 2-pyrrolidone, N,N dimethylformamide, and dimethylsulfoxide; ether solvents such as tetrahydrofuran, 1,4-dioxane, and 1,2-dimethoxyethane; and nonpolar solvents such as benzene, toluene, and xylene. , alcoholic solvents such as ethanol and methanol, chloroform, methylene chloride and other organic solvents, water and the like, or mixed solvents thereof are used. The base used varies depending on the starting material and solvent. Preferably, for example, alkali metal hydroxides such as sodium hydroxide and lithium hydroxide, alkali metal carbonates such as sodium carbonate, sodium methoxide, potassium tertiary Alkali metal salts of alcohols such as butoxide, organic bases such as triethylamine, pyridine and diazabicyclononene, organic metals such as butyllithium and lithium diisobutylamide, and alkali metal hydrides such as sodium hydride. be done. The reaction temperature should be sufficient to drive the reaction to completion without promoting the formation of undesired by-products, preferably between -78 and 150°C, for example. Under favorable reaction conditions, the reaction is preferably complete, eg, in 1 to 24 hours, and the progress of the reaction can be monitored by known chromatographic techniques. Desirable by-products can be removed by techniques known to those skilled in the art, such as conventional chromatographic techniques, extraction procedures or / and crystallization.

[0139] The Horner-Emmons reaction is preferably carried out, for example, with an aldehyde compound derived from the compound (10 g) in the presence of a base of 1.0-5.0 equivalents with respect to the aldehyde compound, with respect to the aldehyde compound at 1.0- 3. A technique of stirring 0 equivalent of a known Horner-Emmons reagent in a solvent can be mentioned. The solvent to be used varies depending on the starting material and the base used, and is not particularly limited as long as it dissolves the starting material to some extent without inhibiting the reaction. Polar solvents such as N, N dimethylformamide and dimethyl sulfoxide, ether solvents such as tetrahydrofuran, 1,4 dioxane, and 1,2-dimethoxyethane, nonpolar solvents such as benzene, toluene, and xylene, ethanol, and methanol , water, or a mixed solvent thereof is used. The base used varies depending on the starting material and solvent. Preferably, for example, alkali metal hydroxides such as sodium hydroxide and lithium hydroxide, alkali metal carbonates such as sodium carbonate, sodium methoxide, and potassium tertiarybutoxide. Alkali metal salts of alcohols such as triethylamine, pyridine, organic bases such as diazabicyclononene, organic metals such as butyllithium and lithium diisobutylamide, alkali metal hydrides such as sodium hydride, or sodium amide and alkali metal ammonium salts such as The reaction temperature should be sufficient to drive the reaction to completion without promoting the formation of undesired by-products, preferably between -78 and 150°C, for example. Under favorable reaction conditions, the reaction is preferably complete, eg, in 1 to 24 hours, and the progress of the reaction can be monitored by known chromatographic techniques. Desirable by-products can be removed by techniques known to those skilled in the art, such as conventional chromatographic techniques, extraction procedures or / and crystallization.

[0140] The Peterson reaction is preferably carried out, for example, with an aldehyde compound derived from the compound (10 g) and in the presence of a base of 1.0-5.0 equivalents with respect to the aldehyde compound, 1.0-3.0 with respect to the aldehyde compound. A method of stirring 0 equivalent of a known Peterson reagent in a solvent can be mentioned. The solvent to be used varies depending on the starting materials and the base to be used, and is not particularly limited as long as it does not inhibit the reaction and dissolves the starting materials to some extent. Preferred examples include 1-methyl 2-pyrrolidone, Polar solvents such as N,N dimethylformamide and dimethyl sulfoxide; Monotel solvents, nonpolar solvents such as benzene, toluene and xylene, alcoholic solvents such as ethanol and methanol, water and the like, or mixed solvents thereof are used. The base to be used varies depending on the starting material and solvent. Preferably, for example, alkali metal hydroxides such as sodium hydroxide and lithium hydroxide, alkali metal carbonates such as sodium carbonate, sodium methoxide, and potassium tertiarybutoxide. organic bases such as triethylamine, pyridine, diazabicyclononene, etc.; organic metals such as butyllithium and lithium diisobutylamide; alkali metal hydrides such as sodium hydride; or sodium amide, etc. and alkali metal ammonium salts of. The reaction temperature should be sufficient to complete the reaction without promoting the formation of undesired by-products, preferably from -78 to 150°C, for example. Under preferred reaction conditions, the reaction is preferably complete, eg, in 1 to 24 hours, and the progress of the reaction can be monitored by known chromatographic techniques. Undesired by-products can be removed by techniques known to those skilled in the art such as conventional chromatographic techniques, extraction procedures or / and crystallization.

[0141] [Conversion of compound (10k) to ratatam compound (6b)] Latatam compound (6b) can be prepared by subjecting compound (10k) as a starting material to an intramolecular amidation reaction according to [Steps 9-12]. That is, [Step 912] is the same method as [Step 93].

[0142] [Conversion to compound (101) force compound (10m)] [Steps 9-13] is a method of preparing compound (10m) by subjecting compound (101) to a nucleophilic reaction with an organometallic reagent that is commercially available or prepared by a method known to those skilled in the art. That is, in this step, different forces depending on the starting materials can be used. Ltd., September 1991, p. 9-72). Preferably, for example, compound (101) is stirred in a solvent with 0.5-5.0 equivalents of an organometallic reagent relative to compound (101). The solvent to be used varies depending on the starting material and is not particularly limited, but a solvent or a mixed solvent thereof that dissolves the starting material to some extent without inhibiting the reaction is preferable. Alternatively, a halogen-based solvent, methylene chloride, 1,2-dichloroethane, chloroform, or other halo Non-polar solvents such as polar solvents or toluene or xylenes can be used. The reaction temperature varies depending on the starting materials and is not particularly limited, but should be a temperature sufficient to complete the reaction without promoting the formation of undesired by-products. For example — 78 degrees to 50 degrees. Under preferred reaction conditions, the reaction is preferably complete, eg, in 0.5 to 24 hours, and the progress of the reaction can be monitored by known chromatographic techniques. Undesired by-products can be removed by techniques known to those skilled in the art such as conventional chromatographic techniques, extraction procedures or / and crystallization. Alternatively, for example, R 5 and R 6 It is also preferred to use the compound (101) in which a carbonyl group is formed with as a starting material.

[0143] [Conversion from compound (10m) to compound (10η)] [Steps 9-14] deprotect compound (10m) by a deprotection method known to those skilled in the art (e.g., T. Green et al., "Protective Groups in Organic ≥>synthesis", John Wiley & Sons. Inc., New York, 1981). After deprotection of the protective group on the nitrogen atom, intramolecular reductive amination reaction Maruzen Co., Ltd., February 1978, pp. 1380-1384). Alternatively, preferably, for example R 5 and R 6 This step can also be carried out using the compound (10m) in which a carbonyl group is formed in as a starting material.

[0144] [Conversion from compound (10η) to compound (6b)] [Step 9 15] is a deprotection step of protecting group V of compound (1 On) followed by oxomole 2 Holin ring closure step force. The deprotection step includes deprotection methods known to those skilled in the art (see, for example, T. Greene, "Protective Groups in Organic ≥>synthesis," John Wiley & Sons. Inc., New York, 1981). reference). Also, for example, and R 6 is a hydrogen atom, the compound (10m) is converted to an ester derivative (R 5 and R 6 to form a carbonyl group), reduction reactions known to those skilled in the art can also be used. The oxomorpholine ring closure step is the same as [Step 4-2].

[0145] [Reference example 4] [Chemical 21] indicates a single or double bond and Ar, Z, Z, R 5 , R. 6 , Xa, p, q and r are as above 2 1 2 L has the same meaning, L is a phosphite group such as a diethylphosphonyl group, triphenylphosphite Ten Phosphonium salts such as phonium bromide, silyl groups such as trimethylsilyl groups, ester groups such as methyl ester groups and ethyl ester groups, or carboxyl groups. ]

[0146] In the above [Reference Example 4], the leaving group L was introduced into ratatam compound (6b) according to [Step 10-1]. This is an example of a method of producing compound (1) by subjecting it to a condensation reaction of aldehyde compound (5) and [Step 10-2].

[0147] [Preparation of compound (1)] The condensation reaction in [Step 10-2] is not particularly limited as long as the force varies depending on the starting material and the conditions are similar to those of this reaction, and known methods described in many documents can be used. reaction, Horner-Emmonsix reaction, Peterson reaction, or Knoevenage 1 reaction, etc. June, p. 57-85) preferred! / .

[0148] The Wittig reaction is preferably performed, for example, on compound (11) (wherein L is a phosphonium Ten salt), preferably, for example, 0 5 - 2.0 equivalents relative to compound (11) of aldehyde compound (5), preferably, for example, 1.0 - 5 equivalents relative to compound (11) 0 equivalents of base and solvent A method of medium stirring can be used. In this reaction, compound (11) and a base are first treated to form phosphorus ylide, and then aldehyde (5) is added, or compound (11) and aldehyde compound (5) coexist with a base. is there a way to add The solvent to be used varies depending on the starting material and the base used, and is not particularly limited as long as it does not inhibit the reaction and dissolves the starting material to some extent. Preferred examples include nitromethane, acetonitrile, 1-methyl Polar solvents such as 2-pyrrolidone, N,N dimethylformamide, and dimethylsulfoxide; ether solvents such as tetrahydrofuran, 1,4 dioxane, and 1,2 dimethoxyethane; nonpolar solvents such as benzene, toluene, and xylene; Alcoholic solvents such as methanol, halogen-based solvents such as chloroform and methylene chloride, water, etc., or mixed solvents thereof are used. The base to be used varies depending on the starting material and solvent. Preferably, for example, alkali metal hydroxides such as sodium hydroxide and lithium hydroxide, alkali metal carbonates such as sodium carbonate, sodium methoxide, and potassium tertiaryb toxide. organic bases such as triethylamine, pyridine and diazabicyclononene; organic metals such as butyllithium and lithium diisobutylamide; and alkali metal hydrides such as sodium hydride. The reaction temperature should be sufficient to complete the reaction without promoting the formation of undesired by-products, preferably from -78 to 150°C, for example. Under preferred reaction conditions, the reaction is preferably complete, eg, in 1 to 24 hours, and the progress of the reaction can be monitored by known chromatographic techniques. Undesired by-products can be removed by techniques known to those skilled in the art, such as conventional chromatographic techniques, extraction procedures or / and crystallization. The Horner-Emmons reaction is preferably performed, for example, on compound (11) (where L 10 is a phosphite ester group), preferably, for example, 0.5 to 2.0 equivalents of aldehyde compound (5) relative to compound (11), preferably, for example, relative to compound (11) and 1 · 0 - 5.0 equivalents of the base are stirred in the solvent. In this reaction, compound (11) and a base are first treated to form a carbanion and then aldehyde (5) is added, or a base is added in the presence of compound (11) and aldehyde compound (5). There is The solvent to be used varies depending on the starting materials and the base used, and is not particularly limited as long as it does not inhibit the reaction and dissolves the starting materials to some extent. Polar solvents such as thio-2-pyrrolidone, N,N dimethylformamide, and dimethylsulfoxide; ether solvents such as tetrahydrofuran, 1,4 dioxane, and 1,2 dimethoxyethane; nonpolar solvents such as benzene, toluene, and xylene; Alcoholic solvents such as methanol, water, etc., or mixed solvents thereof are used. The base used varies depending on the starting material and solvent. Preferably, for example, alkali metal hydroxides such as sodium hydroxide and lithium hydroxide, alkali metal carbonates such as sodium carbonate, sodium methoxide, potassium tertiary Alkali metal salts of alcohols such as butoxide, organic bases such as triethylamine, pyridine, diazabicyclononene, etc., organic metals such as butyllithium and lithium diisobutylamide, alkali metal hydrides such as sodium hydride, or sodium amide, etc. and alkali metal ammonium salts of. The reaction temperature should be sufficient to complete the reaction without promoting the formation of unwanted by-products, preferably from -78 to 150°C, for example. Under preferred reaction conditions, the reaction is preferably complete, eg, in 1 to 24 hours, and the progress of the reaction can be monitored by known chromatographic techniques. Undesired by-products can be removed by techniques known to those skilled in the art such as conventional chromatographic techniques, extraction procedures or / and crystallization. The Peterson reaction is preferably performed, for example, on compound (11) (wherein L is a silyl group Ten ) and preferably, for example, 0.5-2.0 equivalents relative to compound (11) of aldehyde compound (5), preferably, for example, 1.0-5.0 equivalents relative to compound (11) A method of stirring an equivalent amount of a base in a solvent can be mentioned. In this reaction, compound (11) is first treated with a base to form rubanion, and then aldehyde (5) is added, or compound (11) and aldehyde compound (5) coexist. , there is a method of adding a base. The solvent to be used varies depending on the starting materials and the base to be used, and is not particularly limited as long as it does not inhibit the reaction and dissolves the starting materials to some extent. Preferred examples include 1-methyl-2-pyrrolidone, Polar solvents such as N, N dimethylformamide and dimethyl sulfoxide, ether solvents such as tetrahydrofuran, 1,4 dioxane, and 1,2-dimethoxyethane, nonpolar solvents such as benzene, tonolene, and xylene, ethanol, and methanol An alcoholic solvent such as water, or a mixed solvent thereof is used. The base used varies depending on the starting material and solvent. Preferably, alkalis such as sodium hydroxide and lithium hydroxide are used. Metal hydroxides, alkali metal carbonates such as sodium carbonate, alkali metal salts of alcohols such as sodium methoxide and potassium tertiarybutoxide, organic bases such as triethylamine, pyridine, diazabicyclononene, butyllithium, lithium Examples include organic metals such as diisobutylamide, alkali metal hydrides such as sodium hydride, alkaline metal ammonium salts such as sodium amide, and the like. The reaction temperature should be sufficient to drive the reaction to completion without promoting the formation of undesired by-products, preferably e.g. 78~; 150°C. Under preferred reaction conditions, the reaction is preferably complete in, for example, 1 hour to 24 hours, and the progress of the reaction can be monitored by known chromatographic techniques. Undesired by-products can be removed by techniques known to those skilled in the art, such as conventional chromatographic techniques, extraction procedures or / and crystallization. Knoevenagel reaction is preferably carried out, for example, compound (11) (wherein L 10 ter group or carboxyl group) and preferably, for example, 0.5 to 2.0 equivalents of aldehyde compound (5) relative to compound (11), preferably, for example, 1 relative to compound (11) 0 to 5.0 equivalents of a base are stirred in a solvent. In this reaction, compound (11) and a base are first treated to form a carbanion, and then aldehyde (5) is added. is there a way to add The solvent to be used varies depending on the starting material and the base to be used, and is not particularly limited as long as it does not inhibit the reaction and dissolves the starting material to some extent. Preferred examples include 1-methyl 2-pyrrolidone, Polar solvents such as N,N dimethylformamide and dimethylsulfoxide; ether solvents such as tetrahydrofuran, 1,4 dioxane, and 1,2-dimethoxyethane; nonpolar solvents such as benzene, toluene, and xylene; An alcoholic solvent, water, etc., or a mixed solvent thereof is used. The base to be used varies depending on the starting material and solvent. Preferably, for example, alkali metal hydroxides such as sodium hydroxide and lithium hydroxide, alkali metal carbonates such as sodium carbonate, sodium methoxide, and potassium tertiarybutoxide. organic bases such as triethylamine, pyridine, diazabicyclononene, etc.; organic metals such as butyllithium and lithium diisobutylamide; alkali metal hydrides such as sodium hydride; or sodium amide, etc. and alkali metal ammonium salts of. The reaction temperature is preferably The temperature should be sufficient to drive the reaction to completion without promoting the formation of undesirable by-products, preferably from -78 to 150°C, for example. Under preferred reaction conditions, the reaction is preferably complete, eg, in 1 to 24 hours, and the progress of the reaction can be monitored by known chromatographic techniques. Undesired by-products can be removed by techniques known to those skilled in the art such as conventional chromatographic techniques, extraction procedures or / and crystallization. [Preparation of compound (11)] Compound (11) can be prepared using ratatam compound (6b) as a starting material according to [Step 10-1]. Preferably, for example i) Wittig reagent (1 1) (wherein L is a phosphor 10 Yuum salt) is prepared by a method known to those skilled in the art (for example, "The Chemical Society of Japan, Experimental Chemistry Course (Volume 19) Organic Synthesis [1]", Maruzen Co., Ltd., June 1992, pp. 430-438), followed by reaction with an organophosphorus compound such as triphenylphosphine (see, for example, Organic Reaction, 1965, 14, 270). ii) Horner-Emmons reagent (1 1) (where L is the phosphite Ten ) prepared the ratatam compound (6b) by a method known to those skilled in the art (for example, “The Chemical Society of Japan, Experimental Chemistry Course (Volume 19) Organic Synthesis [1]”, Maruzen Co., Ltd., June 1992, p. 430 — 438), followed by the Arbuzov reaction with alkylphosphinites (see, e.g., Chemical Review, 1981, 81, 415) or the Becker 1XJ core with metal phosphonites (columns, Journal oi the American Chemical Society, 1945, Volume 1, page 1180). Alternatively, it can also be prepared from the ratatam compound (6b) and chloroformic phosphate in the presence of a base (see, for example, Journal of Organic Chemistry, 1989, vol. 54, p. 4750). iii) Peterson's reagent (1 1) (where V, and L are silyl groups) reacted with ratatam compound (6b) and trialkylsilyl chloride in the presence of a base. Ten (Refer to Journal of Organometallic Chemistry, 1983, Vol. 248, p. 51. iv) Esterole isomer! Here (here, L is an ester group or a carboxyl group), the ratatam compound (6 Ten b), carbonic acid diesters, halogenated carbonates, and carbon dioxide (e.g., “The Chemical Society of Japan, Experimental Chemistry Course (Vol. 22) Organic Synthesis [IV]”, Maruzen Co., Ltd., 1992 6 March, p. 14—30, and p. 54—71). Yun S S¾J 53I indicates a single or double bond and Ar, Z, Z, R 5 , R. 6 , p, q, Xa and r are as above 2 1 2 the same meaning, X and y are integers from 0 to 2, L is a halogen such as chlorine, bromine, iodine, etc. 11 atoms or sulfonate groups such as triflate groups, L is a methyl ester group, and 12 Indicates an ester group such as a thyl ester group or a carboxylic acid. ]

[0154] In the above [Reference Example 5], i) Aldehyde compound (5) is converted to [Step 11-1] or [Step 11-4] via [Step 11-5]. In [Step 11 2], it is subjected to a condensation reaction with amine compound (16), converted to amide compound (13), and then subjected to Ring Closing Metathesis reaction in [Step 11 3] and subsequent double bond modification reaction. and ii) lead aldehyde compound (5) to compound (14) according to [Step 11 4], and amide compound (15) in [Step 11 6]. After the conversion, it is subjected to the Heck reaction of [Step 117] and the subsequent double bond modification reaction to produce compound (1).

[0155] [Preparation of compound (1)] In case i), compound (1) can be prepared from amide compound (13) according to [Step 11-3]. "Step 113" consists of a Ring Closing Metathesis reaction followed by a double bond modification reaction. That is, the first-stage Ring closing metathesis reaction varies depending on the starting materials, but if the conditions are similar to this reaction, a method known to those skilled in the art (for example, Comprehensive Organometallic Chemistry, 1982, 8, page 499) can be used. Angewandte Chemie International Edition, 2000, Vol. 39, p. 3012, etc.) The second-step double bond modification reaction can be performed, for example, by i) catalytic hydrogenation (for example, "Nippon Kagaku Experimental Chemistry Lectures, Vol. 26, Organic Synthetic Reaction [VIII]”, Maruzen Co., Ltd., April 1992, p. Kagaku Koza (Vol. 26) Organic Synthetic Reaction [VII]”, Maruzen Co., Ltd., September 1991, p 83 134), iii) oxidation of carbon-carbon double bonds (e.g., “The Chemical Society of Japan ed. Chemistry Course (Vol. 26) Organic Synthetic Reaction [V], Maruzen Co., Ltd., October 1991, p. 237-267).

[0156] The Ring Closing Metathesis reaction is preferably carried out, for example, by treating the amide compound (13) with In this method, amide compound (13) is stirred in a solvent in the presence of 0·0; Preferred solvents to be used include halogen solvents such as methylene chloride and chloroform, ether solvents such as tetrahydrofuran, 1,4-dioxane and 1,2-dimethoxyethane, and benzene, toluene, xylene and the like. Examples include nonpolar solvents and the like, and mixed solvents thereof. The metal catalyst to be used varies depending on the starting materials and solvents. Imidazolidinylidene]dichloro-(tricyclohexylphosphine)ruthenium (IV), [1,3-bis-(2,4,6-trimethylphenyl)-2-imidazolidinylidene]dichloro(ortho-isopropoxyphenylmethyl Ruthenium-based catalysts such as bis(tricyclohexylphosphine) 3-phenyl-1H-indene-1-ylideneruthenium (II) dichloride, 2,6-diisopropylphenylimide neophylidene biphen Molybdenum-based catalysts such as molybdenum (VI), 2, 6-diisopropylphenylimide neophylidene molybdenum (VI) bis(hexafluorotertiary butoxide) and the like are used. The reaction temperature should be sufficient to complete the reaction without promoting the formation of undesired by-products, preferably between room temperature and 100°C. Under preferred reaction conditions, the reaction is preferably complete, eg, in 1 to 24 hours, and the progress of the reaction can be monitored by known chromatographic techniques. Undesired by-products can be removed by techniques known to those skilled in the art, such as conventional chromatographic techniques, extraction procedures or / and crystallization. The double bond modification reaction is preferably, for example, catalytic hydrogenation, for the closed ring form obtained from the Ring Closing M etathesis reaction, preferably, for example, from 0.01 to 0.2 for the closed ring form. In the presence of an equivalent amount of metal catalyst, preferably, the reduction reaction of the closed-ring product is carried out under a hydrogen stream of, for example, 1 to 10 atmospheres. This reaction is preferably carried out in the presence of a solvent from the viewpoint of operability and stirring efficiency. Ether solvents such as tetrahydrofuran, 1,4 dioxane, 1,2-dimethoxyethane, etc. Nonpolar solvents such as benzene, toluene, xylene, etc. Polar solvents such as ethyl acetate, acetonitrile, etc. etc., or a mixed solvent thereof. The metal catalyst to be used is preferably platinum, platinum oxide, platinum black, Raney nickel, noradium carbon, etc., depending on the starting material and solvent. The reaction temperature should be sufficient to complete the reaction without promoting the formation of unwanted by-products, preferably, for example room temperature. ~; 100°C. Under preferred reaction conditions, the reaction is preferably complete, eg, in 1 to 24 hours, and the progress of the reaction can be monitored by known chromatographic techniques. Undesired by-products can be removed by techniques known to those skilled in the art such as conventional chromatographic techniques, extraction procedures or / and crystallization.

[0158] In the case of ii), compound (1) can be prepared from amide compound (15) according to [Step 117]. That is, [Step 117] consists of a Heck reaction followed by a double bond modification reaction. That is, the Heck reaction in the first stage varies depending on the starting material, but if the conditions are similar to this reaction, a method known to those skilled in the art (for example, "The Chemical Society of Japan, Experimental Chemistry Course (Volume 19) Organic Synthesis Reaction [ 1]”, Maruzen Co., Ltd., June 1992, pp. 123-132). The double bond modification reaction in the second step is, for example, i) catalytic hydrogenation (for example, "The Chemical Society of Japan, Experimental Chemistry Course (Volume 26) Organic Synthetic Reaction [VIII]", Maruzen Co., Ltd., April 1992 , p. 251-266), ii) hydroboration (e.g., "The Chemical Society of Japan, Experimental Chemistry Course (Volume 26) Organic Synthetic Reaction [VII]", Maruzen Co., Ltd., September 1991, ρ 83 — 134), iii) oxidation of carbon-carbon double bonds (e.g., ``The Chemical Society of Japan, Experimental Chemistry Course (Vol. 26) Organic Synthetic Reaction [V]'', Maruzen Co., Ltd., October 1991, p. 237—see 267), etc.

[0159] The Heck reaction preferably includes, for example, a method in which compound (15) is stirred in a solvent in the presence of a transition metal catalyst in an amount of 0.0; The solvent to be used varies depending on the starting material and the transition metal catalyst to be used, and is not particularly limited as long as it dissolves the starting material to some extent without inhibiting the reaction. ,4-dioxane, 1,2-dimethoxyethane, benzene, toluene, xylene, 1-methyl-2-pyrrolidone, N,N-dimethylformamide and the like. The reaction temperature should be a temperature sufficient to complete the coupling reaction, preferably room temperature to 150°C, for example. This reaction is preferably carried out under an inert gas atmosphere. preferably under a nitrogen or argon atmosphere. The transition metal catalyst is preferably, for example, a palladium complex, and more preferably, for example, palladium acetate (11), dichlorobis(triphenylphosphine)palladium (II), tetrakis(triphenylphosphine)palladium (0 ), tris(dibenzylideneacetone)dipalladium(0), and other known palladium complexes. In addition, in order to allow the reaction to proceed efficiently, the transition metal catalyst used preferably contains, for example, 1.0 to 5.0 equivalents of a phosphorus ligand (preferably, for example, triphenylphosphine, tri-o-tolylphosphine , tri-tert-butylphosphine, 2 (di-tert-butylphosphino)biphenyl, etc.) are also preferably added as appropriate. In addition, favorable results may be obtained in the presence of a base, and the base to be used is not particularly limited as long as it is used in a coupling reaction like this reaction, but is preferably, for example, a compound Triethylamine, N,N diisopropylethylamine, N,N dicyclohexylmethylamine, tetraptylammonium chloride and the like are exemplified in an amount of 0·1 to 5.0 equivalents relative to (15). Under preferred reaction conditions, the reaction is preferably complete, eg, in 1 to 24 hours, and the progress of the reaction can be monitored by known chromatographic techniques.

[0160] [Preparation of amide compound (13)] The amidation reaction in [Step 11 2] is not particularly limited as long as the reaction conditions differ depending on the starting materials. "Chemical Society of Japan, New Experimental Chemistry Course (Volume 14) Synthesis and Reaction of Organic Compounds [II]", Maruzen Co., Ltd., February 1978, pp. 1136-1162). Preferably, for example, i) a method of converting the compound (12) into an acid halide and then reacting the acid halide with the amine compound (16) under basic conditions Kagaku Koza (Vol. 14) Synthesis and Reaction of Organic Compounds

[0011] , Maruzen Co., Ltd., February 1978, p. and the amine compound (16) (described, for example, in "Handbook for Organic Chemistry Experiments [4]", Kagaku Dojin, September 1990, pp. 27-52).

[0161] In the case of i), the conversion reaction of compound (12) to an acid halide is preferably carried out, for example, by converting compound (12) to halogenation of 1.0-10.0 equivalents relative to compound (12). A method of stirring in a solvent in the presence of the agent can be mentioned. The halogenating agent to be used varies depending on the starting material. Although not particularly limited, preferred examples include choyuruku oralide, phosphorus pentachloride, oxalyl chloride, and the like. The solvent to be used is not particularly limited as long as it dissolves the starting material to some extent without inhibiting the reaction, but preferred examples include methylene chloride, chloroform, toluene, and the like. In some cases, the reaction may proceed efficiently by appropriately adding 0.1 to 1.0 equivalent of an organic base such as pyridine or dimethylformamide to compound (12). The reaction temperature is preferred / should be sufficient to complete the reaction without promoting the formation of by-products, preferably ice cold to 150°C, for example. Under preferred reaction conditions, the reaction is preferably complete, eg, in 1-24 hours, and the progress of the reaction can be monitored by known chromatographic techniques. Desirable by-products can be removed by techniques known to those skilled in the art, such as conventional chromatographic techniques and / or crystallization.

[0162] The subsequent coupling reaction is preferably carried out, for example, in the presence of the acid halide and a base of 1.0-100.0 equivalents relative to the halide, up to 1.0-5.0 equivalents relative to the halide. and a method of stirring the amine compound (16) in a solvent. The base used varies depending on the starting material and is not particularly limited, but preferred examples include pyridine, triethylamine, N,N-diisopropylethylamine, lutidine, quinoline and isoquinoline. . The solvent to be used is not particularly limited as long as it dissolves the starting material to some extent without inhibiting the reaction. Preferred examples include methylene chloride, chloroform, toluene, tetrahydrofuran, 1,4-dioxane, and the like. be. Bases may also be used as solvents. Alternatively, a two-layer distribution system can be used in which an alkaline aqueous solution, preferably an aqueous solution such as sodium hydroxide or potassium hydroxide, is used as a base, and a halogen solvent such as methylene chloride or 1,2-dichloroethane. The reaction temperature should be sufficient to complete the reaction without promoting the formation of undesired by-products, and is preferably, for example, ice cold to 100°C. Under preferred reaction conditions, the reaction is preferably complete, eg, in 1 to 24 hours, and the progress of the reaction can be monitored by known chromatographic techniques. Undesired by-products can be removed by techniques known to those skilled in the art, such as conventional chromatographic techniques or / and crystallization.

[0163] In the case of ii), preferably, for example, compound (12) and 1.0-5.0 for compound (12) A method of stirring 1.0 to 5.0 equivalents of amine compound (16) with respect to compound (12) in a solvent in the presence of an equivalent amount of a condensing agent can be mentioned. The condensing agent to be used varies depending on the starting material and is not particularly limited. Preferred examples include 1,3-dicyclohexylcarposimide, 1-ethyl-3-(3'-dimethylaminopropyl)carposimide, benzotriamide, azole-1-yloxytris(dimethylamino)phosphonium hexafluorophosphate, diethylcyanophosphonate, or bis(2-oxo-3-oxazolidinyl)phosphinic chloride. For efficient reaction, for example, N-hydroxysuccinimide, N-hydroxybenzotriazole, etc. may be preferably added in an amount of 1.0 to 2.0 equivalents relative to compound (12). From the viewpoint of operability and stirring efficiency, this reaction is preferably carried out in the presence of a solvent. Halogen-based solvents such as methylene chloride and 1,2-dichloroethane, and polar solvents such as tetrahydrofuran and N,N-dimethylformamide are preferably used. The reaction temperature is preferred, and should be sufficient to complete the reaction without promoting the formation of by-products, preferably between ice cold and 100°C. Under favorable reaction conditions, the reaction is preferably complete, eg, in 1-24 hours, and the progress of the reaction can be monitored by known chromatographic techniques. Undesired by-products can be removed by techniques known to those skilled in the art, such as conventional chromatographic techniques and / or crystallization.

[0164] [Preparation of amine compound (16)] The amine compound (16) used is either commercially available or can be prepared by methods known to those skilled in the art (see, eg, Tetrahedron Letters, 1998, 39, p5421).

[0165] [Preparation of compound (12)] Compound (12) is prepared by: i) aldehyde compound (5) according to [Step 111], or ii) aldehyde compound (5) according to [Step 114], compound (14) (In this case L is 12 Indicates an ester group. ), it can be prepared according to [Step 11 5].

[0166] [Conversion from aldehyde compound (5) to compound (12)] [Step 11 1] is the first step to lead the aldehyde compound (5) to the cinnamate compound. , followed by a second step of hydrolyzing the ester group to a carboxylic acid group. Cinnamic acid ester compounds can be prepared from aldehyde compounds (5) and various Horner-Emmons reagents by methods known to those skilled in the art (see, for example, W. S. Wadsworth. Jr., Organic Reactions, 1997, 25, 73). . Preferably, e.g. aldehyde compound (5) and preferably, e.g. By using 0 equivalent of the base, the cinnamic acid ester compound can be obtained in high yield. The Horner-Emmons reagent can be prepared by methods known to those skilled in the art. For example, the alkylation of commercially available trialkylphosphonoacetic acids (see, for example, Synthetic Communication, 1991, 22, 2391), or the Arbuzov reaction with alkylphosphinites of alphahalogenoacetic acid derivatives ( Chemical Review, 1981, 81, 415) or Becker reaction using a metal phosphonite (see, for example, Journal of the American Chemical Society, 1945, 67, 1180). be able to. The solvent to be used is preferably a polar solvent such as 1-methyl-2-pyrrolidone, N,N dimethinoleformamide, dimethylsulfoxide, or an ether such as tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane. Non-polar solvents such as benzene, toluene and xylene, alcoholic solvents such as ethanol and methanol, water and the like, or mixed solvents thereof are used. The base to be used varies depending on the starting material and solvent. Preferred examples include alkali metal hydroxides such as sodium hydroxide and lithium hydroxide, alkali metal carbonates such as sodium carbonate, sodium methoxide, and potassium tert-butoxide. organic bases such as triethylamine, pyridine and diazabicyclononene; organic metals such as butyllithium and lithium diisobutylamide; alkali metal hydrides such as sodium hydride; ummoyua salt and the like. The reaction temperature should be sufficient to complete the reaction without promoting the formation of undesired by-products, and is preferably, for example, from 78 to 150°C. Under preferred reaction conditions, the reaction is preferably complete, eg, in 1 to 24 hours, and the progress of the reaction can be monitored by known chromatographic techniques. Undesirable by-products may be produced by conventional chromatographic techniques, extraction procedures or / and crystallization. It can be removed by techniques known to those skilled in the art. For the hydrolysis reaction of the cinnamic acid ester compound as a starting material to compound (12), a deprotection technique known to those skilled in the art can be used (for example, Γ. W. Green. "Protective Groups in Organic Synthesis," John Wiley & Sons. Inc., 1981, pl 54—186).

[0167] [Conversion from compound (14) to compound (12)] Compound (12) can be prepared by coupling compound (14) as a starting material with a corresponding alkene compound according to [Step 115]. That is, the coupling reaction of [Step 11-5] can be performed by a method known to those skilled in the art, and the Heck reaction (for example, R. F. Heck, "Org. Reactions.", 1982, vol. 27, p. 345). Suzuki reaction (see e.g. A. Suzuki, "Chem. Rev.", 1995, vol. 95, p. 2457), Stilled pplling reaction (see e.g. J. K. Stille, "Angew. Chem. Int. Ed. Engl. , 1986, Vol. 25, ρ 508).

[0168] The Heck reaction is preferably carried out with, for example, a halide, triflate compound (14), preferably, for example, with 1.0 to 5.0 equivalents of an alkene compound relative to compound (14), preferably, for example, , in the presence of 0.01-0.2 equivalents of a transition metal catalyst, a coupling reaction is performed on compound (14). This reaction is preferably carried out in the presence of a solvent from the viewpoint of operability and stirring efficiency. but preferably acetonitrile, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyhetane, benzene, toluene, xylene, 1-methyl 2-pyrrolidone, N, and N dimethyl formamide. The reaction temperature should be a temperature sufficient to complete the coupling reaction, preferably room temperature to 150°C, for example. This reaction is preferably carried out under an inert gas atmosphere, more preferably under a nitrogen or argon atmosphere. The transition metal catalyst is preferably, for example, a palladium complex, and more preferably, for example, palladium(II) acetate, dichlorobis(triphenylphosphine)palladium(II), tetrakis(triphenylphosphine)palladium(0) and tris(dibenzylideneacetone)dipalladium(0). In addition, a phosphorus ligand (preferably, for example, triphenylphosphine, tri-o-tolylphosphine, tri-phenylphosphine, Tertiary-butylphosphine, 2-(di-tert-butylphosphino)biphenyl, etc.) can also be added as appropriate. Favorable results may also be obtained in the presence of a base, and the base to be used is not particularly limited as long as it is used in a coupling reaction similar to this reaction, but preferred examples include triethylamine, N, N diisopropylethylamine, N,N dicyclohexylmethylamine, tetrabutylammonium chloride and the like. Under preferred reaction conditions, the reaction is preferably complete, eg, in ~24 hours, and the progress of the reaction can be monitored by known chromatographic techniques. In the Suzuki reaction, for example, a halide or triflate compound (14) is preferably combined with, for example, 1.0 to 5.0 equivalents of a boronic acid compound or a boronic acid ester compound with respect to compound (14). is preferably carried out, for example, in the presence of a transition metal catalyst in an amount of 0.01-0.5 equivalents relative to compound (14). This reaction is preferably carried out in the presence of a solvent from the viewpoint of operability and stirring. Although it is not particularly limited as long as it can be used, preferably, for example, acetonitrile, tetrahydrofuran, 1,4 dioxane, 1,2-dimethoxyethane, benzene, tonolene, xylene, 1-methinole 2-pyrrolidone, N,N dimethyl formamide, water, etc., or a mixed solvent thereof. The reaction temperature should be a temperature sufficient to complete the coupling reaction, and is preferably room temperature to 200°C, for example. This reaction is preferably carried out under an inert gas atmosphere, more preferably under a nitrogen or argon atmosphere. The transition metal catalyst is preferably a known palladium complex, more preferably palladium acetate(11), dichlorobis(triphenylphosphine)palladium(II), tetrakis(triphenylphosphine)palladium(0), tris(triphenylphosphine)palladium(0), Known palladium complexes such as (dibenzylideneacetone) dipalladium (0) can be mentioned. In addition, a phosphorus ligand (preferably, for example, triphenylphosphine, tri-o-trinolephosphine, tricyclohexylphosphine, tri-tert-butylphosphine, etc.) or the like can be appropriately added in order to allow the reaction to proceed efficiently. Further, in order to allow the reaction to proceed efficiently, a quaternary ammonium salt, preferably tetrabutylammonium chloride, tetrabutylammonium bromide, etc., can be appropriately added. This reaction can obtain favorable results in the presence of a base. The type varies depending on the starting material, the solvent used, etc., and is not particularly limited, but is preferably, for example, sodium hydroxide, barium hydroxide, potassium fluoride, cesium fluoride, sodium carbonate, potassium carbonate, carbonate Cesium, potassium phosphate and the like can be mentioned. Under preferred reaction conditions, the reaction is preferably complete, eg, in 1-24 hours, and the progress of the reaction can be monitored by known chromatographic techniques.

[0170] Stille coupling reaction is preferably carried out, for example, by combining halide or triflate compound (14) with 1 0-10.0 equivalents of trialkyltin compound relative to compound (14), preferably, for example , in the presence of 0.01-0.2 equivalents of a transition metal catalyst relative to compound (14), in a solvent. In order to allow the reaction to proceed efficiently, preferably, for example, 0.; to 5.0 equivalents of copper (I) halide or / and lithium chloride are appropriately used with respect to compound (14). can. Preferable examples of the solvent used in this reaction include toluene, xylene, N,N dimethylformamide, N,N dimethylacetamide, 1-methyl 2pyrrolidone, dimethylsulfoxide and the like. The reaction temperature should be a temperature sufficient to complete the coupling reaction, preferably room temperature to 100°C, for example. The transition metal catalysts used are palladium complexes, preferably for example palladium(II) acetate, dichlorobis(triphenylphosphine)palladium(II), tetrakis(triphenylphosphine)palladium(0), tris(dibenzylideneacetone) Examples include known palladium complexes such as dipalladium (0), more preferably tetrakis(triphenylphosphine) noradium (0), tris(dibenzylideneacetone) dipalladium (0), and the like. This reaction is preferably carried out in an inert gas atmosphere, more preferably in a nitrogen or argon atmosphere. Under preferred reaction conditions, the reaction is preferably complete, eg, in ~24 hours, and the progress of the reaction can be monitored by known chromatographic techniques.

[0171] [Conversion from compound (5) to compound (14)] Compound (14) can be prepared by subjecting compound (5) as a starting material to Horner-Emmons reaction with halogenated phosphonoacetic acid according to [Step 114] (for example, Organic Letter, 2000, 2 Vol., p. 1975).

[0172] [Conversion from compound (14) to compound (15)] Compound (15) should be prepared according to [Step 11 6] using compound (14) as a starting material. can be done. [Step 116] and the preparation of the amine compound to be used are the same as [Step 112]. [Chemical 23] [In the formula, indicates a single or double bond and Ar, Z, Z, R 5 , R. 6 , Xa, p, q and r are as above 2 1 2 L has the same meaning, L is a halogen atom such as a chlorine atom or a bromine atom, or a mesyl group, tosyl 12 L is a phosphite ester such as a diethylphosphonyl group 13 L and L are a hydroxyl group, a hydroxyl group with a protecting group, an amino group, or a protecting group 14 15 V is an ester group such as a methyl ester group or ethyl ester group, or 3 Indicates a carboxylic acid group. ]

[0174] The above [Reference Example 6] is obtained from the aldehyde compound (5) and the Homer-Emmons reagent (17) 12-1] to lead to compound (18), after the amidation reaction in [Step 12-2], to form a ratatam ring according to [Step 12-3], and finally in [Step 12-4] to form the second This is an example of a method of producing compound (1) by subjecting it to a ring-forming reaction.

[0175] [Preparation of compound (1)] Compound (1) can be prepared from ratatam compound (21) according to [Step 12-4]. [Step 12-4] removes the alcohol group or amine group of L and L of compound (21). 14 15 It consists of a protection reaction followed by a ring closure reaction. As the deprotection reaction, a deprotection reaction described in many known documents can be used (see, for example, T. W. Green. "Protective Groups in Organic Synthesis", John Wiley & sons. Inc., 1981). ). The ring closure reaction is not particularly limited as long as the reaction conditions vary depending on the starting material, and methods known to those skilled in the art can be used. Preferably, for example, i) a method of forming a cyclic ether from a diol (see, for example, Journal of Fluorine Chemistry, 1997, vol. 2, pp. 119, or Scientia Pharmaceutica, 1996, vol. 64, pp. 3, etc.), ii ) formation of aminoalcohols and cyclic amines (Petrochemia, 1990, Vol. 30, pp. 56) (see also WO2003 / 076386, Tetrahedron Letters, 1982, Vol. 23, pp. 229, etc.). More preferably, for example, the deprotected product is treated with 0.1 to 10 equivalents of an organic acid such as p-toluenesulfonic acid and camphorsulfonic acid, or an inorganic acid such as sulfuric acid and hydrochloric acid, relative to the deprotected product. By heating in the presence, in a solvent or in the absence of solvent, or preferably, for example, the deprotected product is treated with 0.1-1.0 tetrakistriphenylphosphine palladium, tris Compound (1) can be obtained in high yield by heating in the presence of an organic metal such as triphenylphosphine ruthenium. The solvent used in the reaction varies depending on the starting materials and reagents used, and is not particularly limited as long as it dissolves the starting materials to some extent without inhibiting the reaction. Preferred examples include methylene chloride, chloroform, 1,4-dioxane, 1,2-dimethoxyethane, dimethylsulfoxide, toluene, tetrahydrofuran, dimethylformamide, ethanol, methanol, water, etc., or a mixed solvent thereof. The reaction temperature should be sufficient to complete the reaction without promoting the formation of undesired by-products, and is preferably, for example, ice cold to 100°C. Under preferred reaction conditions, the reaction is preferably complete, eg, in 1 to 24 hours, and the progress of the reaction can be monitored by known chromatographic techniques. Undesired by-products can be removed by techniques known to those skilled in the art, such as conventional chromatographic techniques or / and crystallization. [Preparation of ratatam compound (21)] The ratatam compound (21) can be prepared from the cinnamide compound (20) as a starting material by a cyclization reaction accompanied by the elimination of L from the cinnamide compound (20) according to [Step 123]. Suwa 12 Thus, for example, compound (20) is preferably treated with, for example, 1.0 to 5.0 equivalents of a base relative to compound (20) to give the desired ratatam compound (21) in high yield. Obtainable. This reaction is preferably carried out in the presence of a solvent from the viewpoint of operability and stirring efficiency. Although it is not particularly limited as long as it is a solvent, preferred examples include polar solvents such as 1-methyl 2-pyrrolidone, N,N dimethylformamide, and dimethylsulfoxide; Ether-based solvents, non-polar solvents such as benzene, toluene and xylene, alcohol-based solvents such as ethanol and methanol, water and the like, or mixed solvents thereof are used. The base to be used varies depending on the starting material and solvent. Preferably, for example, alkali metal hydroxides such as sodium hydroxide and lithium hydroxide, alkali metal carbonates such as sodium carbonate, sodium methoxide, and potassium tertiarybutoxide. organic bases such as triethylamine, pyridine and diazabicyclononene; organic metals such as butyllithium and lithium diisobutylamide; alkali metal hydrides such as sodium hydride; alkalis such as sodium amide. metal ammonium salts and the like. The reaction temperature is preferably The temperature should be sufficient to drive the reaction to completion without promoting the formation of harsh by-products, preferably between -78 and 150°C, for example. Under preferred reaction conditions, the reaction is preferably complete, eg, in 1 to 24 hours, and the progress of the reaction can be monitored by known chromatographic techniques. Undesired by-products can be removed by techniques known to those skilled in the art such as conventional chromatographic techniques, extraction procedures or / and crystallization.

[0177] [Cinnamide compound ( 2 0) Preparation] Cinnamide compound (20) is converted to compound (18) according to the amidation reaction of [Step 12-2], preferably, for example, 1.0 to 5.0 equivalents of amine compound relative to compound (18) (19). The amidation reaction is not particularly limited as long as the force varies depending on the starting material. Kagaku Koza (Vol. 14) Synthesis and Reaction of Organic Compounds [II]", Maruzen Co., Ltd., February 1978, p. 1136-1162). Preferably, for example, i) a method of converting the compound (18) into an acid halide and then reacting the acid halide with the amine compound (19) under basic conditions (Volume 14) Synthesis and reaction of organic compounds

[0011] ”, Maruzen Co., Ltd., February 1978, p. 19) and the like (described, for example, in "Organic Chemistry Experiment Guide [4]", Kagaku Dojin, September 1990, pp. 27-52).

[0178] In the case of i), the conversion reaction of compound (18) to an acid halide is preferably carried out, for example, by converting compound (18) to halogenation of 1.0-10.0 equivalents relative to compound (18). A method of stirring in a solvent in the presence of the agent can be mentioned. The halogenating agent to be used varies depending on the starting material and is not particularly limited, but preferred are, for example, choyuruku oralide, phosphorus pentachloride, oxalyl chloride and the like. The solvent to be used is not particularly limited as long as it dissolves the starting material to some extent without inhibiting the reaction, but preferred examples include methylene chloride, chloroform, toluene, and the like. Further, the reaction may proceed efficiently by appropriately adding 0.1 to 1.0 equivalent of an organic base such as pyridine or dimethylformamide to compound (18). The reaction temperature is preferred / should be sufficient to complete the reaction without promoting the formation of by-products, preferably ice cold to 150°C, for example. Under preferred reaction conditions, the reaction is preferably complete, eg, in 1-24 hours, and the progress of the reaction can be monitored by known chromatographic techniques. Desirable by-products can be removed by techniques known to those skilled in the art, such as conventional chromatographic techniques and / or crystallization.

[0179] The subsequent coupling reaction is preferably carried out, for example, in the presence of the acid halide and a base of 1.0-100.0 equivalents relative to the halide, up to 1.0-5.0 equivalents relative to the halide. and the amine compound (19) are stirred in a solvent. The base used varies depending on the starting material and is not particularly limited, but preferred examples include pyridine, triethylamine, N,N diisopropylethylamine, lutidine, quinoline, isoquinoline, and the like. . The solvent to be used is not particularly limited as long as it dissolves the starting material to some extent without inhibiting the reaction, but preferred examples include methylene chloride, chloroform, toluene, tetrahydrofuran, 1,4-dioxane and the like. Bases may also be used as solvents. Alternatively, a two-layer distribution system can be used in which an alkaline aqueous solution, preferably an aqueous solution of, for example, sodium hydroxide or potassium hydroxide, is used as a base, and a halogen-based solvent such as methylene chloride or 1,2-dichloroethane. . The reaction temperature should be sufficient to complete the reaction without promoting the formation of undesired by-products, and is preferably, for example, ice cold to 100°C. Under preferred reaction conditions, the reaction is preferably complete, eg, in 1-24 hours, and the progress of the reaction can be monitored by known chromatographic techniques. Undesired by-products can be removed by techniques known to those skilled in the art, such as conventional chromatographic techniques or / and crystallization.

[0180] In the case of ii), preferably, for example, in the presence of compound (18) and 1.0-5.0 equivalents of a condensing agent relative to compound (18), 1.0-5 relative to compound (18) 0 equivalent of amine compound (19) is stirred in a solvent. The condensing agent to be used varies depending on the starting material and is not particularly limited, but is preferably, for example, 1,3-dicyclohexylcarposimide, 1-ethyl-3-(3'-dimethylaminopropyl)carposimide, benzotriamine. azole-1-yloxytris(dimethylamino)phosphonium hexafluorophosphate, diethylcyanophosphonate, or bis(2-oxo-3-oxazolidinyl)phosphinic chloride. In order to allow the reaction to proceed efficiently, for example, N— Hydroxysuccinimide, N-hydroxybenzotriazole or the like may be added in an amount of 1.0 to 2.0 equivalents relative to compound (18). From the viewpoint of operability and stirring efficiency, this reaction is preferably carried out in the presence of a solvent. Halogen-based solvents such as methylene chloride and 1,2-dichloroethane, and polar solvents such as tetrahydrofuran and N,N-dimethylformamide can be preferably used. The reaction temperature is preferred, and should be sufficient to complete the reaction without promoting the formation of by-products, preferably between ice cold and 100°C. Under favorable reaction conditions, the reaction is preferably complete, eg, in 1-24 hours, and the progress of the reaction can be monitored by known chromatographic techniques. Undesired by-products can be removed by techniques known to those skilled in the art, such as conventional chromatographic techniques and / or crystallization.

[0181] [Preparation of amine compound (19)] Amine compounds (19) are commercially available or can be prepared by methods known to those skilled in the art. If it is not commercially available, it can be prepared, for example, by converting the corresponding aldehyde group to a vinyl group and then amino-hydroxylating it (for example, Journal of the American Chemical Society, 2001, vol. 123, p. 1862). reference).

[0182] [Preparation of compound (18)] [Step 12-1] consists of synthesis of cinnamic acid ester compound by condensation reaction of aldehyde compound (5) and Horner-Emmons reagent (17), followed by deprotection of ester group to carboxylic acid. That is, the Horner-Emmons reaction is carried out using an aldehyde compound (5) as a starting material by a method known to those skilled in the art (e.g., "The Chemical Society of Japan, Experimental Chemistry Course (Volume 19) Organic Synthesis [1]", Maruzen Co., Ltd., June 1992, p. 57-85). Preferably, the aldehyde compound (5) and preferably, for example, 1.0 to 5.0 equivalents of Horner-Emmons reagent (17) with respect to the aldehyde compound (5), preferably, for example, the aldehyde compound The desired cinnamic acid ester compound is obtained by reacting (5) in the presence of 1.0 to 5.0 equivalents of a base. The solvent to be used varies depending on the starting materials and reagents to be used and is not particularly limited. Polar solvents such as dimethylformamide, N,N dimethylformamide, and dimethylsulfoxide; ether solvents such as tetrahydrofuran, 1,4 dioxane, and 1,2 dimethoxyethane; nonpolar solvents such as benzene, toluene, and xylene; ethanol, methanol, etc. alcohol solvent, water, etc., or a mixed solvent thereof is used. The base to be used varies depending on the starting material and solvent. Alkali metal salts of alcohols such as lithium tertiarybutoxide, organic bases such as triethylamine, pyridine and diazabicyclononene, organic metals such as butyllithium and lithium diisobutylamide, alkali metal hydrides such as sodium hydride, Alternatively, alkaline metal ammonium salts such as sodium amide and the like are included. The reaction temperature should be sufficient to complete the reaction without promoting the formation of unwanted by-products, preferably -78 to 150°C, for example. Under preferred reaction conditions, the reaction is preferably complete, eg, in 1 to 24 hours, and the progress of the reaction can be monitored by known chromatographic techniques. Undesired by-products can be removed by techniques known to those skilled in the art such as conventional chromatographic techniques, extraction procedures or / and crystallization. The hydrolysis reaction to compound (18) starting from the cinnamic acid ester compound can be carried out using a deprotection technique known to those skilled in the art (see T. W. Green. "Protective Groups in Organic Synthesis", John Wiley & Sons. Inc., 1981, pl 54-186.). For example, with respect to the cinnamic acid ester compound, preferably in an alcoholic solvent such as methanol or ethanol, preferably, for example, 1.0 to 50.0 equivalents with respect to the cinnamic acid ester compound Compound (18) can be obtained in high yield by reaction in the presence of an alkali metal hydroxide such as sodium hydroxide and potassium hydroxide. [Preparation of compound (17)] Compound (17) is commercially available or, if not, can be prepared by methods known to those skilled in the art. For example, the alkylation of commercially available trialkylphosphonoacetic acids (see, e.g., Synthetic Communication, 1991, 22, 2391), or the Arbuzov reaction with alkylphosphinites of alphahalogenoacetic acid derivatives ( See, e.g., Chemical Review, 1981, vol. 81, p. 415) or metal It can be prepared by Becker reaction using phosphonite (for example, see Journal of the American Chemical Society, 1945, vol. 67, p. 1180).

[0184] [Preparation of compound (2)] Compound (2) can be obtained using a commercially available method, a technique known to those skilled in the art (Tetrahedron Letters, 2002, vol. 43, p. 3793-3794, or Synthetic Communications, 1984, vol. 14, p. 857). — See 864.).

[0185] [General manufacturing method 2] A representative [general production method 2] of the compound of general formula (I) according to the present invention is described below. [Chemical 24] (1) (4) (I) [Wherein, A, X, Y, R, R, L and η have the same meanings as above, W is an optionally substituted C16 alkyl group, a 6- to 14-membered aromatic hydrocarbon group , a 5- to 14-membered aromatic heterocyclic group, a 6- to 14-membered non-aromatic hydrocarbon group, or a 5- to 14-membered non-aromatic heterocyclic group, which may optionally have a protecting group. ]

[0186] The above [General production method 2] is an example of a method for producing the compound of general formula (I) by condensing compound (1) and compound (4) according to [Step 2-1]. be.

[0187] [Preparation of compound of general formula (I)] The compound of general formula (I) can be prepared according to [Step 21]. [Step 21] is the same as [Step 11] above. In addition, when W has a protecting group, those skilled in the art should be familiar with the techniques of protection (see T. Greene et al., "Protective Groups in Organic Synthesis", John Wiley & Sons. Inc., New York, 1999). From reference 0 ί, it can be deprotected appropriately to lead to the desired compound of general formula (I).If necessary, by ion exchange, the compound obtained by the above method can be converted into the desired anion Μ — having the general formula (I) can lead to compounds of The ion exchange is preferably carried out, for example, by using an anionic ion exchange resin or by using an organic acid (such as acetic acid, trifluoroacetic acid, benzenesulfonic acid, methanesulfonic acid, citric acid, maleic acid, etc.) or an inorganic acid (preferably , for example, hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, nitric acid, phosphoric acid, etc.).

[0188] [Preparation of compound (4)] Compound (4) can be obtained by using a commercially available force or a technique known to those skilled in the art (Synthesis 1971, vol. 11, p. 588-590, Synthetic Communications, 1994, vol. 24, p. 7-67- 772, or see JP-A-5-194517).

[0189] The compound of general formula (I) or a pharmacologically acceptable salt thereof of the present invention has excellent solubility, and according to the present invention, a prodrug of a cinnamide compound having A / 3 production inhibitory activity. As a therapeutic agent or preventive agent for neurodegenerative diseases caused by A / 3, such as Alzheimer's disease and Down's syndrome. In addition, the compounds of the present invention improve the solubility of the parent cinnamide compound and liberate the bioactive parent compound enzymatically and non-enzymatically. That is, it functions as a prodrug.

[0190] The prophylactic or therapeutic agent for diseases caused by Aβ of the present invention can be formulated by a commonly used method. Examples include tablets, capsules, syrups, lozenges, inhalants, suppositories, injections, ointments, eye drops, eye ointments, nose drops, ear drops, poultices, lotions and the like. For formulation, commonly used excipients, binders, lubricants, coloring agents, flavoring agents, and, if necessary, stabilizers, emulsifiers, absorption enhancers, surfactants, ρΗ adjusters, preservatives Ingredients, anti-oxidants, etc. can be used, and ingredients generally used as raw materials for pharmaceutical formulations can be blended and formulated by conventional methods. Examples of these components include animal and vegetable oils such as soybean oil, beef tallow, synthetic glycerides; hydrocarbons such as liquid paraffin, squalane and solid paraffin; ester oils such as otatyldodecyl myristate and isopropyl myristate; higher alcohols such as alcohol and behenyl alcohol; silicone resins; e.g. silicone oils; Surfactants such as reoxyethylene hydrogenated castor oil, polyoxyethylene polyoxypropylene block copolymer; e.g., hydroxyethyl cellulose, polyacrylic acid, carboxylic vinylolepolymer, polyethyleneglycol, polyvinylolepyrrolidone, methinoresenolulose. lower alcohols such as ethanol and isopropanol; polyhydric alcohols such as glycerin, propylene glycol, dipropylene glycol and sorbitol; sugars such as glucose and sucrose; silicic anhydride and silicic acid Examples include inorganic powders such as aluminum magnesium and aluminum silicate, and purified water. Examples of excipients include lactose, cornstarch, sucrose, glucose, mannitol, sorbitol, crystalline cellulose, and silicon dioxide. gum, tragacanth, gelatin, silpyrrolidone, polypropylene glycol, polyoxyethylene block polymer, megnolemine, etc. Disintegrants include starch, agar, gelatin powder, crystalline cellulose, calcium carbonate, sodium hydrogen carbonate, citrate. Calcium acid, dextrin, pectin, carboxymethyl cellulose, calcium isotropic S, lubricants such as magnesium stearate, talc, polyethylene glycol, silica, hydrogenated vegetable oil, etc., and coloring agents may be added to pharmaceuticals. Permitted flavoring agents include cocoa powder, hearth brain, aroma powder, hearth oil, borneol, cinnamon powder, and the like. For example, an oral formulation contains a compound or a salt thereof as an active ingredient, or a hydrate thereof, an excipient, and, if necessary, a binder, a disintegrant, a lubricant, a coloring agent, a flavoring agent, and the like. After that, it is made into, for example, powders, fine granules, granules, tablets, coated tablets, capsules, etc. by conventional methods. Tablets and granules may of course be coated with sugar or other suitable coatings as necessary. In the case of syrups, injection preparations, etc., pH adjusters, solubilizers, tonicity agents, etc., and, if necessary, solubilizers, stabilizers, etc. are added, and formulated by conventional methods. In addition, in the case of external preparations, the production method is not particularly limited, and they can be produced by conventional methods. Various raw materials that are commonly used in pharmaceuticals, quasi-drugs, cosmetics, etc. can be used as base raw materials, such as animal and vegetable oils, mineral oils, ester oils, waxes, higher alcohols, fatty acids, , silicone oils, surfactants, phosphorus Raw materials such as lipids, alcohols, polyhydric alcohols, water-soluble polymers, clay minerals, purified water, etc., and if necessary, pH adjusters, antioxidants, chelating agents, antiseptic antifungal agents, Colorants, perfumes, etc. can be added. Furthermore, if necessary, components having a differentiation-inducing action, such as blood flow promoters, bactericides, antiphlogistic agents, cell activators, vitamins, amino acids, moisturizing agents, keratolytic agents, etc., can be added. . The dosage of the therapeutic agent or prophylactic agent according to the present invention varies depending on, for example, the degree of symptoms, age, sex, body weight, dosage form, type of salt, specific type of disease, etc. is about 30 g to 10 g, preferably 100 g to 5 g, more preferably lmg to lg, as an amount of the compound of formula (I) or a pharmacologically acceptable salt thereof per day orally. is administered by injection in an amount of about 30 μg to 1 g, preferably 100 μg to 500 mg, more preferably 100 μg to 30 mg each in one or several divided doses. Best Mode for Carrying Out the Invention

[0192] The present invention will be described in more detail below with reference to Examples and Test Examples, but these are merely illustrative. In any case, it is not intended to be limited to the following specific examples. Those skilled in the art will be able to carry out the present invention to its fullest extent by making various modifications to the scope of the claims, not only to the following examples and test examples, but also to the scope of the claims. The specification is intended to be included within the scope of such claims.

[0193] The following abbreviations are used in the examples below. THF: Tetrahydrofuran DMF : N, N'—dimethylformamide DME: ethylene glycol dimethinoleate IPEA: Diisopropylethylamine EDC: 1—ethyl 3—(3-dimethylaminopropyl) carposimide hydrochloride HOBT : 1-Hydroxybenzotriazole LAH: lithium aluminum hydride BOPCl : N, N-bis(2-oxo-3-oxazolidinole)phosphinic acid chloride Grubbs catalyst second generation: tricyclohexylphosphine [1 , 3-bis(2, 4, 6 Trimethinolefenyl) 4, 5 Dihydroimidazole-2ylidene][benzylidene]ruthenium (IV) dichloride TMED: N, N, Ν', Ν' Tetramethylethylenediamine TMSI: iodotrimethylsilane t: tertiary s: secondary DMSO: dimethinolesnorefoxide AIBN: 2, 2—azobis(isobutyronitrile) NMP:1—methyl 2-pyrrolidinone Example 1 3— {4- {1- {"(S)- 1- (4-phno-reolophenyl)ethinole Ί- 2 oxopiperidine- (3E)-ylidenemethyl} 2 methoxyphenyl} 5 methyl 1 (phosphonooxymethyl) Synthesis of 3H-imidazole 1um trifluoroacetate [Chemical 25] Chloromethyl ditertiarybutyl phosphate (CAS No.229625 -50-7, 185 mg), sodium iodide (214 mg) and diisopropylethylamine (2 l^L) in acetone (4 mL) solution under nitrogen atmosphere , (E)-1-[(1S)-1-(4-fluorophenyl)ethyl]-3[3-methoxy-4-(4-methyl-1H-imidazole-1-vinole)benzylidene]piperidine- 2On (CAS# 870843-42-8, 200mg) was added and the reaction was stirred at 60°C for 1 hour. The reaction mixture was concentrated under reduced pressure, methylene chloride (0.2 mU) and trifluoroacetic acid (0.3 mU) were added to the resulting residue, and the solution was stirred at room temperature for 2-5 hours. 25% aqueous solution of acetonitrile was mixed with reversed-phase C18 silica It was subjected to gel column chromatography (elution solvent: 30% acetonitrile aqueous solution containing 0·1% trifluoroacetic acid), and the target fraction was concentrated and lyophilized to obtain 247 mg of the title compound. The physical properties of this product are as follows. 'H-NMRCCD OD) δ (ppm): 1.58 (d, J = 7.2Hz, 3H), 1.63–1.90 (m, 2 3 H), 2.53(s, 3H), 2.80— 2.90 (m, 2H), 2.95— 3.05 (m, 1H), 3.35— 3.42 (m, 1H), 3.92(s, 3H), 5.94(d, J=12.8Hz, 2H) , 6.08(q, J = 7.2Hz z, 1H), 7.10(t, J = 8.8Hz, 2H) , 7.22(d, J = 8.0Hz, 1H), 7.32(s, 1H ), 7.38(dd, J = 8.8, 5.2Hz, 2H) , 7.58(d, J = 8.0Hz, 1H), 7.68(d, J=l. 6Hz, 1H), 7.80(s, 1H), 9.42( d, J=l.6Hz, 1H). Example 2 monohydrogen phosphate 1 {4-"(E)- {1-"(IS)- 1-(4-fluorophenyl)ethyl Ί 2 -oxopiperidine- 3 ylidene}methyl Ί 2 methoxyphenyl} 4 methyl 1 H-imidazole- 3—Synthesis of thiomethyl [Chemical 26] 3-{4-{1{[(S)-1-(4-fluorophenyl)ethyl]2-foxopiperidine-(3E)ylidenemethyl}2-methoxyphenyl}5-methyl-1-(phosphonyl)ethyl]2-{4-{1{[(S)-1-(4-fluorophenyl)ethyl}2-methoxyphenyl}5-methyl-1-(phospho An aqueous solution (4 mL) of 3H-imidazole-1-ium trifluoroacetate (150 mg) was subjected to reversed-phase C18 silica gel column chromatography (elution solvent: water → 35% acetonitrile aqueous solution) to give the desired fraction. After concentration and lyophilization, 112 mg of the title compound was obtained. The physical properties of this product are as follows. 'H-NMRCCD OD) δ (ppm): 1.59 (d, J = 7.2 Hz, 3H), 1.63–1.90 (m, 2 3 H), 2.53(s, 3H), 2.78— 2.85 (m, 2H), 2.95— 3.04 (m, 1H), 3.35— 3.42 (m, 1H), 3.96(s, 3H), 5.88(d, J=12.8Hz, 2H) , 6.09(q, J=7.2H z, 1H), 7.10(t, J = 8.8Hz, 2H), 7.21 (dd, J = 8.0, 1.2Hz, 1H), 7.31 (d, J=l.2Hz, 1H), 7.38(dd, J = 8.8, 5.2Hz, 2H) , 7.59(d, J = 8.0Hz, 1H), 7.65(d, J=l.6Hz, 1H), 7.80(s, 1H), 9.38(d, J=l. 6Hz, 1H). Example 3 1 acetoxymethyl 3 -|4-{l-r(S) -1- (4-phnoreolophenyl)ethynole Ί 2 -oxopiperidine-(3E) ylidenemethyl}-2 methoxyphenyl}-5 methyl- Synthesis of 3H—imidazole 1ium iodide [Chemical 27] (E)-1-[(1S)-1-(4-fluorophenyl)ethyl]3-[3-methoxy-4-(4-methyl-1H-imidazole-1-inole)benzylidene]piperidine-2-one (CAS No.870843-42-8, lOOmg) and chloromethinoleacetate (0.03m:L) in DME (2mU), sodium iodide (54mg) and ΙΡΕΑ (0 05mU) were added, and the reaction mixture was heated to 80°C. The reaction solution was allowed to cool to room temperature, and the precipitated solid was collected by filtration, washed with diethyl ether, and air-dried to obtain 70 mg of the title compound. The physical property values ​​are as follows. ESI—MS; m / z 492[M + ]. — NMR(CD OD) δ (ppm) : 1.59(d, J = 7.2 3 Hz, 3H), 1.63-1.80 (m, 2H), 2.17(s, 3H), 2.52(s, 3H), 2.79— 2.8 6(m, 2H), 2.94-3.03 (m, 1H), 3.20— 3.41 (m, 1H), 3.96 (s, 3H), 6.09(q, J = 7.2Hz, 1H), 6.19(s, 2H), 7.10(t, J = 8.8Hz, 2H), 7.22(brd, J = 8.0Hz, 1H), 7.32(brs, 1H), 7.38(dd, J = 8.8, 5.2Hz, 2H), 7.57(d, J = 8.0Hz, 1H), 7.70(s, 1H), 7.80 (brs, 1H). Example 4 3— ί_4 — LL1R._2R)_— 2H, 1— (3.4.5 trifluorophenyl) Synthesis of Ί2-oxopiperidine-(3Ε)ylidenemethyl}2-methoxyphenyl}5-methyl-1(phosphonooxymethyl)3Η-imidazolone-1ium trifluoroacetate [Chemical 28] 1.2.3 Synthesis of trifluoro-5-((E)-propeninole)benzene To a solution of 1-bromo-3,4,5-trifluorobenzene (8 5 g) and trans-1-propene-1-ylboronic acid (4.1 g) in dioxane (95 mL) and water (5 mL) under a nitrogen atmosphere, Tetrakistriphenylphosphine palladium(0) (4.66 g) and cesium fluoride (21·4 g) were added and the reaction was stirred at 80°C for 5 hours. After allowing the reaction solution to cool to room temperature, he added hexane and water to the reaction solution, filtered off the precipitated insoluble matter, and partitioned the organic layer. The obtained organic layer was washed with water, the insoluble matter was filtered off again, and the organic layer was partitioned. The obtained organic layer was washed successively with water and saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (elution solvent: hexane) to obtain 5.83 g of the title compound. The physical properties of this product are as follows. 'H-NMRCCDCl) δ (ppm): 1. 88 (d, J = 6. 0 Hz, 3H), 6. 18 (qd, J = 6. 0, 1 3 6. 0Hz, 1H), 6. 24(d, J=16. 0Hz, 1H), 6. 85— 6. 96 (m, 2H) . Synthesis of (IS, 2S)-1-(3,4,5-trifluorophenylene)propane-1,2-diol 1,2,3-Trifluoro-5-((E)-propenyl)benzene (5.83 g) was added to a mixed solution of butanol (170 mU and water (170 mU) under ice-cooling, and the reaction mixture was Stirred overnight at ° C. Then sodium sulfite (51 g) was added to the reaction mixture and the mixture was stirred at room temperature for 1 hour. was extracted three times with methylene chloride. After the combined organic layer was washed with a 2N aqueous sodium hydroxide solution, the sodium hydroxide layer was re-extracted with methylene chloride. The combined organic layer was dried over anhydrous magnesium sulfate and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane:ethyl acetate=9:1-1:1) to obtain 5.54 g of the title compound. The physical properties of this product are as follows. 'H-NMRCCDCl) δ (ppm): 1.12 (d, J = 6.4 Hz, 3H), 2.20 (brs, 1H), 2. 3 79(brs, 1H), 3.78(qd, J = 6.4, 6.4Hz, 1H), 4.34(d, J = 6.4Hz, 1H), 6.96-7.05 (m, 2H) .

[0199] Synthesis of (1R, 2S)-1-azido 1- (3, 4, 5-trifluorophenylene)propane-2-ol Under a nitrogen atmosphere, sodium hydroxide pellets (11 Omg) were added to a solution of (IS, 2S)-1-(3,4,5-trifluorophenyl)propane-1,2-diol (5.54 g) in dimethyl carbonate (15 mU). Then, the reaction solution was stirred for 45 minutes at 70° C. Then, the external temperature of the reaction solution was raised to 100° C., and dimethyl carbonate in the solution was removed by blowing nitrogen. ) was added, dimethyl carbonate was removed by blowing nitrogen, THF was added to the residue, insoluble materials were filtered off through celite, and the filtrate was concentrated under reduced pressure to obtain 6.13 g of a carbonate compound. Under a nitrogen atmosphere, water (0.5 mU and sodium azide (1.92 g) was added to a solution of the obtained carbonate in DMF (20 mL), and the reaction mixture was stirred at 110°C overnight. After reconstitution, diethyl ether was added to the reaction mixture, and the organic layer was partitioned, washed with water (three times) and saturated brine in that order, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane:ethyl acetate=19:1→9:1) to obtain 5.16 g of the title compound, whose physical properties are as follows. 'H-NMRCCDCl) δ (ppm): 1.14 (d, J = 6.4Hz, 3H), 1.79 (brs, 1H), 3. 3 97(qd, J = 6.4, 4.8Hz, 1H), 4.42(d, J = 4.8Hz, 1H), 6.96— 7.05 (m, 2H).

[0200] "(1R.2S)—2 hydroxy 1— (3, 4, 5 trifluorophenyl) propinole Ί canoleva Synthesis of Minic Acid Tert-Butyl Ester In a nitrogen atmosphere, (1R,2S)-1-azido-1-(3,4,5-trifluorophenyl)propan-2ol (5.16 g) in THF (75 mU solution, triphenylphosphine (5 85 g) was added. The reaction mixture was stirred at room temperature for 10 minutes, then water (5 mL) was added, and the mixture was stirred at 60° C. for 3.5 hours. Ditert-butyl dicarbonate (5.35 g) was added to the solution, and the reaction mixture was stirred at room temperature for 45 minutes, concentrated under reduced pressure, and the resulting residue was subjected to silica gel column chromatography (toluene:ethyl acetate = 9:1) to obtain 5.88 g of the title compound, whose physical properties are as follows. 'H-NMR CCDCl) δ (ppm): 1. 07 (d, J = 6. 4Hz, 3H), 1. 41 (s, 9H), 4. 10 3 (brs, 1H) , 4. 47 (brs, 1H) , 5. 44 (brs, 1H) , 6. 92— 7. 01 (m, 2H) .

[0201] 4-2-Trobenzoic acid (1R, 2R)-2 tertiary-butoxycarbonylamino-1-methyl-2-(3.4.5-trifluorophenyl) ethyl ester synthesis Under a nitrogen atmosphere, [(1R, 23)-2-hydroxy-1-(3,4,5-trifluorophenyl)propyl]carbamic acid tertiary butyl ester (5 88 g), 4-ditrobenzoic acid (4. 84 g) and triphenylophosphine (7·59 g) dissolved in THF (100 mL), diisopropyl azodicarboxylate (6 mL) was added dropwise under water cooling, and the reaction mixture was stirred at room temperature for 2 hours. The reaction solution was concentrated under reduced pressure, and the obtained residue was purified by silica gel column chromatography (toluene:ethyl acetate=97:3). The resulting powder was triturated by him with toluene-hexane to give 6.69 g of the title compound. The physical property values ​​of this product are as follows. 'H-NMR CCDCl) δ (ppm): 1.37 (s, 9H), 1.38 (d, J = 6.4Hz, 3H), 4.85 3 (brs, 1H) , 5. 16 (d, J = 9. 2Hz, 1H) , 5. 41 (qd, J = 6. 4, 6. 0Hz, 1H) , 6. 9 2- 7. 01 (m , 2H) , 8. 16 (d, J = 8. 8Hz, 2H) , 8. 29 (d, J = 8. 8Hz, 2H) .

[0202] Synthesis of (1R, 2R)-2-Hydroxy-1- (3, 4, 5-trifluorophenyl)propinole Ίrubamic Acid Tertiary Butyl Ester 4-Ditrobenzoic acid (1R, 2R) 2 Tertiary-butoxycarbonylamino-1-methyl-2-(3,4,5-trifluorophenyl)ethyl ester (7 03 g) in methanol (9 OmL) and THF (1OmL) was added potassium carbonate powder (6.43 g) and the reaction was stirred at room temperature for 1 hour. Ethyl acetate and water were added to the reaction solution, and the organic layer was partitioned. The resulting organic layer was washed with saturated brine (twice), dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. Diethyl ether was added to the obtained residue, the insoluble matter was filtered off, and the filtrate was concentrated. The obtained residue was purified by silica gel column chromatography (toluene:ethyl acetate=6:1) to obtain 4.49 g of the title compound. The physical properties of this product are as follows. 'H-NMR CCDCl) δ (ppm): 1. 28 (d, J = 6. 4Hz, 3H), 1. 44 (s, 9H), 4. 01 3 (brs, 1H) , 4. 48 (brs, 1H) , 5. 35 (brs, 1H) , 6. 90— 7. 00 (m, 2H) .

[0203] (1R, 2R)—1-amino-1-(3,4,5-trifluorophenylene)propane-2-phenolic salt formation, [(1R, 2R)-2-Hydroxy-1-(3,4,5-trifluorophenyl)propinole]carbamic acid tert-butyl ester (4.49 g) in ethyl acetate (50 mU solution, 4 N A solution of hydrochloric acid in ethyl acetate (20 mL) was added, the reaction mixture was stirred at room temperature for 5 hours, and the reaction mixture was concentrated under reduced pressure to obtain 3.5 g of the title compound. Street. ESI-MS; m / z 206 [M" + H].

[0204] 1—”(1R. 2R)— 2—hydroxy-1— (3.4.5—trifluorophenyl)propyl Ί—3 — {1—“3—methoxy-4— (4—methyl-1H—imidazole Synthesis of -1-yl)phenyl Ί-(E)-methylidene}piperidin-2-one (E)-5-chloromethyl-2-[3-methoxy-4-(4-methyl-1H-imidazole-1-i)benzylidene]valeric acid trifluorophosphate (CAS No. 870850-40 (1, 3.69 g) and (1R, 2R)-1-amino-1-(3,4,5-trifluorophenylene)propan-2-ol hydrochloride (1.98 g) in DMF ( IPEA (4 mU, HOBT (l.l lg) and EDC (1.57 g) were added to the 40 mU solution, and the reaction mixture was stirred at room temperature for 3.5 hours. Ethyl acetate and saturated aqueous sodium bicarbonate were added to the reaction mixture, The organic layer was separated, dried over magnesium sulfate and concentrated under reduced pressure, and the obtained solid was suspended in diisopropyl ether and collected by filtration to obtain 3.16 g of the condensate. (3.16 g) in DMF (50 mL) at 0 °C, sodium hydride (containing 40% mineral oil, 278 mg) was added, and the reaction mixture was allowed to warm to room temperature. Stirred for 15 minutes. Ethyl acetate and water were added to the reaction solution, and the organic layer was partitioned. The obtained organic layer was dried over magnesium sulfate and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (carrier: Chromatorex NH; elution solvent: heptane→ethyl acetate) to obtain 2.3 g of the title compound. The physical properties of this product are as follows. 'H-NMRCCDCl) δ (ppm): 1.31 (d, J = 6.0 Hz, 3H), 1.76–1.96 (m, 2 3 H), 2.31 (s, 3H), 2.78— 2.85 (m, 2H), 3.23— 3.30 (m, 1H), 3.49— 3.57 (m, 1H), 3.86(s, 3H), 4.43— 4.51 ( m, 1H), 5.24(d, J=7.6Hz, 1H), 6.93(brs, 1H), 7.03(brs, 1H), 7.05(t, J=10.0Hz, 2H), 7.08(brd, J= 7.2Hz, 1H), 7.25(d, J = 7.2Hz, 1H), 7.73(s, 1H), 7.85(s, 1H). Synthesis of 1—(3.4.5 trifluorophenyl)propyl Ί 2 oxopiperidine-(3E) ylidenemethyl 2 methoxyphenyl 5-methyl-1(phosphonooxymethyl) 3H-imidazolone 1-thium trifluoroacetate 1-[(1R, 2R)- 2-hydroxy-1- (3, 4, 5-trifluorophenyl)propyl]- 3-{1 [3-methoxy-4-(4-methyl-1H-imidazole-1-inole)phenyl] (E )-methylidene}piperidin-2-one (62 mg), chloromethinoresister sialbutinolephosphate (CAS No. 229625-50-7, 50 mg), sodium iodide (19 mg) and IPEA (0.05 mU of DME (3 mL) The solution was stirred for 3 hours at 80° C. The reaction mixture was allowed to cool to room temperature and concentrated under reduced pressure. The reaction mixture was concentrated under reduced pressure, and the residue was purified by reverse-phase C18 silica gel column chromatography (elution solvent: water containing 0.1% trifluoroacetic acid-acetonitrile system) to give 31 mg of the title compound. The physical property values ​​of the object are as follows. ESI—MS; m / z 596[M + ]. — NMR(CD OD) δ (ppm) : 1.27(d, J = 6.4 3 Hz, 3H), 1.68-1.80 (m, 1H), 1.90— 2.01 (m, 1H), 2.53(s, 3H) , 2.7 6-2.85 (m, 2H), 3.25— 3.39 (m, 1H), 3.62 — 3.72 (m, 1H), 3.94 (s, 3H), 4.35-4.45 (m, 1H), 5.53(d, J = 7.6Hz, 1H), 5.87(d, J = 9.6Hz , 2H), 7.10- 7.20 (m, 4H) , 7.40 (s, 1H), 7.51 (d, J = 8.4Hz, 1H), 7.7 9(s, 1H), 9.37(s, 1H). Example 5 3—”2 Funoleo mouth 1 4” (s) - — 4 “(1R, 2R)— 2 t 卞Roxy 11 (3, 4, 5 trifunoleolophenyl) p!: 2 pills Ί - Synthesis of -6-methyl-3-oxulfolin-(2Z)ylidenemethinole Ί-phenyl Ί 5-methyl--1-phosphono-xymethino I 3H-imidazole-1 im trifluoroacetate [Chemical 29] To a solution of 3,4-difluorobenzaldehyde (40 Og) in DMF (533 mU) at room temperature, 4-methylimidazole (46.4 g) and potassium carbonate (78. Og) were added, and the reaction mixture was heated to 90°C. After allowing the reaction mixture to cool to room temperature, ethyl acetate and water were added to the reaction mixture, and the organic layer was partitioned, washed with saturated brine, dried over magnesium sulfate, and dried. The residue was purified by silica gel column chromatography (elution solvent: heptane-ethyl acetate system) and solidified with tert-butyl methyl ether to give 10.1 g of the title compound. The physical properties of 'H-NMRCCDCl) δ (ppm): 2.33 (d, J = 0.8 Hz, 3H), 7.07 (brs, 1H), 7. 3 57(dd, J = 7.2, 7.2Hz, 1H), 7.76— 7.82 (m, 2H) , 7.87(brs, 1H), 10. 01(d, J=l.6Hz, 1H). Synthesis of (1R.2R)- 2- (tertiarybutyldiphenylsilanyloxy)-1- (3.4.5- trifluorophenyl)propyl Ί-rubamic acid tert-butyl ester Under a nitrogen atmosphere, [(1R , 2R)-2-hydroxy-1-(3,4,5-trifluorophenyl)propyl]ylbamic acid tertiary-butyl ester (61 mg) and imidazole (817 mg). mg) in DMF (3 mU solution, tert-butyldiphenylsilane chloride (2 OmU) was added in 4 portions and the reaction mixture was stirred at room temperature for 3 hours. Ethyl acetate and water were added to the reaction mixture, and organic The layers were separated, the organic layer was washed successively with 1N hydrochloric acid, water, saturated aqueous sodium hydrogencarbonate solution and saturated brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure.The residue was subjected to silica gel column chromatography. After purification by chromatography (elution solvent: hexane:dimethyl ether 49:1→19:1), 684 mg of the title compound was obtained.The physical properties of this product are as follows. 'H-NMRCCDCl) δ (ppm): 0.95(s, 9H) 1.13(d, J = 6.4Hz, 3H), 1.47( 3 s, 9H), 4.02(brs, 1H), 4.46(brs, 1H), 5.34(brs, 1H), 6.69— 6.80 (m, 2H), 7.28-7.46 (m, 8H), 7.55(d, J = 8.4Hz, 2H) .

[0208] (1R.2R)—2 Synthesis of tert-butyldiphenylsilanyloxy-1-(3.4.5-trifluorophenyl)propylamine [(1R, 2R)-2 tert-butyldiphenylsilanyloxy-1-(3,4,5-trifluorophenyl)propyl]carbamic acid tert-butyl ester (370 mg) in methylene chloride (2 mU solution, Trifluoroacetic acid (0.5 mU) was added, and the reaction solution was stirred at room temperature for 11 hours. A saturated aqueous sodium hydrogencarbonate solution and ethyl acetate were added to the reaction solution, and the organic layer was partitioned. After successively washing with an aqueous solution and saturated brine, the mixture was concentrated under reduced pressure to obtain 275 mg of the title compound, whose physical properties are as follows. 'H-NMRCCDCl) δ (ppm): 0.93 (d, J = 6.4 Hz, 3H), 1.02 (s, 9H), 3.81 3 (d, J = 4.8Hz, 1H), 3.91 (dq, J = 4.8, 6.0Hz, 1H), 6.88— 6.97 (m, 2H), 7.32-7.46 (m, 6H), 7.57(d, J = 8. OHz, 2H) , 7.55(d, J = 8. OHz, 2 H).

[0209] Synthesis of (S)-1-(1R,2R)-2-tert-butyldiphenylsilaniloxy-1-(3,4,5-trifluorophenyl)propylamino Ίpropan2ol To a suspension of lithium perchlorate (750 mg) in diethyl ether (l mL) were added (S) (1) propylene oxide (0. l mL) and (1R, 2R)-2- 1—(3,4,5-Trifluorophenyl)propylamine (212 mg) A solution of ethyl ether (1 mL) was added and the reaction was stirred overnight at room temperature under a nitrogen atmosphere. Methylene chloride and ice water were added to the reaction solution, and the organic layer was partitioned. The aqueous layer was re-extracted with methylene chloride, and the organic layers were combined, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (elution solvent: ethyl acetate:heptane 9:1→4:1) to obtain 172 mg of the title compound. The physical property values ​​of this product are as follows. 'H-NMRCCDCl) δ (ppm): 0.83 (d, J = 6.0 Hz, 3H), 1.06 (s, 9H), 1.08 3 (m, 3H), 2.20-2.50 (m, 3H) , 3.47(brs, 1H), 3.59(brs, 1H), 3.86 (brs, 1H), 6.78-6.95 (m, 2H) , 7.36— 7.48 ( m, 6H) , 7.67(d, J = 6.8Hz , 4H).

[0210] (S)—4—“(lR.2R) 2—Tertiarybutyldiphenylsilanyloxy 1-(3. 4.5 Synthesis of trifluorophenylole)propyl Ί-6-methylmorpholine-2.3 dione Under nitrogen atmosphere, (S)-1[(1R, 2R)-2-tertiarybutyldiphenylsilanyloxy ,5-trifluorophenyl)propylamino]propane-2-ol (171 mg), TEA (0.17 mU) and 4-(N,N-dimethylamino)pyridine (8 mg) in Oxalyl (45 U) was added dropwise, and the reaction mixture was stirred at the same temperature for 2 hours. Ice water and ethyl acetate were added to the reaction mixture, and the organic layer was partitioned. The extract was washed successively with saturated aqueous sodium bicarbonate and saturated brine, dried over anhydrous magnesium sulfate, concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (elution solvent: heptane:ethyl acetate 9:1→3:1). Purification yielded 96 mg of the title compound, whose physical properties are as follows. 'H-NMRCCDCl) δ (ppm): 1.02(s, 9H), 1.19(d, J = 6.0Hz, 3H), 1.28 3 (d, J = 6.4Hz, 3H), 3.20(dd, J = 5.6, 13.2Hz, 1H), 3.68(dd, J = 2.4, 13.2Hz, 1H), 4.42(dq, J = 5.6, 6.0Hz, 1H) 4.62(ddq, J = 2.4, 5.6, 6.4Hz, 1H), 5.51(d, J = 5.6Hz, 1H), 6.82— 6.94 (m, 2H), 7.40— 7.54 (m, 6H), 7.62 (d, J = 8.0Hz, 2H) , 7.67(d, J = 8.0Hz, 2H) .

[0211] (S) 4-(1R, 2R)— 2 tertiarybutyldiphenylsilanyloxy 1-(3, 4^ 5- 1 ^fluorophenyl propyl Ί - 2 hydroxy- 6 methylmorpholine- 3 - Composite on (S)- 4 [(1R, 2R)- 2 tert-butyldiphenylsilanyloxy 1- (3, 4, 5-trifluorophenylene)propyl]- 6-methylmorpholine-2, To a solution of 3 dione (95 mg) in THF (3 mU) at -20°C, a THF solution (0.25 mU) of 1 06 monolithium butylborohydride was added dropwise, and the reaction mixture was stirred at the same temperature for 30 minutes. A 5N aqueous sodium hydroxide solution (0.03 mL) and 30% aqueous hydrogen peroxide (0.07 mL) were added to the reaction mixture, and the reaction mixture was stirred under ice-cooling for 1 hour. Sodium hydrogen powder (20 mg) was added, the reaction mixture was stirred at room temperature for 30 minutes, saturated brine and ethyl acetate were added, and the organic layer was partitioned, washed with saturated brine. , dried over anhydrous magnesium sulfate, and concentrated under reduced pressure.The obtained residue was purified by silica gel column chromatography (elution solvent: heptane:ethyl acetate 1:1) to obtain 93 mg of the title compound. It is as follows. 'H-NMR CCDCl ) δ (ppm) : 1. 01 (s, 9H) , 1. l l (d, J = 6. 0Hz, 3H) , 1. 19 3 (d, J = 6. 4Hz, 3H) , 2. 88 and 2. 99 (dd, J = 12. 0, 12. 0Hz, 1H) , 3. 12 and 3. 48 (dd, J = 2. 4 , 12. 0Hz, 1H) , 3. 16 and 3. 91 (d, J = 2. 8Hz, 1H) , 4. 35-4. 55 (m, 2H) , 5. 11 and 5. 30 (d , J = 3. 6Hz, 1H) , 5. 40 and 5. 49 (d, J = 6. 8Hz, 1H) , 6. 79— 6. 94 (m, 2H) , 7. 38— 7. 54 (m, 6H) , 7. 65 (d, J = 8. 0Hz, 2H) , 7. 69 (d, J = 8. 0Hz, 2H) . (Z)-(S)-2-"1-"3-fluoro-4-(4-methyl-1H-imidazol-1-yl)phenyl methylidene-4-"(1R, 2R)-2-hydroxy-1- ( Synthesis of 3,4,5-trifluorophenyl)propyl, 6-methylmorpholine-3-one (S)-4 [(1R, 2R)-2 tertiarybutyldiphenylsilanyloxy 1- (3, 4, 5 trifluorophenylole)propyl]-2 hydroxy-6-methyl morpholine-3-one under a nitrogen atmosphere. (2 16 g) and triphenylphosphine hydrobromide (1.61 g) in acetonitrile (70 mU solution) was heated under reflux for 1 hour. 3-Fluoro-4-(4-methyl-1H-imidazol-1yl)benzaldehyde (869 mg) and TEA (2 68 mL) were added, and the reaction mixture was stirred at room temperature for 10 hours under a nitrogen atmosphere. After concentration, the resulting residue was triturated. A mixed solution of 30 mU of fluoroacetic acid and 30 mU of methylene chloride (30 mU) was stirred at room temperature for 13 hours. After successive washing with saturated brine and concentration under reduced pressure, the resulting residue was purified by silica gel column chromatography (carrier: Chromatorex NH; elution solvent: heptane:ethyl acetate 1:1→ethyl acetate). Solidification with butane ethyl acetate gave 1.32 g of the title compound, whose physical properties are as follows. 'H-NMRCCDCl) δ (ppm): 1.33 (d, J = 6.4 Hz, 3H), 1.42 (d, J = 6.0 Hz 3 , 3H), 2.30(s, 3H), 3.19(dd, J=12.4, 9.2Hz, 1H), 3.63(dd, J=12.4 , 2.0Hz, 1H), 4.44— 4.49 (m, 2H), 5.36( d, J = 6.8Hz, 1H), 6.80(s, 1H), 6.97(s, 1H), 7.09(dd, J = 8.4, 6.4Hz, 2H), 7.29(t, J = 8.4Hz, 1H ), 7.44(dd, J = 8.4, 2.0Hz, 1H), 7.71(dd, J=12.8, 1.2Hz, 1H), 7. 74 (s, 1H). 3-"2 fluoro-4-"(S)- 4-"(1R.2R)- 2-hydroxy-1- (3.4.5 trifluorophenyl)propyl-6-methyl-3-foxomorpholine-(2Z) ylidenemethyl- Ί-phenyl Synthesis of Ί 5-methyl-1-phosphonooxymethyl-3H-imidazole-1-um trifluoroacetate (Z)-(S)-4-[(lR,2R)-2-hydroxy-1-(3,4,5-triphenyl-phenyl)propyl]-2-[1[3-methoxy-4-(4-methyl-1 H-imidazole-1-yl)phenyl]methylidene]6-methinolemonolephorin 3-one (25 mg), black methinoregisthalib, cinolephosphate (CAS No. 229625-50-7, 20 mg), shoei sodium ( 23 mg) and ΙΡΕΑ (0 OlmU in acetone (0 5 mU solution was stirred at 60°C for 2 hours. The reaction mixture was allowed to cool to room temperature, insoluble matter was filtered off, and the filtrate was concentrated under reduced pressure. A mixed solvent of methylene chloride and TFA (1:1; 2 mL) was added to the resulting residue, and the reaction mixture was stirred at room temperature for 1 hour, concentrated under reduced pressure, and the residue was subjected to reverse-phase C18 silica gel column chromatography. (Elution solvent: 50% acetonitrile aqueous solution containing 0.1% trifluoroacetic acid) to obtain 14 mg of the title compound, whose physical properties are as follows: ESI—MS; + ]. — NMR(CD OD) δ (ppm) : 1.19(d, J = 5.2 Hz, 3H), 1.39(d, J = 6.4Hz, 3H), 2.54 (s, 3H), 3.20— 3.30 (m, 1H), 3.89(brd, J=12.0Hz, 1H), 4.43— 4.61 (m , 2H) , 5.39(d, J = 8.0Hz, 1H), 5.96(brd, J=12.0Hz, 2H) , 6.75(s, 1H), 7.22— 7.34 (m, 2H) , 7.58-7.70 (m, 2H) , 7.77(s, 1H), 7.89(d, J=12.8Hz, 1H), 9.53(s, 1H) Example 6 3- {2 methoxy-4-"(3S, 8aS)- 5 oxo 3- (3, 4, 5 trifluorophenyl) hexahydroindolizine-(6E)-ylidenemethyl Ί-phenyl} 5-methyl-1-ho Synthesis of sulfonoxymethyl-3H-imidazole-1ium trifluoroacetate [Chemical 30] (2R.5S)— 5—(3.4.5 Trifluorophenyl)pyrrolidine dicarboxylic acid (R)— 5 oxopyrrolidine 1,2 dicarboxylic acid 1 tert-butyl ester 2 ethinole ester (CAS. 3,4,5-trifluorophenylmagnesium bromide (0.35M solution in diethyl ether; 55 mL) was added dropwise over 20 minutes, and the reaction mixture was stirred for 5 hours at 40° C. To this solution was added saturated ammonium chloride. Water and ethyl acetate were added, the reaction mixture was warmed to room temperature, and the organic layer was separated, washed with saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. Purification by silica gel column chromatography (heptane→heptane:ethyl acetate 1:1) yielded (R)-2-tertiary rib. 4.8 g of toxycarbonylamino-5-oxo-5-(3,4,5-trifluorophenylene)pentanoic acid ethyl ester were obtained. The resulting (R)-2-tertiarybutoxycarbonylamino-5-oxo-5-(3,4,5-trifluorophenyl)pentanoic acid ethyl ester in ethyl acetate (30 mU solution, 4N hydrochloric acid in ethyl acetate solution ( 30 mU was added, and the solution was stirred for 16 hours.The reaction mixture was concentrated under reduced pressure, ethyl acetate and saturated aqueous sodium bicarbonate were added to the residue, and the organic layer was partitioned.The resulting organic layer was dried over anhydrous magnesium sulfate. To a solution of the residue in ethyl acetate (50 mL) was added 10% palladium on carbon (100 mg), and the reaction was stirred under a hydrogen atmosphere of 1 atm for 6 hours.The reaction was filtered over celite. The filtrate was concentrated under reduced pressure to obtain 2.91 g of the title compound, whose physical properties are shown below. ESI—MS; m / z 274[M" + H].

[0215] “(2R.5S)—5—(3.4.5 Trifluorophenyl)pyrrolidine-2-ino-methanol (2R, 5S)-5-(3,4,5-trifluorophenylene)pyrrolidine-dicarboxylic acid cetinoleestenol (2.91 g) in THF (50 mU) at 15°C with LAH (483 mg) for 1 hour The reaction mixture was stirred for 19 hours at -15° C. Water (0.5 mL), 5N aqueous sodium hydroxide solution (0.5 mL) and water (1.5 mL) were sequentially added to the reaction mixture, and the mixture was The mixture was stirred at room temperature for 30 minutes, the reaction mixture was filtered through celite, and the filtrate was concentrated under reduced pressure to obtain 2.4 g of the title compound, whose physical properties are as follows. ESI— MS; m / z 232 [M" + H].'H-NMRCCDCl) δ (ppm): 1.51— 1.63( 3 m, 1Η), 1.66-1.77 (m, 1H), 1.89— 2.00 (m, 1H), 2.10— 2.20 (m, 1H), 3.43(dd, J=10.0, 5.6Hz, 1H), 3.47— 3.55 (m, 1H), 3.64 (dd, J = 10.0, 3.6Hz, 1H), 4.23(t, J = 8.0Hz, 1H), 7.02(t, J = 8.0Hz, 2H) .

[0216] Synthesis of (E)-3-(2R, 5S)-1-(3F, tenonole)5-(3, 4, 5-triphenylene) pyrrolidine 2-yl Ίacrylic acid ethyl ester [(2R,5S)-5-(3,4,5-trifluorophenylene)pyrrolidine-2-inole]methanol (2.17 g) and vinyloleacetic acid (0.67 mL) dissolved in THF (50 mL) Reamine (1.95 mL) and BOPCU (2.85 g) were added and the reaction was stirred at room temperature for 12 hours. To the reaction solution A mixture of Ruen:THF (1:1) and 1N aqueous hydrochloric acid were added, and the organic layer was partitioned. The obtained organic layer was washed with a 1N aqueous sodium hydroxide solution, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. To a solution of oxalyl chloride (1.77 g) in methylene chloride (15 mU) was added dropwise a solution of DMSO (1.17 g) in methylene chloride (5 mL) at 78°C, and the reaction mixture was stirred at the same temperature for 20 minutes. To this reaction solution, a solution of the residue in dichloromethane (10 mU) was added dropwise at -78°C, and the reaction solution was stirred at the same temperature for 70 minutes. The mixture was stirred for 1 hour at 78° C. A toluene-THF (1:1) mixture and saturated ammonium chloride aqueous solution were added to the reaction mixture, the mixture was allowed to warm to room temperature, and the organic layer was partitioned. The extract was washed successively with 1N aqueous hydrochloric acid, saturated aqueous sodium bicarbonate and saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. To a suspension of sodium hydride (containing 40% mineral oil, 746 mg) in THF (70 mU), triethylphosphonoacetic acid (3.7 mL) was added at 0°C, and the reaction mixture was stirred at the same temperature for 1 hour. A THF (30 mU) solution of the above residue was added to the reaction solution, and the reaction solution was stirred at room temperature for 1 hour. Ethyl acetate and a saturated aqueous solution of ammonium chloride were added to the reaction solution, and the organic layer was partitioned. The organic layer was dried over anhydrous magnesium sulfate and concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (heptane→heptane:ethyl acetate 1:1) to obtain 1.33 g of the title compound. The physical property values ​​are as follows. ESI-MS; m / z 368 [M" + H]. Synthesis of (3S. 8aR) - 3- (3. 4, 5 triphenylene) 2, 3. 6. 8a tetrahydro-indolizin 5-ones (E)-3-[(2R, 5S)-1- (3F, 5-5-(3,4,5-triphenyl)pyrrolidine-2-yl]acrylic acid ethyl ester (1.33 g) A solution of Grubbs catalyst second generation (153 mg) in methylene chloride (60 mU) was heated to reflux for 2 hours. The reaction mixture was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (heptane:ethyl acetate 1:1→ethyl acetate) to give the title compound. 680 mg of product was obtained. The physical properties of this product are as follows. ESI-MS; m / z 268 [M" + H].'H-NMRCCDCl) δ (ppm): 1.74— 1.86( 3 m, 2Η), 2.10-2.18 (m, 1H), 2.29— 2.42 (m, 1H), 2.95— 3.00 (m, 2H)4.22-4.32 (m, 1H), 5.01(d, J = 9.2Hz, 1H), 5.98— 6.05 (m, 1H) , 6.07-6.32 (m, 1H), 6.67— 6.76 (m, 2H) .

[0218] Synthesis of (3S.8aR)-3-(3.4.5 trifluorophenyl)hexahydroindolizinone (3S, 8aR)-3-(3, 4, 5 triphenylene) 2, 3, 6, 8a tetrahydro-1H indolizine 5-one (680 mg) in methanol (20 mU solution, platinum oxide (100 mg) was added, and the reaction mixture was stirred at room temperature for 2.5 hours under a hydrogen atmosphere of 1 atm.The reaction mixture was filtered through celite, and the filtrate was concentrated under reduced pressure to obtain 684 mg of the title compound. It is as follows. ESI-MS; m / z 270[M" + H].

[0219] (E)-(3S)-(3.4.5 ref. Synthesis of 1H-imidazole-1-yl)benzylidene Ί-(9S)xahydroindolizine-5-one (3S, 8aR)-3-(3,4,5-trifluorophenyl)hexahydroindolizinone (684 mg) and N,N,N',N'-tetramethylethylenediamine ( To a solution of 1.34 mU of methylene chloride (15 mU), 0.542 mU of trimethinolesilane iodide was added dropwise at 0°C and the reaction was stirred at 0°C for 30 min. Iodine (967 mg) was added to the reaction. The reaction solution was stirred for 1 hour at 0° C. A saturated aqueous sodium thiosulfate solution and ethyl acetate were added to the reaction solution, the mixture was allowed to warm to room temperature, and the organic layer was partitioned. The resulting organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate, concentrated under reduced pressure, and a solution of the residue in triethyl phosphite (5 mL) was stirred at 120° C. for 1 hour. The residue was allowed to cool and concentrated under reduced pressure.To a solution of THF (15 mU and ethanol (3 mU) was added 3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzaldehyde (549 mg) and lithium hydroxide monohydrate. (319 mg) was added, and the reaction mixture was stirred at room temperature for 15 hours.Ethyl acetate and saturated brine were added to the reaction mixture, and the organic layer was partitioned. After drying with Nesium, concentration under reduced pressure, the residue is purified by silica gel column chromatography (carrier: Chromatorex NH; elution solvent: heptane:ethyl acetate 1:1→ethyl acetate→ethyl acetate:methanol 9:1). This gave 762 mg of the title compound. The physical property values ​​of this product are as follows. ESI—MS; m / z 468[M"+H].'H-NMRCCDCl) δ (ppm): 1.65-1.8 3 7(m, 3H), 2.06-2.14 (m, 1H), 2.30— 2.39 (m, 5H) , 2.69— 2.80 (m, 1H), 3.15(brt, J=16.8Hz, 1H), 3.76— 3.85 ( m, 1H), 3.86(s, 3H), 5.10(d, J = 8.8Hz, 1H), 6.79(dd, J = 8.4, 6.4Hz, 2H), 6.95(s, 1H), 7.05 (brs, 1H), 7.08(brd, J = 8.0Hz, 1H), 7.26(d, J = 8.0Hz, 1H), 7.7 4(brs, 1H), 7.85 (s, 1H). 3— {2 Methoxy-4-(3S.8aS)- 5-Kxo 3- (3.4.5 Triphenylene)-Hexahydroindolizine-(6E)-Ylidenemethyl Ί-Phenyl I- 5-Methyl 1-Phospho Synthesis of nooxymethyl-3H-imidazole-1um trifluoroacetate (E)-(3S)-(3,4,5-trifluorophenyl)6-[3-methoxy-4-(4-methylol-1H-imidazol-1-yl)benzylidene]9S)-hexahydroindolizine —5 On (130 mg), chloromethyl ditertiarybutyl phosphate (CAS No.2296 25—50—7, 108 mg), sodium iodide (125 mg) and ΙΡΕΑ (0 05 mL) in DME (5 mU solution at 80° C. The reaction mixture was allowed to cool to room temperature and concentrated under reduced pressure.To a solution of the obtained residue in chloroform (1 mL) was added TFA (lmU, and the mixture was stirred at room temperature for 1 hour. The reaction solution was concentrated under reduced pressure, and the residue was purified by reverse-phase C18 silica gel column chromatography (elution solvent: water containing 0.1% trifluoroacetic acid-acetonitrile system) to obtain 80 mg of the title compound. Values ​​are ESI—MS; m / z 578[M + ]. — NMR(CD OD) δ (ppm): 1.70— 1.87 (m 3 , 3H), 2.08-2.16 (m, 1H), 2.33— 2.48 (m, 2H) , 2.53(s, 3H) , 2.80 -2.93 (m, 1H), 3.10— 3.20 (m, 1H), 3.85— 3.95 (m, 1H), 3.96 (s, 3H), 5.12(d, J = 8.8Hz, 1H), 5.90(d, J=12.8Hz, 2H) , 6.92— 7.00 (m , 2H), 7.26(dd , J = 8.4, 1.2Hz, 1H), 7.33(d, J=l.2Hz, 1H), 7.59 (d , J = 8.4Hz, 1H), 7.66(brs, 1H), 7.67(brs, 1H), 9.40 (d, J=l.6Hz, 1H).

[0221] Example 7 3— {4- {(S)- 4- "(S)- 1-(2,6-difluoropyridine-3-yl)ethyl Ί-6-methyl-3-oxomorpholine-(2Z)ylidenemethyl} 2-methoxyphenyl} 5-methyl-1-phosphonooxymethyl-3H-^^sol-1-im chloride Synthesis of 1-(2.6-difluoroviridine-3-yl)ethanol Under a nitrogen atmosphere, diisopropylamine (134 mU) was added dropwise to a mixed solution of n-butyllithium hexane solution (2 62 M, 368 mU) and tetrahydrofuran (800 mU) at 60°C or lower. After stirring, a tetrahydrofuran solution (lOOmU) of 2,6-difluoropyridine (100 g) was added dropwise to the reaction mixture at 60°C or lower. After stirring the reaction mixture at the same temperature for 1 hour, acetaldehyde ( 97.6 mL) was added dropwise.After that, 2N aqueous hydrochloric acid (lOOOmU was added dropwise to the reaction mixture, ethyl acetate (lOOOmU and tonolene (lOOOmL) were added, and the organic layer was partitioned. The organic layer was concentrated under reduced pressure, 129 g of the title compound was obtained, and the physical properties of this product are as follows. 'H-NMRCCDCl) δ (ppm): 1.51 (d, J = 5.6 Hz, 3H), 2.00 (s, 1H), 5.13 3 -5. 16 (m, 1H), 6.84(dd, J = 8.0, 2. 1Hz, 1H), 8.05(dd, J=16.0, 8.0 Hz, 1H).

[0222] (S)-1-(S)-1-(2.6-difluoropyridine-3-yl)ethylamino Ί-propane 2—Oar (+ )—Gee Ό —Synthesis of tolu oil D A solution of thionyl bromide (337 g) in toluene (1500 mU) was added to A toluene (300 mU solution of obiridin 3-yl)ethanol (216 g) was added, and the reaction mixture was stirred at room temperature for 3 hours. Ice water and toluene were added to the reaction mixture, and the organic layer was partitioned. ), dried over anhydrous magnesium sulfate, filtered through a silica gel pad, and added with (S)-1-amino-2-propanol (157 g), cesium carbonate (1.28 kg) and DMF (2500 mL). The reaction mixture was stirred overnight at room temperature, filtered, and the filtrate was concentrated under reduced pressure.The residue was diluted with ethanol (100 mL), and (+) -di-p toluoyl-D tartaric acid (152 g) in ethanol was added to the solution. (500 mL) solution was added, and the reaction mixture was stirred at room temperature for 1 hour.The precipitated crystals were filtered and washed with ethanol.The crystals were dried at 80°C for 2 hours, and ethanol (2000 mL) and heptane (1000 mL) were added. After being suspended in the mixed solvent, the solution was heated and stirred at 80° C. After 1 hour, the reaction solution was allowed to cool to room temperature, and the precipitated crystals were filtered, washed with ethanol, and dried overnight at 80° C. As a result, 155 g of the title compound was obtained, and the physical properties of this product are as follows. 'H-NMR CDMSO-d) δ (ppm): 1. 02 (d, J = 6. OHz, 6H), 1. 37 (d, J = 6. 6 8Hz, 6H) , 2. 36 (s, 6H) , 2. 37— 2. 51 (m, 4H) , 3. 67— 3. 71 (m, 2H) , 4. 14 - 4. 16 (m, 2H) , 5. 65 (s, 2H) , 7. 21 (dd, J = 8. 0, 2. OHz, 2H) , 7. 31 ( d, J = 8. 4Hz, 4H) , 7. 82 ( d, J = 8. 4, Hz, 4H) , 8. 27 (dd, J = 17. 6, 8. OHz , 2H) . Synthesis of (S)-4-(S)-1-(2.6-difluoropyridine-3-yl)ethyl Ί-6-methylmorpholine 2.3 dione (S)-1 [(S)-1-(2,6-difluoropyridine-3-yl)ethylamino]propan-2-ol (+)-di-ρ-toluoyl D tartrate (199 g) was added with 5N sodium hydroxide. Lithium water (450 mU, water (1000 mU, and 50% toluene THF (2000 mU) were added, and the organic layer was partitioned. The aqueous layer was extracted with 50% toluene THF (800 mU) three times. The organic layers were combined and concentrated under reduced pressure. To the residue was added diethyl oxalate (200 mL), and the reaction mixture was heated and stirred at 140-150° C. After 3 hours, the reaction mixture was diluted with toluene (500 mL) and ice-cooled with stirring. The crystals were collected by filtration, washed with toluene and diethyl ether, and air-dried to obtain 103 g of the title compound, whose physical properties are as follows. H-NMR(CDC1) δ (ppm): 1.43 (d, J = 6.8Hz, 3H), 1.70 (d, J = 6.8Hz 3 , 3H), 3.36(dd, J=13.2, 8.8Hz, 1H), 3.52(dd, J=13.2, 2.1Hz, 1H) , 4.72-4.78 (m, 1H), 5.59(q, J=6.8Hz , 1H), 6.88(dd, J = 8.0, 2.8 Hz, 1H), 8.01(dd, J=16.8, 8.0Hz, 1H).

[0224] Synthesis of (S) 4-(S)-1-(2,6-difluoropyridin-3-yl)ethyl Ί2-hydroxy 6-methylmorpholin-3-one (S)-4[(S)-1-(2,6-difluoropyridine-3-yl)ethyl]6-methylmorpholine-2,3-dione (4.5 g) in THF was added at 50°C or lower to 1 M —s Lithium butyno-rehydroborate in THF (20 mL) was added dropwise and the reaction was stirred for 2 hours. A 5N sodium hydroxide aqueous solution (1.66 mL) and a 30% hydrogen peroxide solution (6.78 mL) were sequentially added dropwise to the reaction solution at 10°C or lower, and the reaction solution was stirred for 1 hour. Sodium bisulfite (520 mg) was added to the reaction solution, and the reaction solution was stirred for 30 minutes. Saturated saline and 50% toluene-THF were added to the reaction solution, and the organic layer was partitioned. The aqueous layer was extracted with 50% toluene-THF. The organic layers were combined and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (heptane:ethyl acetate 1:1→ethyl acetate) to obtain 4.52 g of the title compound. The physical properties of this product are as follows. 'H-NMRCCDCl) δ (ppm): 1.25 (d, J = 6.8 Hz, 2.58H), 1.30 (d, J = 6.8 3 Hz, 0.42H), 1.60(d, J=6.8Hz, 2.58H), 1.62(d, J=6.8Hz, 0.42H), 2.90(dd, J=12.8, 8.8Hz, 0.86H), 3.09(dd , J=12.8, 8.8 Hz, 0.14H ), 3.ll(dd, J=12.8, 2.1Hz, 0.86H), 3.31(dd, J=12.8, 2.1Hz, 0.14H), 4.39-4.49 (m , 1H), 5.14(s, 0.14H), 5.30(s, 0.86H), 5.50 (q, J =6.8Hz, 0.14H), 5.71(q, J = 6.8Hz, 0.86H), 6.87 (dd, J = 8.0, 2.8Hz, 1H), 7.96(dd, J=16.8, 8.0Hz, 1H).

[0225] (Z)-(S)-4-(S)-1(2.6difluoropyridine-3-yl)ethyl, 2- {1-"3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl Synthesis of Ίmethylidene}6-methylmorpholine-3-one (S)-4-[(S)-l-(2,6-Difluoropyridin-3-yl)ethyl]-2-hydroxy-6-methylmorpholin-3-one (4 3 g) in an acetonitrile solution Trifueninorephos Phonium bromide (6.52 g) was added and the reaction was heated to reflux for 1 hour. Triethylamine (5·28 mL) and 3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzaldehyde (3·42 g) were added to the reaction solution, and the reaction solution was heated under reflux for 1.5 hours. The reaction mixture was concentrated under reduced pressure, the residue was diluted with 2N aqueous hydrochloric acid and ethyl acetate, and the aqueous layer was partitioned. After the organic layer was washed with 2N aqueous hydrochloric acid, all the aqueous layers were combined and made alkaline with a concentrated aqueous sodium hydroxide solution. The alkaline aqueous solution was extracted with ethyl acetate and the organic layer was partitioned. The obtained organic layer was washed with saturated sodium hydrogen carbonate, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (carrier: Chromatorex NH; elution solvent: heptane:ethyl acetate 1:1→ethyl acetate) to obtain 4.06 g of the title compound. The physical properties of this product are as follows. ESI—MS; m / z 455[M" + H].—NMR(CDC1) δ (ppm): 1.44 (d, J = 6 3 4Hz, 3H), 1. 67(d, J = 7. 2Hz, 3H) , 2. 31 (s, 3H) , 3. 23(dd, J=12. 8, 10. 0Hz, 1H), 3 42(dd, J=12. 8, 2. 8Hz, 1H), 3. 84 (s, 3H) , 4. 37 (m, 1H), 5. 74(q, J = 7. 2Hz, 1H) , 6. 81 (s, 1H), 6. 87(dd, J = 8. 0, 2. 8Hz, 1H), 6. 93(dd, J=l. 2, 1. 2Hz, 1H), 7. 20(d, J = 8. 0Hz, 1H), 7. 31 (dd, J = 8. 4, 1. 6Hz, 1H), 7. 50(d, J=l. 6Hz, 1H), 7. 77 (s, 1H), 8. 00 (m, 1H). 3— {4- {(S)- 4- (S)- 1-(2.6-difluoropyridine-3-yl)ethyl Ί-6-methyl-3-oxomorpholine-(2Ζ)ylidenemethyl} 2-methoxyphenyl} 5-methyl-1-phosphonooxymethyl-3H-imidazole-1-im chloride (Ζ) (S) 4 [(S)- 1 2, 6 difluoropyridine-3-yl)ethyl] 2- {1 [3-methoxy-4-(4-methyl-1H-imidazole-1-yl)phenyl]methylidene} 6 To an acetone (10 mU solution) of methylmorpholine-3-one (500 mg) were added chloromethyl ditertiarybutyl phosphate (427 mg), sodium iodide (494 mg) and diisopyrhetilamine (47.1 L). After the reaction mixture was filtered, the filtrate was concentrated under reduced pressure, trifluoroacetic acid (3 mL) was added to the residue, and the reaction mixture was stirred for 30 minutes at room temperature.The reaction mixture was concentrated under reduced pressure, and diluted with ethyl acetate. dilute and hydroxylate The pH was adjusted to 8-9 with a sodium aqueous solution and a saturated sodium bicarbonate aqueous solution, and the organic layer was partitioned. The aqueous layer was acidified with concentrated hydrochloric acid and diluted with chloroform. After collecting the precipitated oil, it was solidified with ethyl acetate to obtain 129 mg of the title compound. The physical property values ​​of this product are as follows. 'H-NMRCDMSO-d) δ (ppm): 1.33 (d, J = 6.4 Hz, 3H), 1.56 (d, J = 7. 2Hz, 3H), 2.43(s, 3H), 2.99(dd, J=12.8, 9.2Hz, 1H), 3.53(dd, J=l 2.8, 1.6Hz, 1H), 3.87(s, 3H), 4.40— 4.43 (m, 1H), 5.85— 5.89 (m, 3H), 6.73(s, 1H), 7.25(dd, J = 8.4, 2.4Hz, 1H), 7.47— 7.55 (m, 2H), 7.73(s, 1H), 7.85(s, 1H), 8.27(dd, J=17.6, 8.4Hz, 1H), 9.68(s, 1H). Example 8 3-{4 "(3S.8aS) 3-(4-chlorophenyl) 5-oxohexahydroindolizine-(6E) ylidenemethyl Ί 2 methoxyphenyl} 5 methyl-1(phosphonooxymethyl) 3H-imidazolone 1 lm trifluoro Synthesis of acetate [Chemical 32] (R)—2—kusha JJ-b-oxycarbonylamino-5— (4—chlorophenyl J—5 (R)— 5 Oxopyrrolidine 1,2 dicarboxylic acid 1 tertiary butyl ester 2 ethinoleestenol (CAS. No. 128811—48—3;4. Chromophenylmagnesium bromide (1 0 M ditinole ether solution; 17 lmU was added dropwise over 20 minutes, and the reaction mixture was stirred from −40° C. to 0° C. for 1 hour. Water was added to the solution in small portions. Added at 0°C and extracted with ethyl acetate. The liquid was washed with saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (heptane-ethyl acetate system) to obtain 5.6 g of the title compound as a colorless oil. The physical properties of this product are as follows. ESI—MS; m / z 392[M"+Na].'H-NMRCCDCl) δ (ppm): 1.28(t, J = 3 7.2Hz, 3H), 1.42(s, 9H), 2.00— 2.50 (m, 2H), 2.95— 3.20 (m, 2H), 4. 10-4.50 (m, 2H), 4. 10— 5.20 (m, 2H) , 7.41— 7.47 (m, 2H) , 7.86 -7.92 (m, 2H).

[0228] (R) -5- (4-chlorophenyl) 3, 4-dihydro-2H-pyrrole-2-carboxylic acid (R)-2 Tertiary-butoxycarbonylamino-5-(4-chloro-phenyl)-5-oxopentanoic acid ethyl ester (5.6 g) in ethyl acetate (30 mU solution, 4N hydrochloric acid ethyl acetate solution (30 mL) was added at room temperature. and the reaction mixture was stirred at room temperature for 2 hours.The reaction mixture was concentrated under reduced pressure to obtain 5.0 g of a yellow oily substance. was added dropwise, and the reaction mixture was stirred at room temperature for 20 minutes, extracted with ethyl acetate, washed with saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure to obtain the title compound. 3.5 g of a pale yellow oil was obtained, the physical properties of which are as follows. ESI—MS; m / z 525[2M" + Na].—NMR(CDC1) δ (ppm): 1.32(t, J = 3 7.2Hz, 3H), 2.18-2.43 (m, 2H), 2.90— 3.03 (m, 1H), 3.05— 3.20 (m, 1H), 4.25(q, J = 7.2Hz, 2H), 4.85— 4.95 (m , 1H), 7.36— 7.41 (m , 2H), 7.79-7.85 (m, 2H) .

[0229] Synthesis of (2R, 5S)-5- (4-chlorophenyl)pyrrolidine 1, 2-dicarboxylic acid 1 tert-butyl ester and 2-ethyl ester (R)-5-(4-Chrophenyl)3,4-dihydro-2H-pyrrole-2-carboxylic acid ethyl ester (3 5 g) was dissolved in methanol (80 mU acetic acid (20 mU) at 45°C in sodium borohydride (1.05 g ) was added over 5 min.The reaction was stirred for 3 h at −45° C. to 0° C. To the reaction was added disodium hydrogen phosphate aqueous solution, and the reaction was stirred at room temperature for 20 min. The solvent was distilled off under reduced pressure, the residue was extracted with ethyl acetate, and the organic layer was evaporated. After washing with sodium hydroxide solution, the extract was dried over anhydrous magnesium sulfate and concentrated under reduced pressure to obtain 3.6 g of a yellow oil. Triethylamine (7.49 mL) and ditert-butyl dicarbonate (3.76 g) were added to a dichloromethane (50 mU solution) of the resulting oil, and the reaction mixture was stirred at room temperature for 1 hour. The reaction mixture was poured into ice water. The extract was washed with saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure.The residue was purified by silica gel column chromatography (heptane-ethyl acetate system) to give 3 g of the title compound. was obtained as a yellow oil having the following physical properties. ESI—MS; m / z 376 [M" + Na].'H-NMRCCDCl) δ (ppm): l. 17 and 1 3 41 (s, 9H) , 1. 26 - 1. 38 (m, 3H) , 1. 84— 2. 10 (m, 2H) , 2. 16— 2. 36 (m, 2H) , 4. 20 -4. 30 (m, 2H) , 4. 30— 5. 00 (m, 2H) , 7. 25— 7. 35 (m, 2H) , 7. 45— 7. 60 (m, 2H) . Synthesis of (2S. 5R)-2-(4-chlorophenyl)5((E)2-methoxycarbonylvinylvinyl)pyrolysine-1-monocarboxylic acid tert-butyl ester (2R, 5S)-5-(4-chloro-phenyl)pyrrolidine 1,2-dicarboxylic acid 1 tert-butyl ester 2-ethyl ester (3 3 g) in tetrahydrofuran (50 mU) was added with lithium borohydride (813 mg). The reaction mixture was stirred at room temperature for 12 hours, added to ice water, extracted with ethyl acetate, washed with saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. To a solution of oxalyl chloride (1 24 mL) in dichloromethane (40 mL) was added dropwise DMSO (1.09 mU) at 70°C, and the reaction mixture was stirred at the same temperature. To this was added dropwise a solution of the previous alcohol (3 0 g) in dichloromethane (20 mU) at 60°C, and the reaction mixture was stirred at the same temperature for 15 minutes. was added dropwise, and the reaction mixture was stirred for 30 minutes from −60° C. to 0° C. The reaction mixture was poured into water, extracted with ethyl acetate, washed with saturated brine, and diluted with anhydrous magnesium sulfate. After drying and concentrating under reduced pressure, 3.0 g of the aldehyde derivative was obtained as a pale yellow oil.To a solution of trimethylphosphonoacetate (2.63 g) in DMF (20 mU) was added sodium hydride (60% oil, 0.0 g). 579 g) was added at room temperature and the reaction was stirred for 20 minutes.This solution was added to the previous aldehyde (3.0 g) in DMF (10 mU) at room temperature and the reaction was stirred at room temperature for 1 hour. Pour the reaction solution into water, Extracted with ethyl acetate. The extract was washed with saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (heptane-ethyl acetate system) to obtain 2.8 g of the title compound as a yellow oil. The physical property values ​​of this product are as follows. ESI—MS; m / z 388[M" + Na].—NMR(CDC1) δ (ppm): 1.00— 1.50 3 (m, 9H), 1.75-1.95 (m, 2H) , 2.05— 2.20 (m, 1H), 2.20— 2.35 (m, 1H), 3.77(s, 3H), 4.30— 5.00 (m, 2H) , 5.95— 6.10 (m, 1H), 6.95— 7.05 (m, 1H), 7.18(d, J = 8.4Hz, 2H) , 7.30(d, J = 8.4Hz, 2H) .

[0231] Synthesis of (E)-3-"(2R, 5S)-1-(3-butenyl)5-(4-chlorophenyl)pyrrolidin 2-yl Ίacrylic acid methyl ester Ethyl acetate (5m A 4N hydrochloric acid ethyl acetate solution (19.4 mU) was added dropwise to the U solution at room temperature, and the reaction mixture was stirred at 50°C for 30 minutes. The reaction mixture was concentrated under reduced pressure to obtain 2.5 g of a yellow solid. A yellow solid (2 5 g), diethyl cyanophosphonate (1.97 mU) was added dropwise at 0°C to a solution of vinyl acetic acid (1.1 lmU and triethylamine (3 63 mU) in DMF (40 mU), and the reaction mixture was incubated at the same temperature. The reaction mixture was poured into ice water and extracted with ethyl acetate.The extract was washed successively with 1N aqueous hydrochloric acid, saturated aqueous sodium bicarbonate, and saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (heptane-ethyl acetate system) to obtain 2.2 g of the title compound as a yellow oily substance with the following physical properties. ESI—MS; m / z 334[M" + H].—NMR(CDC1) δ (ppm): 1.30— 3.20 ( 3 m, 6H), 3.76 and 3.79(s, 3H) , 4.60— 5.20 (m, 4H) , 5.70— 6.20 (m , 2H), 6.90-7.40 (m, 5H) .

[0232] (3S.8aR)— 3— Synthesis of (4-chlorophenyl)-2, 3.6.8a tetrahydro-1H indolizin-3-one (E) 3-[(2R,5S)-1(3-butenyl)-5-(4-chlorophenyl)pyrrolidin-2-yl]acrylic acid methyl ester (2 2 g) in dichloromethane (lOOmU) was added with G Second generation rubbs catalyst (559 mg) was added and the reaction was heated to reflux under a nitrogen atmosphere for 5 hours. The reaction solution was cooled to room temperature, triethylamine (4 mL) was added to the reaction solution, and the reaction solution was stirred for 20 minutes. The reaction solution was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (heptane ethyl acetate system) to obtain 1·3 g of the title compound as a brown oil. The physical properties of this product are as follows. ESI— MS; m / z 248[M" + H].'H-NMRCCDCl) δ (ppm): 1.70— 1.90 ( 3 m, 2H), 2.05-2.15(m, 1H), 2.25— 2.45 (m, 1H), 2.90— 3.05 (m, 2H), 4.20-4.35 (m, 1H), 5.10(d, J = 8.8Hz, 1H), 5.98— 6.04 (m, 1H ), 6.06-6.12(m, 1H), 7.00— 7.08 (m, 2H) , 7.20— 7.28 (m, 2H) .

[0233] (3S.8aS) Synthesis of 3-(4-chloro-phenyl)hexahydroindolizin-5-one Platinum oxide (151 mg) was added to a methanol (50 mU) solution of (3S, 8&1¾—3-(4-chlorophenyl)-2, 3, 6, 8a tetrahydro-1H-indolizin-3one (1.3 g). The reaction solution was stirred at room temperature for 5 hours under a hydrogen atmosphere, platinum oxide was removed from the reaction solution by filtration, the filtrate was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (heptane ethyl acetate system) to give the title compound. 1. Og was obtained as a pale brown solid with the following physical properties. ESI— MS; m / z 250[M" + H].— NMR(CDC1 ) δ (ppm): 1.50— 1.90 ( 3 m, 4H), 1.90-2.10 (m, 2H) , 2. 15— 2.50 (m, 4H) , 3.52— 3.65 (m, 1H), 5.08(d, J = 8.8Hz, 1H), 7.06(d , J = 8.4Hz, 2H) , 7.25(d, J = 8.4Hz, 2H).

[0234] Synthesis of (3S, 8aR)-3-(4-chlorophenyl)-5-oxooctahydroindolizin-6-yl Ίphosphonic acid diethyl ester (3S, 8aS)- 3- (4-chlorophenyl)hexahydroindolizin-5-one (1. Og) and N, N, N' , N' - tetramethylethylenediamine (2 05mU of trimethylsilane iodide (0 763 mU) was added dropwise at 0°C to a solution of (40 mL) in dichloromethane, and the reaction mixture was stirred at 0°C for 30 minutes. The reaction mixture was stirred at the same temperature for 40 minutes.The reaction mixture was added to ice-aqueous sodium thiosulfate solution and extracted with ethyl acetate.The extract was washed with 1N hydrochloric acid and saturated brine, and diluted with anhydrous magnesium sulfate. After drying, reduce pressure After concentration, the iodide was obtained. A solution of the obtained iodide in triethyl phosphite (20 mL) was stirred at 130°C for 2 hours. The reaction solution was returned to room temperature and concentrated under reduced pressure to obtain 2.5 g of the title compound. The physical property values ​​of this product are as follows. ESI-MS; m / z 386[M" + H].

[0235] (E) - Synthesis of (3S.8aS)-3-(4-chloro-phenyl)6-'3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene-hexahydroindolizin-5-one 3 Methoxy-4-(4-methyl-1H-imidazole-1-yl)benzaldehyde (875 mg) and [(3S, 8aR)-3-(4-chlorophenyl)-5-foxoctahydroindolizine Lithium hydroxide (355 mg) was added to a mixed solution of 6-inole]phosphonic acid diethyl ester (2.5 g) in tetrahydrofuran (8 mU-ethanol (30 mU), and the reaction solution was stirred at room temperature for 5 hours in the dark. The reaction mixture was poured into ice water and extracted with ethyl acetate.The extract was washed with saturated brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure.The residue was purified by silica gel column chromatography (heptane ethyl acetate system). , 1.43 g of the title compound was obtained as a colorless solid having the following physical properties. ESI—MS; m / z 448[M" + H].—NMR(CDC1) δ (ppm): 1.66— 1.88( 3 m, 3Η), 2.02-2.12(m, 1H), 2.26- 2.40 (m, 2H), 2.30(s, 3H), 2.6 8-2.82 (m, 1H), 3.10- 3.20 (m, 1H), 3.76 — 3.90 (m, 1H), 3.85(s, 3H), 5.20(d, J = 8.8Hz, 1H), 6.94 (s, 1H), 7.02— 7.16 (m, 2H) , 7. 12 (d, J = 8.4Hz, 2H), 7.20— 7.34 (m, 1H), 7.28(d, J = 8.4Hz, 2H) , 7.7 2(d, J=l.6Hz, 1H), 7.76(d, J = 2.0Hz , 1H).

[0236] 3- 4- "(3S, 8aS) 3-(4-chloro-phenyl) 5 foxohexahydroindolizine-(6E) ylidenemethyl Ί- 2-methoxyphenyl} 5-methyl- 1 (phosphonofoximethyl) 3H-imidazolone 1 lm trifluoro Synthesis of acetate Under a nitrogen atmosphere, a solution of chloromethyl ditertiarybutyl phosphate (43.5 mg), sodium iodide (50.4 mg) and N,N-diisopropylethylamine (4 88) in acetone (4 mU) was added to (E) -(3S, 8aS)-3-(4-chlorophenyl)-6-[3-methoxy-4 -(4-Methyl-1H-imidazol-1-yl)benzylidene]hexahydroindolizin-5-one (50 mg) was added and the reaction was stirred at 60°C for 1 hour. After cooling the reaction solution with water, insoluble matter in the reaction solution was removed by filtration, and the filtrate was concentrated under reduced pressure. To a solution of the residue in dichloromethane (2 mL) was added trifluoroacetic acid (0.5 mL) and the reaction was stirred at room temperature for 1 hour. The reaction mixture was concentrated under reduced pressure, and the residue was purified by reverse-phase C18 silica gel column chromatography (elution solvent: water containing 0.1% trifluoroacetic acid—acetonitrile system) to give 32 mg of the title compound as a colorless solid. rice field. The physical properties of this product are as follows. ESI—MS; m / z 558[M + ]. — NMR(CD OD) δ (ppm): 1.70— 1.90 (m 3 , 3H), 2.05-2.15(m, 1H), 2.30— 2.50 (m, 2H) , 2.53(s, 3H) , 2.80 -2.95 (m, 1H), 3.05— 3.20 (m, 1H), 3.85— 4.00 (m, 1H), 3.95(s, 3H), 5.18(d, J = 9.2Hz, 1H), 5.96 (d, J=12.4Hz, 2H), 7. 18(d, J = 8.4Hz, 2H ), 7.25(d, J = 8.4Hz, 1H), 7.31(d, J = 8.4Hz, 2H), 7.32(s, 1H), 7.59(d, J = 8.4Hz, 1H), 7.62(s, 1H ), 7.69(s, 1H), 9.45(s, 1H). Example 9 3—{4 {(S)—4—"(lR.2R)-1-(3.4-difluorophenyl)-2 hydroxy propyl Ί-6-methyl 3 foxomorpholine-(2Z) ylidenemethinole 2 fluoro-phenyl Synthesis of 5-methyl-1-phosphonooxymethyl-3H-imidazole-1-im trifluoroacetate [Chemical 33] (S)—4—“(lR, 2R)-1-(3,4-difluorophenyl)-2 hydroxypropyl Ί-2-{_1-[3-fluoro 4 Synthesis of Ί (Ζ)-methylidene} 6-methylmorpholine 3-one By the same method as in Example 4, 1.15 g of the title compound was obtained using 1-bromo-3,4-difluorobenzene as a starting material. The physical properties of this product are as follows. 'H-NMRCCDCl) δ (ppm): 1.31 (d, J = 6.4Hz, 3H), 1.41 (d, J = 6.8Hz 3 , 3H), 2.20(d, J = 6.4Hz, 1H), 2.30(s, 3H) , 3.15(dd, J=12.8, 9.6Hz z, 1H), 3.57(dd, J=12.8, 2.4Hz, 1H ), 4.42— 4.48 (m, 2H) , 5.38 (d, J = 7.6Hz, 1H), 6.80(s, 1H), 6.97(s, 1H), 7. 12— 7.18 (m, 2H) , 7.26 - 7.31 (m, 2H), 7.44(dd, J = 8.4, 2.0Hz, 1H), 7.71(dd, J=12.8, 1.6 Hz, 1H), 7.73(s, 1H). 3-{4 {(S)-4-"(lR.2R)- 1-(3.4 difluorophenyl)-2 hydroxy propyl Ί-6-methyl 3 foxomorpholine-(2Z) ylidenemethyl 2 fluoro-phenyl Synthesis of 5-methyl-1-phosphonooxymethyl-3H-imidazole-1-im trifluoroacetate (S) -4-[(lR, 2R) -1- (3, 4 difluorophenyl) 2 hydroxypropinole] — 2 {1 [ 3—fluoro 4— (4—methyl 1 H imidazole- 1— phenyl) Di-]-(Z)-methylidene}6-methylmorpholin-3-one (lOOmg), chloromethyl ditertiaryib, cinolephosphate (CAS No. 229625-50-7, 82mg), Sodium Shoui (95mg) and A solution of ΙΡΕΑ (0 04 mU of DME (5 mU) was stirred at 80°C for 2 hours. The reaction solution was allowed to cool to room temperature and concentrated under reduced pressure. (1 mL) was added, and the mixture was stirred at room temperature for 1 hour.The reaction mixture was concentrated under reduced pressure, and the residue was purified by reverse-phase C18 silica gel column chromatography (elution solvent: water containing 0.1% trifluoroacetic acid-acetonitrile system). Purification afforded 90 mg of the title compound, whose physical properties are shown below. ESI—MS; m / z 582[M + ]. — NMR(CD OD) δ (ppm) : 1.25(d, J = 6.0 3 Hz, 3H), 1.41(d, J=6.8Hz, 3H), 2.54(s, 3H), 3.18(dd, J=13.2, 9.6Hz, 1H), 3.82(dd, J=13.2, 2.4Hz, 1H), 4.40—4.48 (m, 1H), 4.51—4.61 (m, 1H), 5.53(d, J=7.6Hz, 1H), 5.93(brd, J=12.4Hz, 2H), 6.74(brs , 1H), 7.16— 7.24 (m, 2H) , 7.30— 7.38 (m, 1H), 7.52— 7.64 (m, 3H), 7. 83(d, J=13. 2Hz, 1H), 9. 53(s, 1H). Example 10 3- {2 methoxy-4-"(6S, 9aS)- 4 oxo 6- (3, 4, 5 trifluorophenyl) hexahydroquinolizine-(3E)-ylidenemethyl Ί-phenyl} 5-methyl- 1-( Synthesis of 3H-imidazole-1-(phosphonooxymethyl)3H-imidazole-1-(1)-trifluoroacetate [Chemical 34] Synthesis of 1(4-bromobutyryl)-2-(3.4.5-trifluorophenyl)2.3-dihydro-1H-pyridin4one 4-Methoxypyridine (1.52 mL), 3,4,5-trifluorophenylmagnesium bromide (0.3 M, THF solution, 50 mL) and 4-bromo 1.02 g of the title compound was obtained from 1.74 mU of butyryl chloride. 'H-NMRCCDCl) δ (ppm): 2.24—2.31 (m, 2H), 2.77—2.88 (m, 3H), 3 3. 06-3. 18 (m, 1H), 3. 51— 3. 55 (m, 2H) , 5.48(brd, J = 8.0Hz, 1H), 5. 98(brs, 1H), 6. 82 — 6. 90 (m, 2H) , 7. 72 (brs, 1H). (4S*.9aR*)—4-(3.4.5 trifluorophenyl)hexahydroquinolizine-2.6 1-(4-bromobutyryl)-2-(3,4,5-triphenoleophenyl)-2,3-dihydro-1H-pyridine-4-one according to the method described in Journal of Organic Chemistryl, Vol. 993, pp. 4198-4199. (1.15 g) with tributyltin hydride (973) and AIBN (201 mg) also gave 331 mg of the title compound. The physical property values ​​of this product are as follows. H-NMR(CDC1) δ (ppm): 1.61-1.69 (m, 1H), 1.72— 1.82 (m, 1H), 3 1.87-1.97 (m, 1H), 1.99— 2.07 (m, 1H), 2.23— 2.31 (m, 1H), 2.39 (ddd, J=14.8, 3.2, 1.6Hz, 1H), 2.47— 2.57 (m, 2H ) , 2.81(ddd, J=l 5.2, 7.2, 0.8Hz, 1H), 2.92 (ddd, J=15.2, 2.4, 1.6Hz, 1H), 3.52— 3.59 (m, 1H), 6.45(brd, J= 7.2Hz, 1H), 6.88— 6.92 (m, 2H) .

[0241] Synthesis of (6S*, 9aR*)— 8-hydroxy-6— (3, 4, 5-trifluorophenylene) octahydroquinolizin 4-one (6S*, 9aR*)-4-(3,4,5-trifluorophenyl)hexahydroquinolizine-2,6-dione (331 mg) in methanol (10 mU) was cooled to 0°C and the reaction Sodium borohydride (64. lmg) was added to the liquid, and the reaction liquid was stirred for 1 hour.Water and ethyl acetate were added to the reaction liquid, and the organic layer was partitioned.The resulting organic layer was washed with saturated brine. The extract was washed, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure to obtain 340 mg of crude alcohol, whose physical properties are as follows. 'H-NMRCCDCl) δ (ppm): 1.57— 1.64 (m, 1H), 1.70— 2.00 (m, 3H), 3 2.00-2.12(m, 1H), 2.20— 2.60 (m, 5H) , 3.28— 3.35 (m, 1 / 2H), 3.81-3.89 (m, 1H), 4.23— 4.26 (m, 1 / 2H) , 5.91(brd, J = 6.4Hz, 1 / 2H), 6.15(brd, J = 4.8 Hz, 1 / 2H), 6.80— 6.94 (m, 2H) .

[0242] Synthesis of (6S*.9aS*)— 6— (3.4.5—trifluorophenylene)octahydroquinolizin-4—one A solution of (6S*, 9aR*)—8-hydroxy-6-(3,4,5-trifluorophenyl)octahydroquinolizin-4-one (161 mg) in methylene chloride (5 mU) was cooled to 0°C and Triethynoleamine (450 μL) and methanesulfoyurc oralide (125 μL) were added to the reaction mixture, and the reaction mixture was stirred at room temperature for 4.5 hours.Water and ethyl acetate were added to the reaction mixture, and the organic layer was separated. The resulting organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure to obtain 203 mg of crude mesyl.NMP (5.0 mL) of 203 mg of crude mesyl was obtained. Sodium borohydride (204 mg) was added to the solution, the reaction mixture was heated to 100° C., and stirred for 2.5 hours After the reaction mixture was allowed to cool to room temperature, water and ethyl acetate were added to the reaction mixture, and an organic The layers were partitioned and the resulting organic layer was washed with saturated brine and dried over anhydrous magnesium sulfate. After drying with simu, it was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (elution solvent: heptane-ethyl acetate system) to obtain 79 mg of the title compound. The physical property values ​​of this product are as follows. 'H-NMR CCDCl) δ (ppm): 1. 38— 2. 00 (m, 6H), 2. 10— 2. 22 (m, 1H), 3 2. 25- 2. 34 (m, 1H) , 2. 42— 2. 62 (m, 2H) , 2. 74— 2. 80 (m, 1H) , 3. 19 - 3. 30 (m, 2H) ) , 6. 00— 6. 05 (brs, 1H) , 6. 79— 6. 83 (m, 2H) . (E)—(6S*, 9aS*)—6—(3,4,5-triphenylene) 3—3 methoxy-4-(4-methyl-1H-imidazole-1-yl)benzylidene Ίoctahydroquinolidine Synthesis of 4 years old (6S*, 9aR*)- 6- (3, 4, 5-trifluorophenyl)octahydroquinolizin-4-one (79 mg) in THF (2. OmU solution, LDA(1 5M THF solution, 372 L) was added.After the reaction was stirred at 0° C. for 1 hour, 3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzaldehyde (66 L) was added to the re...

Claims

Scope of Claim Equation (I) [C1] 〜 ###0001### [In the formula, R and R are the same or different hydrogen atoms or C16 alkyl groups ab Show, X represents a methoxy group or a fluorine atom. Y is -CO- (O) -R ·M (wherein R is the same or ncac selected from the substituent group A1) The following formulas may be substituted with different substituents: C1 represents a 6-alkyl group, a 6- to 14-membered aromatic hydrocarbon ring group, a 5- to 14-membered aromatic heterocyclic group, a 6- to 14-membered non-aromatic hydrogen hydrocarbon ring group, or a 5- to 14-membered non-aromatic heterocyclic group, where n represents 0 or 1, and M represents an anion): -P (= 0) (OR) ·M (wherein R is selected from substitution group A2) CI— represents a 6 alkyl group which may be substituted with one to three identical or different substituents, where M— has the meaning described above), -Ρ (= 0) (ΟΗ) 2·M— (wherein M— has the meaning described above), Ρ (= 0) (—Ο—) (ΟΗ) or Ρ (= 0) (—Ο—) (-0 M+) (wherein M+ is positive Μ bb A is given by equation (A-1) [2] ###0002### [In the formula, (a) R2, R3 and R4 are the same or different, representing a hydrogen atom or a C1-6 alkyl group, X represents a C16 alkylene group (the C16 alkylene group may be substituted with 1 to 3 hydroxyl groups or a C16 alkyl group (the C16 alkyl group may be substituted with 1 to 3 hydroxyl groups)), and X represents an oxygen atom or a methylene group (the methylene 2 The group may be substituted with 1 or 2 C16 alkyl groups! / , Ar represents — X — Ar (wherein Ar is substituted with identical or distinct substituents selected from substituent group A2, including 1, 3, 6, and 14-membered aromatic hydrocarbon rings or 5, and 14-membered aromatic heterocyclic rings, and X represents a single bond or an oxygen atom), (b) — is a benzene ring (the ###0003### The benzene ring is condensed with one to three identical or different substituted groups selected from substituent group A2, resulting in a C3-8 cycloalkyl group (one methylene group of the C3-8 cycloalkyl group may be substituted with an oxygen atom). Or formula (A-2) [C3] ###0004### [In the formula, indicates a single or double bond, and Ar is the same or selected from substituent group A2. 2 R5 and R6 are identical or different groups selected from substituent group A2, and Z and Z are identical or different groups. 1 2 Compounds or pharmacokinetically acceptable compounds represented by [A16 alkyl or C16 phosphate group] may be substituted with one or two identical or distinct substituents selected from substituent group A2, and may be substituted with a methylene group or vinylene group, an oxygen atom, or a C16 alkyl group or C16 phosphate group, where p, q, and r are identical or distinct integers from 0 to 2]. substituent group Al: (1) hydroxyl group, (2) cyano group, (3) C3-8 cycloalkoxy group, (4) C16 alkoxy group (the C16 alkoxy group may be substituted with one to three substituents selected from the group consisting of a halogen atom, a hydroxyl group, a cyano group, a C3-8 cycloalkyl group, and a C3-8 cycloalkoxy group), (5) one or two C16 alkyl groups (the C16 alkyl group may be substituted with one or two identical or distinct substituents selected from the group consisting of one or two substituents, and (3) A carboxyl group, (8) A pyridinyl group, and (9) A sugar residue. Substituent group A2: (1) halogen atom, (2) hydroxyl group, (3) cyano group, (4) C3-8 cycloalkyl group, (5) C3-8 cycloalkoxy group, (6) C1-6 alkyl group (the C1-6 alkyl group may be substituted with 1 to 3 substituents selected from the group consisting of halogen atom, hydroxyl group, cyano group, C3-8 cycloalkyl group, C1-6 alkoxy group and C3-8 cycloalkoxy group), (7) C1-6 alkoxy group (the C1-6 alkoxy group may be substituted with 1 to 3 substituents selected from the group consisting of halogen atom, hydroxyl group, cyano group, C3-8 cycloalkyl group and C3-8 cycloalkoxy group), (8) amino group which may be substituted with 1 or 2 C1-6 alkyl groups (the C1-6 alkyl group may be substituted with 1 to 3 halogen atoms), and (9) A nolebamoyl group is formed by substituting one or two C16 alkyl groups (the C16 alkyl groups may be substituted with one or three halogen atoms). [2] X represents a methoxy group, the compound or a pharmaceutically acceptable salt of the compound according to claim 1. [3] X represents a fluorine atom, the compound or pharmaceutically acceptable salt of claim 1. [4] Y is -P (= 0) (OH) . M (where M represents the anion), -P (= 0) (- O A compound or pharmacoagulably acceptable salt according to claim 1, which exhibits ) (OH) or -P (= 0) (- O-) (- O- M+) (wherein M+ represents a cation). [5] Ar may be replaced by one to three identical or distinct substituents selected from substituent group A2, representing a 6-N / , 14-membered aromatic hydrocarbon ring group or a 5-N / , 14-membered aromatic heterocyclic ring group, the compound or pharmaceutically acceptable salt of claim 1. [6] The compound or pharmaceutically acceptable salt of claim 1, wherein Ar is a phenyl group or a pyridinyl group, and Ar may be replaced by one to three identical or different substituents selected from substituent group A2. [7] Ar represents a phenyl or pyridinyl group, or a phenyl or pyridinyl group substituted with one to three halogen atoms, the compound or pharmaceutically acceptable salt of claim 1. [8] X is a compound or pharmacoposly acceptable salt of the compound described in item 1, wherein X = ∫¹ - ∫¹ (0¹) - 1⁷ (wherein 1⁷ represents a ∫¹ 6alkyl group). [9] X represents a methylene group, the compound or pharmaceutically acceptable salt of claim 1. [10] X represents an oxygen atom, the compound or pharmaceutically acceptable salt of claim 1. [11] The compound or pharmaceutically acceptable salt according to claim 1, wherein Z and Z are the same or different, substituted with one or two C16 anolequinole groups, halogen atoms or hydroxyl groups, methylene groups or oxygen atoms, and R5 and R6 are the same or different, substituted with a C16 anolequinole group, a halogen atom or a hydrogen atom. [12] Z and Z are the same or different methylene groups (one or two methylene groups) The compound or pharmaceutically acceptable salt according to claim 1, wherein C represents a 1-6 alkyl group (which may be substituted with a halogen atom or a hydroxyl group), and p, q and r represent 1. [13] Z and Z are the same or different methylene groups (one or two methylene groups) The compound according to claim 1, wherein C (which may be substituted with a 1-6 alkyl group, a halogen atom or a hydroxyl group), p and q represent 1, and r represents 0. [14] The compound or pharmaceutically acceptable salt of claim 11, wherein Z represents a methylene group (the methylene group may be substituted with 1 or 2 C16 alkyl groups, halogen atoms or hydroxyl groups), Z represents an oxygen atom, and p, q and 1 represent 1. [15] Z represents an oxygen atom, and Z represents a methylene group (the methylene group is 1 or 2, C1-6a 1 2 The compound or pharmaceutically acceptable salt according to claim 11, wherein p, q, and r represent 1 (which may be substituted with a lucyl group, a halogen atom, or a hydroxyl group). [16] Z, Z represents an oxygen atom, and p, q and r represent 1, the compound according to claim 11 or 1 2 This is a pharmacologically acceptable salt. [17] Ar represents a phenyl group substituted with one to three halogen atoms, as described in claim 11. 2 A compound or pharmacologically acceptable salt of [the substance]. [18] Ar represents a phenyl group substituted with two or three halogen atoms, as described in claim 11. 2 A compound or pharmacologically acceptable salt of [the substance]. [19] R5 and R6 are the same or different, representing one or two C16 anolequinole group, a halogen atom or a hydrogen atom, the compound of claim 1 or pharmaceutically acceptable [20] A compound or pharmaceutically acceptable salt of claim 1 selected from the following group. 1) 3- {4-{ 1-{ [ (S)-1-(4-fluorophenyl)ethyl]-2-oxopiperidine-(3E)-ylidenemethyl}-2-methoxyphenyl}-5-methyl-1-(phosphonoxymethyl)3H-imidazonole 1-ium trifluoroacetate, 2) 1-acetoxymethyl-3- {4-{ l- [ (S)-1 (4 fluorophenyl)ethyl ]-2-oxopiperidine-(3E)-ylidenemethyl}-2-methoxyphenyl}-5-methyl-3H-imidazole-1-ium iodide, 3) 3- {4- { l- [ (lR, 2R)- 2-hydroxy-1- (3, 4, 5-triphenorheophenylole)propyl ] 2-oxopiperidine-(3E)ylidenemethyl} 2-methoxyphenyl} — 5-methyl-1- (phosphonoxymethyl) 3H-imidazole-1-ium trifluoroacetate, 4) 3-[2-phosphorone-4-[ (S)-4-[ (1R, 2R)-2-hydroxy-1-(3, 4, 5 trifluorophenylole)propyl]6-methyl-3-oxomorpholine-(2Z)-ylidenemethyl]phenyl]5-methyl-1-phosphonoxymethyl-3H-imidazole-1-ium trifluoroacetic acid, 5) 3-{2-methoxy-4 [(33, 8&3)-5-oxo-3-(3, 4, 5 trifluorophenyl)hexahydroindidine-(6E)-ylidenemethyl]phenyl}-5-methyl-1-phosphonoxymethyl-3H-imidazole-1-ium trifluoroacetic acid, 6) 3-{4-{ (S)-4-[(S)-l-(2,6 difluropyridine-3 yl)ethyl]6 methyl-3 oxomorpholine-(2Z) ilidenemethyl} 2 methoxyphenyl}- 5-methyl-1-phosphonoxymethyl-3H-imidazole-1-ium chloride, 7) 3- {4-{ [ (3S, 8aS) 3-(4-chlorophenyl)-5-oxohexahydroin dridine-(6E) iridenemethyl ] 2 methoxyphenyl} 5 methyl-1 (phosphonoxymethyl) 3H-imidazole-1 trifluoroacetate, 8) 3-{4-{(S)-4-[(lR,2R)-l-(3,4 difluorophenyl)-2 hydroxypropyl]6-methyl-3 oxomorpholine-(2Z) ilidenemethyl}2 fluorophenyl}-5-methyl-1-phosphonoxymethyl-3H-imidazole-1 trifluoroacetate, 9) 3- {2-methoxy-4- [(6S,9aS)-4-oxo-6- (3,4,5-trifluorophenyl)hexahydroquinolidine-(3E)-ylidenemethyl]phenyl}-5-methyl-1-(phosphonoxymethyl)3H-imidazole-1-ium trifluoroacetate, 10) 3-{2 Methoxy-4 [(41^, 9&3)-6-oxo-4-(3, 4, 5 trifluorophenyl)hexahydropyrido[2, lc][l, 4]oxazine-(7E)-ylidenemethyl]phenyl}-5-methyl-1-phosphonoxymethyl-3H-imidazole-1-ium trifluoroacetate, 11) 3-{4-{(S)-4-[(1R, 2R)-2 Hydroxy-1-(3, 4, 5 Triphenylethyl)propyl]-6 Methyl-3 Oxomorpholine-(2Z) Iridenemethyl} 2 Methoxyphenyl]-5 Methyl 1-(Phosphonoxymethyl)3H Imidazole 1 Triphenylethylacetate, 12) 3— {4 [(6S, 9aR)—6— (4 chlorophenyl) 4 oxohexahydroquinolidine-(3E) iridenemethyl] 2 methoxyphenyl} 5 methyl 1—phosphonoxymethyl-3H-imidazole-1 diurnal trifluoroacetate, 13) 3— {2 methoxy-4— [(IS, 6R, 9aR)—1 methyl 4 oxo 6— (3, 4, 5-trifluorophenyl) tetrahydro[1,4]oxadino[3,4-c][1.4]oxadine-(3Z)—iridenemethyl] phenyl}—5—methyl-1—phosphonoxymethyl-3H-imidazole-1 diurnal trifluoroacetate, 14) 3- {4- [(IS, 6R, 9aR)-6- (4 Chloropheninole)-1-Methinole-4 Oxotetrahydro [1,4]oxadino [3,4-c][l,4]oxazine-(3Z)-Iridenemethyl ]— 2 Methoxyphenyl}-5 Methyl 1-Phosphonoxymethyl-3H-Imidazole 1-Ium Trifluoroacetate, 15) 3- {2 Methoxy-4- [(IS, 6S, 8aR)-1 Methyl 4-oxo 6- (3, 4, 5 Trifluorophenyl)-tetrahydropyro [2, lc][l, 4]oxazine-(3Z)-Iridenemethyl]phenylole}-5-Methinole-1-Phosphonoxymethyl-3H-Imidazol-1-Ium trifluoroacetate, 16) 3-{4-[(IS, 6R, 9aR)-6-(3,4-difluorophenyl)-1-methyl 4-oxotetrahydro[1,4]oxadino[3,4-c][I,4]oxazine-(3Z)-ylidenemethyl]-2-methoxyphenyl}-5-methyl 1-phosphonoxymethyl 3Himidazole-1-trifluoroacetate and 17) 3-{4-[(6R, 9aR)-l, 1-dimethinole-4-xiso6-(3, 4, 5-trifluorophenyl)tetrahydro[1, 4]oxadino[3, 4-c][l, 4]oxazine-(3Z)-lydenemethyl]-2 methoxyphenyl}-5 methyl-1-phosphonoxymethyl-3H imidazonole-1 dium trifluoroacetate. The compound according to claim 1, selected from the following group: 1) Monohydrogen phosphate 1 {4 [(E)- {1 [(1S)- 14 fluorophenyl)ethyl] - 2 oxopiperidine-3 ilidene}methyl] 2 methoxyphenyl}-4 methyl 1H-imidazo-3-iomethyl 2) Hydrogen phosphate 1 {4-[ )-{1 [(11^,21¾-2-hydroxy-1-(3,4,5-trifluorophenyl)propyl]-2-oxopiperidine-3-ylidene}methyl]-2-methoxyphenyl}4-methyl-1H-imidazo-3-iomethyl, 3) Monohydrogen phosphate 1 {2 fluoro 4 [(Z)- { (6S)- 4 [(1R, 2R) 2 hydroxy 1- (3, 4, 5-trifluorophenylole)propyl]- 6-methyl 3-oxomolpholine-2 ilidene}methyl]phenyl} 4-methyl 1H-imidazo-3 i methyl, 4) Monohydrogen phosphate 1 (2-methoxy 4 { (E)- [(3S, 8aS)-5-oxo 3-(3,4,5-trifluorophenyl)hexahydroindidine 6(5H)-ylidene]methyl}phenyl) 4-methyl 1H imidazonole 3-iomethyl 5) Monohydrogen phosphate 1-{4-[(Z)- {(6S)- 4-[(1S)- 1-(2,6 difluropyridin 3-yl)ethyl]6 methyl 3 oxomorpholine 2-ylidene}methyl]-2-methoxyphenyl}-4-methyl 1H-imidazo-3-iomethyl, 6) Monohydrogen phosphate 1 (4 { (E)- [(3S, 8aS) 3-(4-chlorophenyl)-5-oxohexahydroinsoldin-6 (5H)-ylidene]methyl}-2 methoxyphenyl)-4-methyl-1H-imidazo-3-iomethyl 7) Monohydrogen phosphate 1 {4 [(Z)— {(6S)— 4 [(1R, 2R)— 1—(3,4 difluorophenyl) 2-hydroxypropyl] 6-methyl 3-oxomorpholine-2-ylidene}methyl] 2-fluorophenylole}-4-methyl 1H imidazo-ole-3-iomethyl, 8) Monohydrogen phosphate 1-(2) Methoxy 4 { (E)-[(6S,9aS)4 oxo 6-(3,4,5 trifluorophenyl)hexahydro-2H quinolidine-3(4H)-ylidene]methyl}phenyl) 4-methyl 1H imidazonole-3-iomethyl 9) Monohydrogen phosphate 1- (2 methoxy- 4- { (E)- [(4R, 9aS)-6 oxo- 4- (3, 4, 5 trifluorophenyl) hexahydropyrid [2, lc][l, 4]oxazine 7(6H)--ylidene]methyl}phenyl) 4-methylone- 1H imidazoone- 3-iomethyl, 10) Phosphate-hydrogen 1 {4-[ )-{(63)-4 [(11^,2)-2-hydroxy-1-(3,4,5 trifluorophenylole)propyl]-6 methyl 3 oxomorpholine-2-ylidene}methyl] 2 methoxyphenyl}-4 methyl 1 H imidazonoline-3 iomethyl, 11) Monohydrogen phosphate 1- (4- { (E)- [(6S, 9aR)-6- (4-chlorophenyl)-4-oxohexahydro-2H quinolidine-3(4H)-ylidene]methyl}- 2 methoxyphenyl() 4-methyl-1H-imidazo-3-iomethyl 12) Monohydrogen phosphate 1-(2-methoxy 4 {(Z)- [(IS, 6R, 9aR)- 1-methylole 4-oxo-6- (3,4,5-trifluorophenyl)tetrahydro-1H-[1,4]oxadino [3,4-c][l,4]oxazine 3(4H)-ylidene]methyl}phenyl)-4-methyl-1H-imidazo-3-iomethyl, 13) Phosphate-hydrogen 1-(4-{ )-[(13, 6R, 9aR)-6-(4 chlorophenyl)-1-methyl-4-oxotetrahydro-1H-[1,4]oxadino[3,4-c][l,4]oxazine-3(4H)-ylidene]methyl}2 methoxyphenyl)4 methyl 1H imidazole-3-iomethyl, 14) Monohydrogen phosphate 1-(2) Methoxy 4 {(Z)- [(IS, 6S, 8aR)- 1-methyl 4-oxo-6- (3, 4, 5 trifluorophenyl) tetrahydro-1H-pyro [2, lc][1, 4]oxazine 3 (4H)-ylidene]methyl}phenyl) 4 methyl 1H imidazo 3-iomethyl 15) Monohydrogen phosphate 1-(4 {(Z)- [(IS, 6R, 9aR)-6-(3,4-difluorophenyl)-1-methyl-4-oxotetrahydro-1H-[1,4]oxadino [3,4-c][l,4]oxazine 3(4H)-ylidene]methyl}-2 methoxyphenyl)-4-methyl-1H imidazonole 3-iomethyl and 16) Monohydrogen phosphate 1-(4 {(Z) [(6R,9aR)-1,1 dimethyl-4 oxo 6-(3,4,5-trifluorophenyl)tetrahydro-1H-[1,4]oxadino [3,4-c] [1,4]oxazine 3(4H)-ylidene]methyl}-2-methoxyphenyl)-4 methyl 1H-imidazole-3-iomethyl. [22] A drug comprising any of claims 1 to 21, the compound described in claim 1 or a pharmaceutically acceptable salt thereof as an active ingredient. [23] The agent of claim 22, which is a preventive or therapeutic agent for a disease caused by amyloid beta. [24] The agent according to claim 23, which causes a disease due to amyloid beta, Alzheimer's disease, senile dementia, Down syndrome, or amyloidosis.